[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fzSRQ2NEoPLX-e2qAQO0uBHYTDgvPgWlQ4DsPO3h8Pmw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"Chiesi Farmaceutici S.p.A.",[4],175,false,13,57,94924,16,18,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"Asthma",53,{"name":18,"count":19},"Chronic Obstructive Pulmonary Disease",34,{"name":21,"count":22},"COPD",14,{"name":24,"count":25},"Fabry Disease",8,{"name":27,"count":25},"Chronic Obstructive Pulmonary Disease (COPD)",{"name":29,"count":30},"Alpha-Mannosidosis",6,{"name":32,"count":30},"Cystic Fibrosis",{"name":34,"count":35},"Pulmonary Disease, Chronic Obstructive",4,[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT06917690","A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa","2026-03","Oleogel-S10",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06166056","A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis","2026-08","CHF6333",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT07163182","Evaluation of Safety, Side Effects and How the Drug CHF6467 Administered Via Intranasal Route is Absorbed, Modified and Removed in Healthy Subjects","2026-08-11","CHF6467 Part 1",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT07301736","Therapeutic Equivalence of CHF5993 pMDI 100\u002F6\u002F12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma","2027-06-03","CHF5993 pMDI with HFA-152a",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05710692","Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease","2027-10","PRX-102 1 mg\u002Fkg every 2 weeks",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT07516951","A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis","2028-02-12","CHF10067",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06328608","A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease","2028-10","PRX-102 1 mg\u002Fkg every two weeks",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT07546981","Efficacy and Safety of CHF 5993 100\u002F6\u002F12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists","2028-10-17","Experimental: Participant Group CHF 5993 pMDI HFA-152a",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT06184503","Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3","2029-09","Velmanase Alfa",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT06663358","A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients","2029-11","Pegunigalsidase-alfa",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,119,137,158,179,208,233,266,287,305,327,345,363,385,403,448,468,505,534,572,609,631,666,694,718,736,761,779,797,822,846,907,948,992,1036,1064,1092,1128,1161,1183,1216,1242,1276,1316,1338,1360,1382,1412,1449,1485,1516,1541,1559,1584,1602,1620,1644,1662,1680,1698,1723,1741,1764,1782,1800,1825,1843,1861,1887,1905,1923,1949,1967,1985,2010,2028,2046,2072,2090,2114,2132,2150,2168,2186,2204,2222,2247,2265,2291,2309,2327,2352,2370,2395,2413,2437,2460,2478,2503,2521,2539,2566,2584,2602,2620,2643,2665,2683,2701,2727,2745,2763,2781,2805,2830,2848,2886,2935,2983,3017,3039,3061,3093,3124,3146,3178,3212,3243,3265,3283,3301,3325,3343,3368,3386,3410,3435,3453,3479,3497,3515,3540,3558,3583,3601,3619,3637,3661,3686,3712,3730,3754,3772,3790,3808,3832,3850,3877,3895,3913,3939,3957,3975,4003,4021,4039,4057,4075,4100,4123,4141,4164,4182,4200,4218,4245,4263,4281,4299,4317,4342,4360,4378,4396,4414,4438,4456,4480,4498,4523,4541,4565,4583,4608,4632,4650,4668,4686,4716,4739,4763,4781,4805,4823,4841,4866,4884,4902,4928,4946,4964,4988,5006,5024,5042,5060,5078,5102,5128,5146,5164,5186,5204,5222,5246,5271,5289,5307,5334,5352,5370,5388,5406,5428,5446,5469,5491,5509,5532,5550,5575,5593,5611,5629,5647,5665,5706,5731],{"intervention":61,"totalTrials":96,"cells":97},1,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":115,"NA":117},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":96,"soonestReadout":60},[107],{"nctId":58,"briefTitle":59,"status":108,"phases":109,"primaryCompletion":60,"completion":110,"start":111,"enrollment":11,"conditions":112,"interventions":113},"RECRUITING",[90,91],"2029-08","2023-08-01",[24],[61,114],"PRX-102 2 mg\u002Fkg every 4 weeks",{"trials":116,"activeCount":100},[],{"trials":118,"activeCount":100},[],{"intervention":114,"totalTrials":96,"cells":120},{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":127,"PHASE4":133,"NA":135},{"trials":122,"activeCount":100},[],{"trials":124,"activeCount":100},[],{"trials":126,"activeCount":100},[],{"trials":128,"activeCount":96,"soonestReadout":60},[129],{"nctId":58,"briefTitle":59,"status":108,"phases":130,"primaryCompletion":60,"completion":110,"start":111,"enrollment":11,"conditions":131,"interventions":132},[90,91],[24],[61,114],{"trials":134,"activeCount":100},[],{"trials":136,"activeCount":100},[],{"intervention":71,"totalTrials":96,"cells":138},{"EARLY_PHASE1":139,"PHASE1":141,"PHASE2":143,"PHASE3":145,"PHASE4":154,"NA":156},{"trials":140,"activeCount":100},[],{"trials":142,"activeCount":100},[],{"trials":144,"activeCount":100},[],{"trials":146,"activeCount":96,"soonestReadout":70},[147],{"nctId":68,"briefTitle":69,"status":108,"phases":148,"primaryCompletion":70,"completion":149,"start":150,"enrollment":151,"conditions":152,"interventions":153},[90,91],"2031-04","2025-07-29",22,[24],[71],{"trials":155,"activeCount":100},[],{"trials":157,"activeCount":100},[],{"intervention":76,"totalTrials":96,"cells":159},{"EARLY_PHASE1":160,"PHASE1":162,"PHASE2":164,"PHASE3":166,"PHASE4":175,"NA":177},{"trials":161,"activeCount":100},[],{"trials":163,"activeCount":100},[],{"trials":165,"activeCount":100},[],{"trials":167,"activeCount":96,"soonestReadout":75},[168],{"nctId":73,"briefTitle":74,"status":169,"phases":170,"primaryCompletion":75,"completion":75,"start":171,"enrollment":172,"conditions":173,"interventions":174},"NOT_YET_RECRUITING",[91],"2026-05",554,[15],[76],{"trials":176,"activeCount":100},[],{"trials":178,"activeCount":100},[],{"intervention":41,"totalTrials":96,"cells":180},{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":187,"PHASE4":204,"NA":206},{"trials":182,"activeCount":100},[],{"trials":184,"activeCount":100},[],{"trials":186,"activeCount":100},[],{"trials":188,"activeCount":96,"soonestReadout":40},[189],{"nctId":38,"briefTitle":39,"status":108,"phases":190,"primaryCompletion":40,"completion":80,"start":191,"enrollment":30,"conditions":192,"interventions":203},[91],"2025-04-18",[193,194,195,196,197,198,199,200,201,202],"Epidermolysis Bullosa","Junctional Epidermolysis Bullosa","Epidermolysis Bullosa, Dystrophic","Epidermolysis Bullosa, Junctional","Skin Abnormalities","Connective Tissue Disease","Collagen Diseases","Skin Diseases","Genetic Diseases, Inborn","Congenital Abnormalities",[41],{"trials":205,"activeCount":100},[],{"trials":207,"activeCount":100},[],{"intervention":209,"totalTrials":96,"cells":210},"CHF10196",{"EARLY_PHASE1":211,"PHASE1":213,"PHASE2":215,"PHASE3":217,"PHASE4":229,"NA":231},{"trials":212,"activeCount":100},[],{"trials":214,"activeCount":100},[],{"trials":216,"activeCount":100},[],{"trials":218,"activeCount":96,"soonestReadout":223},[219],{"nctId":220,"briefTitle":221,"status":169,"phases":222,"primaryCompletion":223,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":228},"NCT07577804","A Study to Evaluate the Efficacy and Safety of CHF10196 Tablets (Florensocatib) Compared With Placebo in Male and Female Participants 12 to 85 Years of Age With Bronchiectasis",[91],"2030-04","2026-11",1808,[227],"Bronchiectasis",[209],{"trials":230,"activeCount":100},[],{"trials":232,"activeCount":100},[],{"intervention":46,"totalTrials":234,"cells":235},2,{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":251,"PHASE3":260,"PHASE4":262,"NA":264},{"trials":237,"activeCount":100},[],{"trials":239,"activeCount":100},[240],{"nctId":241,"briefTitle":242,"status":243,"phases":244,"primaryCompletion":245,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":250},"NCT03056326","A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects","COMPLETED",[89],"2017-07","2016-11",72,[249,32],"Non-Cystic Fibrosis Bronchiectasis",[46,46],{"trials":252,"activeCount":96,"soonestReadout":45},[253],{"nctId":43,"briefTitle":44,"status":108,"phases":254,"primaryCompletion":45,"completion":45,"start":255,"enrollment":256,"conditions":257,"interventions":258},[89,90],"2023-11-29",45,[227],[46,259],"CHF6333 Placebo",{"trials":261,"activeCount":100},[],{"trials":263,"activeCount":100},[],{"trials":265,"activeCount":100},[],{"intervention":66,"totalTrials":96,"cells":267},{"EARLY_PHASE1":268,"PHASE1":270,"PHASE2":272,"PHASE3":281,"PHASE4":283,"NA":285},{"trials":269,"activeCount":100},[],{"trials":271,"activeCount":100},[],{"trials":273,"activeCount":96,"soonestReadout":65},[274],{"nctId":63,"briefTitle":64,"status":169,"phases":275,"primaryCompletion":65,"completion":65,"start":276,"enrollment":277,"conditions":278,"interventions":280},[90],"2026-06-01",240,[279],"Idiopathic Pulmonary Fibrosis",[66,66],{"trials":282,"activeCount":100},[],{"trials":284,"activeCount":100},[],{"trials":286,"activeCount":100},[],{"intervention":259,"totalTrials":96,"cells":288},{"EARLY_PHASE1":289,"PHASE1":291,"PHASE2":293,"PHASE3":299,"PHASE4":301,"NA":303},{"trials":290,"activeCount":100},[],{"trials":292,"activeCount":100},[],{"trials":294,"activeCount":96,"soonestReadout":45},[295],{"nctId":43,"briefTitle":44,"status":108,"phases":296,"primaryCompletion":45,"completion":45,"start":255,"enrollment":256,"conditions":297,"interventions":298},[89,90],[227],[46,259],{"trials":300,"activeCount":100},[],{"trials":302,"activeCount":100},[],{"trials":304,"activeCount":100},[],{"intervention":56,"totalTrials":96,"cells":306},{"EARLY_PHASE1":307,"PHASE1":309,"PHASE2":311,"PHASE3":321,"PHASE4":323,"NA":325},{"trials":308,"activeCount":100},[],{"trials":310,"activeCount":100},[],{"trials":312,"activeCount":96,"soonestReadout":55},[313],{"nctId":53,"briefTitle":54,"status":108,"phases":314,"primaryCompletion":55,"completion":55,"start":315,"enrollment":316,"conditions":317,"interventions":318},[90],"2025-12-17",780,[15],[56,319,320],"CHF5993 pMDI with HFA-134a","CHF718 pMDI with HFA-134a",{"trials":322,"activeCount":100},[],{"trials":324,"activeCount":100},[],{"trials":326,"activeCount":100},[],{"intervention":319,"totalTrials":96,"cells":328},{"EARLY_PHASE1":329,"PHASE1":331,"PHASE2":333,"PHASE3":339,"PHASE4":341,"NA":343},{"trials":330,"activeCount":100},[],{"trials":332,"activeCount":100},[],{"trials":334,"activeCount":96,"soonestReadout":55},[335],{"nctId":53,"briefTitle":54,"status":108,"phases":336,"primaryCompletion":55,"completion":55,"start":315,"enrollment":316,"conditions":337,"interventions":338},[90],[15],[56,319,320],{"trials":340,"activeCount":100},[],{"trials":342,"activeCount":100},[],{"trials":344,"activeCount":100},[],{"intervention":320,"totalTrials":96,"cells":346},{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":351,"PHASE3":357,"PHASE4":359,"NA":361},{"trials":348,"activeCount":100},[],{"trials":350,"activeCount":100},[],{"trials":352,"activeCount":96,"soonestReadout":55},[353],{"nctId":53,"briefTitle":54,"status":108,"phases":354,"primaryCompletion":55,"completion":55,"start":315,"enrollment":316,"conditions":355,"interventions":356},[90],[15],[56,319,320],{"trials":358,"activeCount":100},[],{"trials":360,"activeCount":100},[],{"trials":362,"activeCount":100},[],{"intervention":51,"totalTrials":96,"cells":364},{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":377,"PHASE3":379,"PHASE4":381,"NA":383},{"trials":366,"activeCount":100},[],{"trials":368,"activeCount":96,"soonestReadout":50},[369],{"nctId":48,"briefTitle":49,"status":108,"phases":370,"primaryCompletion":50,"completion":50,"start":371,"enrollment":372,"conditions":373,"interventions":375},[89],"2025-09-15",68,[374],"Healthy Volunteers",[51,376],"CHF6467 Part 2",{"trials":378,"activeCount":100},[],{"trials":380,"activeCount":100},[],{"trials":382,"activeCount":100},[],{"trials":384,"activeCount":100},[],{"intervention":376,"totalTrials":96,"cells":386},{"EARLY_PHASE1":387,"PHASE1":389,"PHASE2":395,"PHASE3":397,"PHASE4":399,"NA":401},{"trials":388,"activeCount":100},[],{"trials":390,"activeCount":96,"soonestReadout":50},[391],{"nctId":48,"briefTitle":49,"status":108,"phases":392,"primaryCompletion":50,"completion":50,"start":371,"enrollment":372,"conditions":393,"interventions":394},[89],[374],[51,376],{"trials":396,"activeCount":100},[],{"trials":398,"activeCount":100},[],{"trials":400,"activeCount":100},[],{"trials":402,"activeCount":100},[],{"intervention":81,"totalTrials":35,"cells":404},{"EARLY_PHASE1":405,"PHASE1":407,"PHASE2":409,"PHASE3":420,"PHASE4":432,"NA":434},{"trials":406,"activeCount":100},[],{"trials":408,"activeCount":100},[],{"trials":410,"activeCount":100},[411],{"nctId":412,"briefTitle":413,"status":243,"phases":414,"primaryCompletion":415,"completion":415,"start":416,"enrollment":417,"conditions":418,"interventions":419},"NCT02998879","Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis",[90],"2020-07","2016-12",5,[29],[81],{"trials":421,"activeCount":100},[422],{"nctId":423,"briefTitle":424,"status":425,"phases":426,"primaryCompletion":427,"completion":428,"start":429,"enrollment":100,"conditions":430,"interventions":431},"NCT04031066","Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis","WITHDRAWN",[91],"2021-10-27","2021-12-29","2021-01-11",[29],[81],{"trials":433,"activeCount":100},[],{"trials":435,"activeCount":96,"soonestReadout":80},[436,443],{"nctId":437,"briefTitle":438,"status":439,"phases":440,"conditions":441,"interventions":442},"NCT04959240","Expanded Access to Velmanase Alfa","AVAILABLE",[],[29],[81],{"nctId":78,"briefTitle":79,"status":108,"phases":444,"primaryCompletion":80,"completion":80,"start":445,"enrollment":417,"conditions":446,"interventions":447},[],"2025-02-19",[29],[81],{"intervention":86,"totalTrials":96,"cells":449},{"EARLY_PHASE1":450,"PHASE1":452,"PHASE2":454,"PHASE3":456,"PHASE4":458,"NA":460},{"trials":451,"activeCount":100},[],{"trials":453,"activeCount":100},[],{"trials":455,"activeCount":100},[],{"trials":457,"activeCount":100},[],{"trials":459,"activeCount":100},[],{"trials":461,"activeCount":96,"soonestReadout":85},[462],{"nctId":83,"briefTitle":84,"status":108,"phases":463,"primaryCompletion":85,"completion":85,"start":464,"enrollment":465,"conditions":466,"interventions":467},[],"2024-11-06",100,[24],[86],{"intervention":469,"totalTrials":234,"cells":470},"CHF5993",{"EARLY_PHASE1":471,"PHASE1":473,"PHASE2":487,"PHASE3":489,"PHASE4":491,"NA":503},{"trials":472,"activeCount":100},[],{"trials":474,"activeCount":100},[475],{"nctId":476,"briefTitle":477,"status":243,"phases":478,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":482,"interventions":483},"NCT05830071","A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)",[89],"2023-10-13","2023-03-29",95,[15,27],[469,484,485,486],"CHF5259","Moxifloxacin 400mg","CHF5993 Placebo",{"trials":488,"activeCount":100},[],{"trials":490,"activeCount":100},[],{"trials":492,"activeCount":100},[493],{"nctId":494,"briefTitle":495,"status":243,"phases":496,"primaryCompletion":497,"completion":497,"start":498,"enrollment":499,"conditions":500,"interventions":501},"NCT05097014","CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD",[92],"2023-02-24","2021-10-28",106,[18],[469,502],"CHF1535",{"trials":504,"activeCount":100},[],{"intervention":502,"totalTrials":234,"cells":506},{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":513,"PHASE4":526,"NA":532},{"trials":508,"activeCount":100},[],{"trials":510,"activeCount":100},[],{"trials":512,"activeCount":100},[],{"trials":514,"activeCount":100},[515],{"nctId":516,"briefTitle":517,"status":243,"phases":518,"primaryCompletion":519,"completion":520,"start":521,"enrollment":522,"conditions":523,"interventions":524},"NCT00929851","BDP\u002FFF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)",[91],"2012-03","2012-07","2009-10",1199,[34],[502,525],"Formoterol fumarate",{"trials":527,"activeCount":100},[528],{"nctId":494,"briefTitle":495,"status":243,"phases":529,"primaryCompletion":497,"completion":497,"start":498,"enrollment":499,"conditions":530,"interventions":531},[92],[18],[469,502],{"trials":533,"activeCount":100},[],{"intervention":535,"totalTrials":234,"cells":536},"Seretide",{"EARLY_PHASE1":537,"PHASE1":539,"PHASE2":541,"PHASE3":554,"PHASE4":556,"NA":570},{"trials":538,"activeCount":100},[],{"trials":540,"activeCount":100},[],{"trials":542,"activeCount":100},[543],{"nctId":544,"briefTitle":545,"status":243,"phases":546,"primaryCompletion":547,"completion":547,"start":548,"enrollment":549,"conditions":550,"interventions":551},"NCT01070524","Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma",[90],"2010-07","2010-01",113,[15],[552,553,535],"CHF 5188 pMDI","Budesonide extrafine pMDI",{"trials":555,"activeCount":100},[],{"trials":557,"activeCount":100},[558],{"nctId":559,"briefTitle":560,"status":243,"phases":561,"primaryCompletion":562,"completion":563,"start":564,"enrollment":565,"conditions":566,"interventions":568},"NCT00901368","FACTO Study (Foster® As Complete Treatment Option)",[92],"2010-09","2010-12","2009-05",431,[567],"Asthmatic Patients",[569,535],"FOSTER",{"trials":571,"activeCount":100},[],{"intervention":573,"totalTrials":234,"cells":574},"ENVARSUS®",{"EARLY_PHASE1":575,"PHASE1":577,"PHASE2":579,"PHASE3":581,"PHASE4":583,"NA":607},{"trials":576,"activeCount":100},[],{"trials":578,"activeCount":100},[],{"trials":580,"activeCount":100},[],{"trials":582,"activeCount":100},[],{"trials":584,"activeCount":100},[585,597],{"nctId":586,"briefTitle":587,"status":243,"phases":588,"primaryCompletion":589,"completion":589,"start":590,"enrollment":591,"conditions":592,"interventions":594},"NCT02432833","Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients",[92],"2017-01-24","2015-05",428,[593],"End Stage Renal Disease",[573,595,596],"PROGRAF®","ADVAGRAF®",{"nctId":598,"briefTitle":599,"status":243,"phases":600,"primaryCompletion":601,"completion":601,"start":602,"enrollment":603,"conditions":604,"interventions":606},"NCT02500212","Pharmacokinetic Study of ENVARSUS in Adult De-novo Kidney Transplant Patients",[92],"2016-06","2015-07",75,[605],"Organ or Tissue Transplant; Complications",[573,596],{"trials":608,"activeCount":100},[],{"intervention":596,"totalTrials":234,"cells":610},{"EARLY_PHASE1":611,"PHASE1":613,"PHASE2":615,"PHASE3":617,"PHASE4":619,"NA":629},{"trials":612,"activeCount":100},[],{"trials":614,"activeCount":100},[],{"trials":616,"activeCount":100},[],{"trials":618,"activeCount":100},[],{"trials":620,"activeCount":100},[621,625],{"nctId":586,"briefTitle":587,"status":243,"phases":622,"primaryCompletion":589,"completion":589,"start":590,"enrollment":591,"conditions":623,"interventions":624},[92],[593],[573,595,596],{"nctId":598,"briefTitle":599,"status":243,"phases":626,"primaryCompletion":601,"completion":601,"start":602,"enrollment":603,"conditions":627,"interventions":628},[92],[605],[573,596],{"trials":630,"activeCount":100},[],{"intervention":632,"totalTrials":234,"cells":633},"Poractant alfa",{"EARLY_PHASE1":634,"PHASE1":636,"PHASE2":638,"PHASE3":651,"PHASE4":653,"NA":664},{"trials":635,"activeCount":100},[],{"trials":637,"activeCount":100},[],{"trials":639,"activeCount":100},[640],{"nctId":641,"briefTitle":642,"status":243,"phases":643,"primaryCompletion":644,"completion":644,"start":645,"enrollment":646,"conditions":647,"interventions":649},"NCT02452476","A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)",[90],"2018-05-24","2016-01-21",123,[648],"Respiratory Distress Syndrome, Newborn",[650,632],"CHF5633",{"trials":652,"activeCount":100},[],{"trials":654,"activeCount":100},[655],{"nctId":656,"briefTitle":657,"status":243,"phases":658,"primaryCompletion":659,"completion":659,"start":660,"enrollment":661,"conditions":662,"interventions":663},"NCT00501982","Efficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap Study",[92],"2008-05","2007-03",208,[648],[632],{"trials":665,"activeCount":100},[],{"intervention":667,"totalTrials":234,"cells":668},"Foster",{"EARLY_PHASE1":669,"PHASE1":671,"PHASE2":673,"PHASE3":675,"PHASE4":686,"NA":692},{"trials":670,"activeCount":100},[],{"trials":672,"activeCount":100},[],{"trials":674,"activeCount":100},[],{"trials":676,"activeCount":100},[677],{"nctId":678,"briefTitle":679,"status":243,"phases":680,"primaryCompletion":521,"completion":548,"start":681,"enrollment":682,"conditions":683,"interventions":684},"NCT00862394","A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma",[91],"2009-02",783,[15],[685,667,685,667],"BDP\u002FFormoterol Next DPI",{"trials":687,"activeCount":100},[688],{"nctId":559,"briefTitle":560,"status":243,"phases":689,"primaryCompletion":562,"completion":563,"start":564,"enrollment":565,"conditions":690,"interventions":691},[92],[567],[569,535],{"trials":693,"activeCount":100},[],{"intervention":695,"totalTrials":96,"cells":696},"Atimos®",{"EARLY_PHASE1":697,"PHASE1":699,"PHASE2":701,"PHASE3":703,"PHASE4":705,"NA":716},{"trials":698,"activeCount":100},[],{"trials":700,"activeCount":100},[],{"trials":702,"activeCount":100},[],{"trials":704,"activeCount":100},[],{"trials":706,"activeCount":100},[707],{"nctId":708,"briefTitle":709,"status":243,"phases":710,"primaryCompletion":711,"completion":711,"start":712,"enrollment":11,"conditions":713,"interventions":714},"NCT01344655","Study to Investigate the Effect of Formoterol vs Salmeterol on Small Airways Physiological Parameters in COPD Patients",[92],"2012-09","2011-04",[34],[695,715],"Serevent™",{"trials":717,"activeCount":100},[],{"intervention":715,"totalTrials":96,"cells":719},{"EARLY_PHASE1":720,"PHASE1":722,"PHASE2":724,"PHASE3":726,"PHASE4":728,"NA":734},{"trials":721,"activeCount":100},[],{"trials":723,"activeCount":100},[],{"trials":725,"activeCount":100},[],{"trials":727,"activeCount":100},[],{"trials":729,"activeCount":100},[730],{"nctId":708,"briefTitle":709,"status":243,"phases":731,"primaryCompletion":711,"completion":711,"start":712,"enrollment":11,"conditions":732,"interventions":733},[92],[34],[695,715],{"trials":735,"activeCount":100},[],{"intervention":737,"totalTrials":96,"cells":738},"Beclometasone Dipropionate \u002F Formoterol Fumarate \u002F Glycopyrronium 100\u002F6\u002F10 mcg",{"EARLY_PHASE1":739,"PHASE1":741,"PHASE2":743,"PHASE3":745,"PHASE4":747,"NA":759},{"trials":740,"activeCount":100},[],{"trials":742,"activeCount":100},[],{"trials":744,"activeCount":100},[],{"trials":746,"activeCount":100},[],{"trials":748,"activeCount":100},[749],{"nctId":750,"briefTitle":751,"status":425,"phases":752,"primaryCompletion":753,"completion":754,"start":755,"enrollment":100,"conditions":756,"interventions":757},"NCT04671355","TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD",[92],"2021-12-22","2022-02-18","2021-10-04",[21],[737,758],"Fluticasone Furoate \u002F Vilanterol Trifenatate 100\u002F25 mcg",{"trials":760,"activeCount":100},[],{"intervention":758,"totalTrials":96,"cells":762},{"EARLY_PHASE1":763,"PHASE1":765,"PHASE2":767,"PHASE3":769,"PHASE4":771,"NA":777},{"trials":764,"activeCount":100},[],{"trials":766,"activeCount":100},[],{"trials":768,"activeCount":100},[],{"trials":770,"activeCount":100},[],{"trials":772,"activeCount":100},[773],{"nctId":750,"briefTitle":751,"status":425,"phases":774,"primaryCompletion":753,"completion":754,"start":755,"enrollment":100,"conditions":775,"interventions":776},[92],[21],[737,758],{"trials":778,"activeCount":100},[],{"intervention":595,"totalTrials":96,"cells":780},{"EARLY_PHASE1":781,"PHASE1":783,"PHASE2":785,"PHASE3":787,"PHASE4":789,"NA":795},{"trials":782,"activeCount":100},[],{"trials":784,"activeCount":100},[],{"trials":786,"activeCount":100},[],{"trials":788,"activeCount":100},[],{"trials":790,"activeCount":100},[791],{"nctId":586,"briefTitle":587,"status":243,"phases":792,"primaryCompletion":589,"completion":589,"start":590,"enrollment":591,"conditions":793,"interventions":794},[92],[593],[573,595,596],{"trials":796,"activeCount":100},[],{"intervention":798,"totalTrials":96,"cells":799},"Administration via pressurized metered dose inhaler",{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":806,"PHASE4":808,"NA":820},{"trials":801,"activeCount":100},[],{"trials":803,"activeCount":100},[],{"trials":805,"activeCount":100},[],{"trials":807,"activeCount":100},[],{"trials":809,"activeCount":100},[810],{"nctId":811,"briefTitle":812,"status":813,"phases":814,"primaryCompletion":815,"completion":815,"start":816,"enrollment":817,"conditions":818,"interventions":819},"NCT05018598","Step-up to Medium Strength Triple Therapy vs High Strength ICS\u002FLABA in Adult Asthmatics Uncontrolled on Medium Strength ICS\u002FLABA","TERMINATED",[92],"2024-04-16","2022-02-25",320,[15],[798,798],{"trials":821,"activeCount":100},[],{"intervention":823,"totalTrials":96,"cells":824},"clevidipine",{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":831,"PHASE4":833,"NA":844},{"trials":826,"activeCount":100},[],{"trials":828,"activeCount":100},[],{"trials":830,"activeCount":100},[],{"trials":832,"activeCount":100},[],{"trials":834,"activeCount":100},[835],{"nctId":836,"briefTitle":837,"status":813,"phases":838,"primaryCompletion":839,"completion":839,"start":840,"enrollment":151,"conditions":841,"interventions":843},"NCT01938547","Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER)",[92],"2024-02-20","2014-03-17",[842],"Pediatric Perioperative Blood Pressure Management",[823],{"trials":845,"activeCount":100},[],{"intervention":847,"totalTrials":35,"cells":848},"Beclomethasone Dipropionate",{"EARLY_PHASE1":849,"PHASE1":851,"PHASE2":853,"PHASE3":866,"PHASE4":903,"NA":905},{"trials":850,"activeCount":100},[],{"trials":852,"activeCount":100},[],{"trials":854,"activeCount":100},[855],{"nctId":856,"briefTitle":857,"status":243,"phases":858,"primaryCompletion":859,"completion":860,"start":861,"enrollment":862,"conditions":863,"interventions":864},"NCT03084718","An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects",[90],"2018-11-28","2018-12-05","2017-07-28",610,[15],[865,847],"CHF 718 pMDI",{"trials":867,"activeCount":100},[868,878,890],{"nctId":869,"briefTitle":870,"status":243,"phases":871,"primaryCompletion":872,"completion":872,"start":873,"enrollment":874,"conditions":875,"interventions":876},"NCT05292586","A Study Testing the Superiority of CHF 1535 pMDI 800\u002F24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid",[91],"2024-06-24","2022-08-31",1377,[15],[877,847],"Beclomethasone Dipropionate\u002FFormoterol Fumarate",{"nctId":879,"briefTitle":880,"status":243,"phases":881,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":885,"interventions":887},"NCT04320342","A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD",[91],"2026-01-12","2022-04-28",3433,[21,886],"COPD Exacerbation",[847,888,889],"Glycopyrronium Bromide","Formoterol Fumarate",{"nctId":891,"briefTitle":892,"status":243,"phases":893,"completion":894,"start":895,"enrollment":896,"conditions":897,"interventions":899},"NCT00497523","Efficacy and Safety of Nebulised Beclomethasone Dipropionate Plus as Needed Salbutamol vs as Needed Salbutamol or as Needed Salbutamol\u002FBeclomethasone Fixed Combination in Young Children With Asthma Symptoms",[91],"2007-01","2006-03",283,[898],"Bronchial Asthma",[900,901,902],"Beclomethasone dipropionate","Beclomethasone dipropionate\u002FSalbutamol combination","Salbutamol",{"trials":904,"activeCount":100},[],{"trials":906,"activeCount":100},[],{"intervention":902,"totalTrials":908,"cells":909},3,{"EARLY_PHASE1":910,"PHASE1":912,"PHASE2":914,"PHASE3":916,"PHASE4":944,"NA":946},{"trials":911,"activeCount":100},[],{"trials":913,"activeCount":100},[],{"trials":915,"activeCount":100},[],{"trials":917,"activeCount":100},[918,930,934],{"nctId":919,"briefTitle":920,"status":243,"phases":921,"completion":922,"start":923,"enrollment":924,"conditions":925,"interventions":926},"NCT00382889","As Needed Beclomethasone\u002FSalbutamol Combination in Single Inhaler for Mild Persistent Asthma",[91],"2004-09","2002-08",480,[15],[927,928,929],"beclomethasone\u002Fsalbutamol combination","beclomethasone","salbutamol",{"nctId":891,"briefTitle":892,"status":243,"phases":931,"completion":894,"start":895,"enrollment":896,"conditions":932,"interventions":933},[91],[898],[900,901,902],{"nctId":935,"briefTitle":936,"status":243,"phases":937,"primaryCompletion":938,"completion":938,"start":939,"enrollment":940,"conditions":941,"interventions":942},"NCT00861926","Study on Foster Efficacy Maintenance and Reliever vs Foster Maintenance + Salbutamol Reliever in Asthmatics (MART2)",[91],"2010-12-07","2009-03-20",1714,[15],[902,943],"Beclomethasone dipropionate + Formoterol",{"trials":945,"activeCount":100},[],{"trials":947,"activeCount":100},[],{"intervention":949,"totalTrials":908,"cells":950},"Beclometasone\u002FFormoterol\u002FGlycopyrrolate",{"EARLY_PHASE1":951,"PHASE1":953,"PHASE2":974,"PHASE3":976,"PHASE4":988,"NA":990},{"trials":952,"activeCount":100},[],{"trials":954,"activeCount":100},[955,965],{"nctId":956,"briefTitle":957,"status":243,"phases":958,"primaryCompletion":959,"completion":959,"start":960,"enrollment":961,"conditions":962,"interventions":963},"NCT02119234","Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients",[89],"2015-02","2014-03",36,[21],[964],"Beclometasone\u002Fformoterol\u002Fglycopyrrolate",{"nctId":966,"briefTitle":967,"status":243,"phases":968,"primaryCompletion":969,"completion":969,"start":970,"enrollment":971,"conditions":972,"interventions":973},"NCT02040597","A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment.",[89],"2015-04","2014-01",42,[27],[949],{"trials":975,"activeCount":100},[],{"trials":977,"activeCount":100},[978],{"nctId":979,"briefTitle":980,"status":243,"phases":981,"primaryCompletion":982,"completion":983,"start":960,"enrollment":984,"conditions":985,"interventions":986},"NCT01917331","Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD",[91],"2016-01","2016-03",1368,[18],[949,987],"Beclometasone\u002FFormoterol",{"trials":989,"activeCount":100},[],{"trials":991,"activeCount":100},[],{"intervention":993,"totalTrials":908,"cells":994},"Formoterol",{"EARLY_PHASE1":995,"PHASE1":997,"PHASE2":1010,"PHASE3":1020,"PHASE4":1032,"NA":1034},{"trials":996,"activeCount":100},[],{"trials":998,"activeCount":100},[999],{"nctId":1000,"briefTitle":1001,"status":243,"phases":1002,"primaryCompletion":1003,"completion":1003,"start":1004,"enrollment":1005,"conditions":1006,"interventions":1007},"NCT01398111","Pharmacokinetic Interaction Study of Glycopyrrolate and Formoterol in Healthy Volunteers",[89],"2011-08","2011-05",44,[21],[1008,1009,993],"Glycopyrrolate + Formoterol","Glycopyrrolate",{"trials":1011,"activeCount":100},[1012],{"nctId":1013,"briefTitle":1014,"status":243,"phases":1015,"primaryCompletion":1016,"completion":1016,"start":922,"enrollment":1017,"conditions":1018,"interventions":1019},"NCT00742248","Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)",[90],"2005-05",54,[18],[993,993],{"trials":1021,"activeCount":100},[1022],{"nctId":1023,"briefTitle":1024,"status":243,"phases":1025,"primaryCompletion":1026,"completion":1027,"start":1028,"enrollment":1029,"conditions":1030,"interventions":1031},"NCT00972140","Formoterol-HFA 3-month Study in Chronic Obstructive Pulmonary Disease (COPD) Patients",[91],"2006-04","2006-10","2005-08",457,[18],[993,993],{"trials":1033,"activeCount":100},[],{"trials":1035,"activeCount":100},[],{"intervention":1037,"totalTrials":234,"cells":1038},"BDP\u002Fformoterol NEXT DPI",{"EARLY_PHASE1":1039,"PHASE1":1041,"PHASE2":1043,"PHASE3":1054,"PHASE4":1060,"NA":1062},{"trials":1040,"activeCount":100},[],{"trials":1042,"activeCount":100},[],{"trials":1044,"activeCount":100},[1045],{"nctId":1046,"briefTitle":1047,"status":243,"phases":1048,"primaryCompletion":562,"completion":1049,"start":1050,"enrollment":1051,"conditions":1052,"interventions":1053},"NCT01176747","Lung Deposition of the BDP\u002FFormoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD Patients",[89,90],"2010-10","2010-08",28,[34,15],[1037],{"trials":1055,"activeCount":100},[1056],{"nctId":678,"briefTitle":679,"status":243,"phases":1057,"primaryCompletion":521,"completion":548,"start":681,"enrollment":682,"conditions":1058,"interventions":1059},[91],[15],[685,667,685,667],{"trials":1061,"activeCount":100},[],{"trials":1063,"activeCount":100},[],{"intervention":928,"totalTrials":234,"cells":1065},{"EARLY_PHASE1":1066,"PHASE1":1068,"PHASE2":1070,"PHASE3":1072,"PHASE4":1088,"NA":1090},{"trials":1067,"activeCount":100},[],{"trials":1069,"activeCount":100},[],{"trials":1071,"activeCount":100},[],{"trials":1073,"activeCount":100},[1074,1078],{"nctId":919,"briefTitle":920,"status":243,"phases":1075,"completion":922,"start":923,"enrollment":924,"conditions":1076,"interventions":1077},[91],[15],[927,928,929],{"nctId":1079,"briefTitle":1080,"status":243,"phases":1081,"primaryCompletion":711,"completion":711,"start":1082,"enrollment":1083,"conditions":1084,"interventions":1085},"NCT01475032","Efficacy Study of the Product \"CHF 1535\" Versus Beclomethasone (BDP) and Free Combo in Asthmatic Children",[91],"2011-09",638,[15],[1086,1087,1087],"CHF 1535","Beclomethasone",{"trials":1089,"activeCount":100},[],{"trials":1091,"activeCount":100},[],{"intervention":1093,"totalTrials":234,"cells":1094},"CHF 5993 100\u002F6\u002F12.5 µg",{"EARLY_PHASE1":1095,"PHASE1":1097,"PHASE2":1099,"PHASE3":1101,"PHASE4":1124,"NA":1126},{"trials":1096,"activeCount":100},[],{"trials":1098,"activeCount":100},[],{"trials":1100,"activeCount":100},[],{"trials":1102,"activeCount":100},[1103,1114],{"nctId":1104,"briefTitle":1105,"status":243,"phases":1106,"primaryCompletion":1107,"completion":1107,"start":1108,"enrollment":1109,"conditions":1110,"interventions":1112},"NCT03197818","Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI)",[91],"2020-05-26","2016-12-14",708,[1111],"COPD (Chronic Obstructive Pulmonary Disease)",[1093,1113],"160 µg budesonide + 4.5 µg formoterol fumarate",{"nctId":1115,"briefTitle":1116,"status":243,"phases":1117,"primaryCompletion":1118,"completion":1118,"start":1119,"enrollment":1120,"conditions":1121,"interventions":1122},"NCT02676076","TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA",[91],"2018-05-17","2016-02-17",1153,[15],[1093,1123],"CHF 1535 100\u002F6 µg",{"trials":1125,"activeCount":100},[],{"trials":1127,"activeCount":100},[],{"intervention":1129,"totalTrials":234,"cells":1130},"Beclometasone dipropionate\u002FFormoterol Fumarate\u002FGlycopyrronium",{"EARLY_PHASE1":1131,"PHASE1":1133,"PHASE2":1144,"PHASE3":1146,"PHASE4":1157,"NA":1159},{"trials":1132,"activeCount":100},[],{"trials":1134,"activeCount":100},[1135],{"nctId":1136,"briefTitle":1137,"status":243,"phases":1138,"primaryCompletion":1139,"completion":1140,"start":1141,"enrollment":1051,"conditions":1142,"interventions":1143},"NCT02975843","Lung Deposition of Beclometasone Dipropionate\u002FFormoterol Fumarate\u002FGlycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients",[89],"2017-03-21","2017-04-11","2016-11-21",[18,15],[1129],{"trials":1145,"activeCount":100},[],{"trials":1147,"activeCount":100},[1148],{"nctId":1149,"briefTitle":1150,"status":243,"phases":1151,"primaryCompletion":1152,"completion":1152,"start":1153,"enrollment":1154,"conditions":1155,"interventions":1156},"NCT03268226","Functional Respiratory Imaging Study (FRI)",[91],"2019-01-30","2017-11-20",20,[18],[1129],{"trials":1158,"activeCount":100},[],{"trials":1160,"activeCount":100},[],{"intervention":889,"totalTrials":234,"cells":1162},{"EARLY_PHASE1":1163,"PHASE1":1165,"PHASE2":1167,"PHASE3":1169,"PHASE4":1179,"NA":1181},{"trials":1164,"activeCount":100},[],{"trials":1166,"activeCount":100},[],{"trials":1168,"activeCount":100},[],{"trials":1170,"activeCount":100},[1171,1175],{"nctId":879,"briefTitle":880,"status":243,"phases":1172,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":1173,"interventions":1174},[91],[21,886],[847,888,889],{"nctId":516,"briefTitle":517,"status":243,"phases":1176,"primaryCompletion":519,"completion":520,"start":521,"enrollment":522,"conditions":1177,"interventions":1178},[91],[34],[502,525],{"trials":1180,"activeCount":100},[],{"trials":1182,"activeCount":100},[],{"intervention":1184,"totalTrials":234,"cells":1185},"BDP\u002FFF\u002FGB",{"EARLY_PHASE1":1186,"PHASE1":1188,"PHASE2":1190,"PHASE3":1192,"PHASE4":1212,"NA":1214},{"trials":1187,"activeCount":100},[],{"trials":1189,"activeCount":100},[],{"trials":1191,"activeCount":100},[],{"trials":1193,"activeCount":100},[1194,1203],{"nctId":1195,"briefTitle":1196,"status":243,"phases":1197,"primaryCompletion":1198,"completion":1198,"start":590,"enrollment":1199,"conditions":1200,"interventions":1201},"NCT02467452","Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)\u002FVilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)",[91],"2017-01",1479,[18],[1184,1202],"FlF\u002FVI + Tiotropium",{"nctId":1204,"briefTitle":1205,"status":243,"phases":1206,"primaryCompletion":983,"completion":983,"start":970,"enrollment":1207,"conditions":1208,"interventions":1209},"NCT01911364","Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease",[91],3686,[18],[1184,1210,1211],"Tiotropium","BDP\u002FFF + Tiotropium",{"trials":1213,"activeCount":100},[],{"trials":1215,"activeCount":100},[],{"intervention":1210,"totalTrials":234,"cells":1217},{"EARLY_PHASE1":1218,"PHASE1":1220,"PHASE2":1222,"PHASE3":1232,"PHASE4":1238,"NA":1240},{"trials":1219,"activeCount":100},[],{"trials":1221,"activeCount":100},[],{"trials":1223,"activeCount":100},[1224],{"nctId":1225,"briefTitle":1226,"status":243,"phases":1227,"primaryCompletion":1228,"completion":1003,"start":1050,"enrollment":1229,"conditions":1230,"interventions":1231},"NCT01176903","Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration",[89,90],"2010-11",65,[27],[1009,1210],{"trials":1233,"activeCount":100},[1234],{"nctId":1204,"briefTitle":1205,"status":243,"phases":1235,"primaryCompletion":983,"completion":983,"start":970,"enrollment":1207,"conditions":1236,"interventions":1237},[91],[18],[1184,1210,1211],{"trials":1239,"activeCount":100},[],{"trials":1241,"activeCount":100},[],{"intervention":1243,"totalTrials":234,"cells":1244},"beclomethasone dipropionate plus formoterol fumarate combination",{"EARLY_PHASE1":1245,"PHASE1":1247,"PHASE2":1249,"PHASE3":1251,"PHASE4":1272,"NA":1274},{"trials":1246,"activeCount":100},[],{"trials":1248,"activeCount":100},[],{"trials":1250,"activeCount":100},[],{"trials":1252,"activeCount":100},[1253,1263],{"nctId":1254,"briefTitle":1255,"status":243,"phases":1256,"completion":1257,"start":1258,"enrollment":1259,"conditions":1260,"interventions":1261},"NCT00394368","EFFICACY AND TOLERABILITY OF BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI",[91],"2005-09","2004-11",180,[898],[1243,1262],"fluticasone propionate plus salmeterol xinafoate combination",{"nctId":1264,"briefTitle":1265,"status":243,"phases":1266,"primaryCompletion":1028,"completion":1267,"start":922,"enrollment":1268,"conditions":1269,"interventions":1270},"NCT00413387","Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)",[91],"2005-10",219,[898],[1243,1271],"budesonide plus formoterol combination",{"trials":1273,"activeCount":100},[],{"trials":1275,"activeCount":100},[],{"intervention":1277,"totalTrials":234,"cells":1278},"Treatment A",{"EARLY_PHASE1":1279,"PHASE1":1281,"PHASE2":1297,"PHASE3":1299,"PHASE4":1312,"NA":1314},{"trials":1280,"activeCount":100},[],{"trials":1282,"activeCount":100},[1283],{"nctId":1284,"briefTitle":1285,"status":243,"phases":1286,"primaryCompletion":1287,"completion":1287,"start":1288,"enrollment":1289,"conditions":1290,"interventions":1291},"NCT03942666","PK Linearity and Steady State PK of CHF 6532 in Healthy Subjects",[89],"2019-11-22","2019-05-10",30,[15],[1277,1292,1293,1294,1295,1296],"Treatment B","Treatment C","Treatment D","Treatment E","Treatment F",{"trials":1298,"activeCount":100},[],{"trials":1300,"activeCount":100},[1301],{"nctId":1302,"briefTitle":1303,"status":813,"phases":1304,"primaryCompletion":1305,"completion":1306,"start":1307,"enrollment":1308,"conditions":1309,"interventions":1311},"NCT04049175","Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma",[91],"2020-10-19","2021-02-01","2019-08-28",810,[1310],"Asthma; Eosinophilic",[1277,1292,1293,1294],{"trials":1313,"activeCount":100},[],{"trials":1315,"activeCount":100},[],{"intervention":1292,"totalTrials":234,"cells":1317},{"EARLY_PHASE1":1318,"PHASE1":1320,"PHASE2":1326,"PHASE3":1328,"PHASE4":1334,"NA":1336},{"trials":1319,"activeCount":100},[],{"trials":1321,"activeCount":100},[1322],{"nctId":1284,"briefTitle":1285,"status":243,"phases":1323,"primaryCompletion":1287,"completion":1287,"start":1288,"enrollment":1289,"conditions":1324,"interventions":1325},[89],[15],[1277,1292,1293,1294,1295,1296],{"trials":1327,"activeCount":100},[],{"trials":1329,"activeCount":100},[1330],{"nctId":1302,"briefTitle":1303,"status":813,"phases":1331,"primaryCompletion":1305,"completion":1306,"start":1307,"enrollment":1308,"conditions":1332,"interventions":1333},[91],[1310],[1277,1292,1293,1294],{"trials":1335,"activeCount":100},[],{"trials":1337,"activeCount":100},[],{"intervention":1293,"totalTrials":234,"cells":1339},{"EARLY_PHASE1":1340,"PHASE1":1342,"PHASE2":1348,"PHASE3":1350,"PHASE4":1356,"NA":1358},{"trials":1341,"activeCount":100},[],{"trials":1343,"activeCount":100},[1344],{"nctId":1284,"briefTitle":1285,"status":243,"phases":1345,"primaryCompletion":1287,"completion":1287,"start":1288,"enrollment":1289,"conditions":1346,"interventions":1347},[89],[15],[1277,1292,1293,1294,1295,1296],{"trials":1349,"activeCount":100},[],{"trials":1351,"activeCount":100},[1352],{"nctId":1302,"briefTitle":1303,"status":813,"phases":1353,"primaryCompletion":1305,"completion":1306,"start":1307,"enrollment":1308,"conditions":1354,"interventions":1355},[91],[1310],[1277,1292,1293,1294],{"trials":1357,"activeCount":100},[],{"trials":1359,"activeCount":100},[],{"intervention":1294,"totalTrials":234,"cells":1361},{"EARLY_PHASE1":1362,"PHASE1":1364,"PHASE2":1370,"PHASE3":1372,"PHASE4":1378,"NA":1380},{"trials":1363,"activeCount":100},[],{"trials":1365,"activeCount":100},[1366],{"nctId":1284,"briefTitle":1285,"status":243,"phases":1367,"primaryCompletion":1287,"completion":1287,"start":1288,"enrollment":1289,"conditions":1368,"interventions":1369},[89],[15],[1277,1292,1293,1294,1295,1296],{"trials":1371,"activeCount":100},[],{"trials":1373,"activeCount":100},[1374],{"nctId":1302,"briefTitle":1303,"status":813,"phases":1375,"primaryCompletion":1305,"completion":1306,"start":1307,"enrollment":1308,"conditions":1376,"interventions":1377},[91],[1310],[1277,1292,1293,1294],{"trials":1379,"activeCount":100},[],{"trials":1381,"activeCount":100},[],{"intervention":1383,"totalTrials":234,"cells":1384},"Lamazym",{"EARLY_PHASE1":1385,"PHASE1":1387,"PHASE2":1389,"PHASE3":1391,"PHASE4":1408,"NA":1410},{"trials":1386,"activeCount":100},[],{"trials":1388,"activeCount":100},[],{"trials":1390,"activeCount":100},[],{"trials":1392,"activeCount":100},[1393,1401],{"nctId":1394,"briefTitle":1395,"status":243,"phases":1396,"primaryCompletion":1397,"completion":1397,"start":1398,"enrollment":25,"conditions":1399,"interventions":1400},"NCT01908725","Lamazym Aftercare Study",[91],"2022-09-30","2013-06",[29],[1383],{"nctId":1402,"briefTitle":1403,"status":243,"phases":1404,"primaryCompletion":1397,"completion":1397,"start":1405,"enrollment":8,"conditions":1406,"interventions":1407},"NCT01908712","Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients",[91],"2013-08",[29],[1383],{"trials":1409,"activeCount":100},[],{"trials":1411,"activeCount":100},[],{"intervention":1413,"totalTrials":234,"cells":1414},"CUSA-081",{"EARLY_PHASE1":1415,"PHASE1":1417,"PHASE2":1419,"PHASE3":1421,"PHASE4":1445,"NA":1447},{"trials":1416,"activeCount":100},[],{"trials":1418,"activeCount":100},[],{"trials":1420,"activeCount":100},[],{"trials":1422,"activeCount":100},[1423,1432],{"nctId":1424,"briefTitle":1425,"status":425,"phases":1426,"primaryCompletion":1427,"completion":1427,"start":1428,"enrollment":100,"conditions":1429,"interventions":1431},"NCT03992443","Efficacy and Safety of CUSA-081 in the Restoration of Dysfunctional Central Venous Access Device (CVAD) Functionality",[91],"2022-03-18","2022-02-28",[1430],"Restoration of Function to CVADs",[1413],{"nctId":1433,"briefTitle":1434,"status":813,"phases":1435,"primaryCompletion":1436,"completion":1437,"start":1438,"enrollment":1439,"conditions":1440,"interventions":1443},"NCT03594175","Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality",[91],"2023-06-08","2023-07-10","2020-02-12",462,[1441,1442],"Catheter Occlusion","Thrombosis",[1413,1444],"Alteplase",{"trials":1446,"activeCount":100},[],{"trials":1448,"activeCount":100},[],{"intervention":1450,"totalTrials":234,"cells":1451},"Roflumilast",{"EARLY_PHASE1":1452,"PHASE1":1454,"PHASE2":1456,"PHASE3":1468,"PHASE4":1481,"NA":1483},{"trials":1453,"activeCount":100},[],{"trials":1455,"activeCount":100},[],{"trials":1457,"activeCount":100},[1458],{"nctId":1459,"briefTitle":1460,"status":243,"phases":1461,"primaryCompletion":1462,"completion":1462,"start":1463,"enrollment":1464,"conditions":1465,"interventions":1466},"NCT01730404","Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients",[90],"2013-10","2012-10",55,[21],[1467,1450],"CHF6001 DPI",{"trials":1469,"activeCount":100},[1470],{"nctId":1471,"briefTitle":1472,"status":813,"phases":1473,"primaryCompletion":1474,"completion":1474,"start":1475,"enrollment":1476,"conditions":1477,"interventions":1478},"NCT04636814","A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)",[91],"2025-12-23","2021-07-12",3973,[18],[1479,1480,1450],"CHF6001 1600µg","CHF6001 3200µg",{"trials":1482,"activeCount":100},[],{"trials":1484,"activeCount":100},[],{"intervention":1486,"totalTrials":234,"cells":1487},"Foster® 100\u002F6 µg\u002Funit dose",{"EARLY_PHASE1":1488,"PHASE1":1490,"PHASE2":1492,"PHASE3":1494,"PHASE4":1512,"NA":1514},{"trials":1489,"activeCount":100},[],{"trials":1491,"activeCount":100},[],{"trials":1493,"activeCount":100},[],{"trials":1495,"activeCount":100},[1496,1504],{"nctId":1497,"briefTitle":1498,"status":813,"phases":1499,"primaryCompletion":1500,"completion":1500,"start":1082,"enrollment":549,"conditions":1501,"interventions":1502},"NCT01351792","A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR)",[91],"2012-11",[18],[1486,1503],"Symbicort® Turbohaler® 200\u002F6 μg\u002Factuation",{"nctId":1505,"briefTitle":1506,"status":243,"phases":1507,"primaryCompletion":519,"completion":519,"start":712,"enrollment":1508,"conditions":1509,"interventions":1510},"NCT01245569","A Study in Patients With Chronic Obstructive Pulmonary Disease",[91],373,[18],[1486,1511],"Seretide Accuhaler® 500\u002F50 µg\u002Factuation",{"trials":1513,"activeCount":100},[],{"trials":1515,"activeCount":100},[],{"intervention":1517,"totalTrials":96,"cells":1518},"Beclomethasone plus formoterol fixed combination",{"EARLY_PHASE1":1519,"PHASE1":1521,"PHASE2":1523,"PHASE3":1525,"PHASE4":1537,"NA":1539},{"trials":1520,"activeCount":100},[],{"trials":1522,"activeCount":100},[],{"trials":1524,"activeCount":100},[],{"trials":1526,"activeCount":100},[1527],{"nctId":1528,"briefTitle":1529,"status":243,"phases":1530,"primaryCompletion":1531,"completion":1531,"start":1532,"enrollment":1533,"conditions":1534,"interventions":1535},"NCT00497237","Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate Plus Formoterol vs Fluticasone Propionate Plus Salmeterol in the 6 Months Step Down Treatment of Asthma",[91],"2010-03","2007-04",382,[15],[1517,1536],"Fluticasone plus salmeterol fixed combination",{"trials":1538,"activeCount":100},[],{"trials":1540,"activeCount":100},[],{"intervention":1536,"totalTrials":96,"cells":1542},{"EARLY_PHASE1":1543,"PHASE1":1545,"PHASE2":1547,"PHASE3":1549,"PHASE4":1555,"NA":1557},{"trials":1544,"activeCount":100},[],{"trials":1546,"activeCount":100},[],{"trials":1548,"activeCount":100},[],{"trials":1550,"activeCount":100},[1551],{"nctId":1528,"briefTitle":1529,"status":243,"phases":1552,"primaryCompletion":1531,"completion":1531,"start":1532,"enrollment":1533,"conditions":1553,"interventions":1554},[91],[15],[1517,1536],{"trials":1556,"activeCount":100},[],{"trials":1558,"activeCount":100},[],{"intervention":1560,"totalTrials":96,"cells":1561},"CHF 1535 100\u002F6 NEXT DPI® 2 months",{"EARLY_PHASE1":1562,"PHASE1":1564,"PHASE2":1566,"PHASE3":1568,"PHASE4":1580,"NA":1582},{"trials":1563,"activeCount":100},[],{"trials":1565,"activeCount":100},[],{"trials":1567,"activeCount":100},[],{"trials":1569,"activeCount":100},[1570],{"nctId":1571,"briefTitle":1572,"status":243,"phases":1573,"primaryCompletion":1003,"completion":1003,"start":1574,"enrollment":1575,"conditions":1576,"interventions":1577},"NCT01345916","Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients",[91],"2011-03",932,[15],[1560,1578,1579],"CHF 1535 100\u002F6 pMDI 2 months","BDP DPI 2 months",{"trials":1581,"activeCount":100},[],{"trials":1583,"activeCount":100},[],{"intervention":1578,"totalTrials":96,"cells":1585},{"EARLY_PHASE1":1586,"PHASE1":1588,"PHASE2":1590,"PHASE3":1592,"PHASE4":1598,"NA":1600},{"trials":1587,"activeCount":100},[],{"trials":1589,"activeCount":100},[],{"trials":1591,"activeCount":100},[],{"trials":1593,"activeCount":100},[1594],{"nctId":1571,"briefTitle":1572,"status":243,"phases":1595,"primaryCompletion":1003,"completion":1003,"start":1574,"enrollment":1575,"conditions":1596,"interventions":1597},[91],[15],[1560,1578,1579],{"trials":1599,"activeCount":100},[],{"trials":1601,"activeCount":100},[],{"intervention":1579,"totalTrials":96,"cells":1603},{"EARLY_PHASE1":1604,"PHASE1":1606,"PHASE2":1608,"PHASE3":1610,"PHASE4":1616,"NA":1618},{"trials":1605,"activeCount":100},[],{"trials":1607,"activeCount":100},[],{"trials":1609,"activeCount":100},[],{"trials":1611,"activeCount":100},[1612],{"nctId":1571,"briefTitle":1572,"status":243,"phases":1613,"primaryCompletion":1003,"completion":1003,"start":1574,"enrollment":1575,"conditions":1614,"interventions":1615},[91],[15],[1560,1578,1579],{"trials":1617,"activeCount":100},[],{"trials":1619,"activeCount":100},[],{"intervention":1621,"totalTrials":96,"cells":1622},"Beclomethasone dipropionate\u002FFormoterol Fumarate\u002FGlycopyrronium",{"EARLY_PHASE1":1623,"PHASE1":1625,"PHASE2":1627,"PHASE3":1629,"PHASE4":1640,"NA":1642},{"trials":1624,"activeCount":100},[],{"trials":1626,"activeCount":100},[],{"trials":1628,"activeCount":100},[],{"trials":1630,"activeCount":100},[1631],{"nctId":1632,"briefTitle":1633,"status":243,"phases":1634,"primaryCompletion":1635,"completion":1635,"start":1636,"enrollment":1637,"conditions":1638,"interventions":1639},"NCT04876677","Functional Respiratory Imaging Study (DARWiIN)",[91],"2022-01-03","2021-05-18",25,[18],[1621],{"trials":1641,"activeCount":100},[],{"trials":1643,"activeCount":100},[],{"intervention":877,"totalTrials":96,"cells":1645},{"EARLY_PHASE1":1646,"PHASE1":1648,"PHASE2":1650,"PHASE3":1652,"PHASE4":1658,"NA":1660},{"trials":1647,"activeCount":100},[],{"trials":1649,"activeCount":100},[],{"trials":1651,"activeCount":100},[],{"trials":1653,"activeCount":100},[1654],{"nctId":869,"briefTitle":870,"status":243,"phases":1655,"primaryCompletion":872,"completion":872,"start":873,"enrollment":874,"conditions":1656,"interventions":1657},[91],[15],[877,847],{"trials":1659,"activeCount":100},[],{"trials":1661,"activeCount":100},[],{"intervention":927,"totalTrials":96,"cells":1663},{"EARLY_PHASE1":1664,"PHASE1":1666,"PHASE2":1668,"PHASE3":1670,"PHASE4":1676,"NA":1678},{"trials":1665,"activeCount":100},[],{"trials":1667,"activeCount":100},[],{"trials":1669,"activeCount":100},[],{"trials":1671,"activeCount":100},[1672],{"nctId":919,"briefTitle":920,"status":243,"phases":1673,"completion":922,"start":923,"enrollment":924,"conditions":1674,"interventions":1675},[91],[15],[927,928,929],{"trials":1677,"activeCount":100},[],{"trials":1679,"activeCount":100},[],{"intervention":1113,"totalTrials":96,"cells":1681},{"EARLY_PHASE1":1682,"PHASE1":1684,"PHASE2":1686,"PHASE3":1688,"PHASE4":1694,"NA":1696},{"trials":1683,"activeCount":100},[],{"trials":1685,"activeCount":100},[],{"trials":1687,"activeCount":100},[],{"trials":1689,"activeCount":100},[1690],{"nctId":1104,"briefTitle":1105,"status":243,"phases":1691,"primaryCompletion":1107,"completion":1107,"start":1108,"enrollment":1109,"conditions":1692,"interventions":1693},[91],[1111],[1093,1113],{"trials":1695,"activeCount":100},[],{"trials":1697,"activeCount":100},[],{"intervention":1699,"totalTrials":96,"cells":1700},"CHF 1535 50\u002F6µg",{"EARLY_PHASE1":1701,"PHASE1":1703,"PHASE2":1705,"PHASE3":1707,"PHASE4":1719,"NA":1721},{"trials":1702,"activeCount":100},[],{"trials":1704,"activeCount":100},[],{"trials":1706,"activeCount":100},[],{"trials":1708,"activeCount":100},[1709],{"nctId":1710,"briefTitle":1711,"status":243,"phases":1712,"primaryCompletion":1713,"completion":1714,"start":1082,"enrollment":247,"conditions":1715,"interventions":1717},"NCT01450774","Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children",[91],"2013-11","2014-02",[1716],"Childhood Asthma",[1699,1718],"beclomethasone dipropionate 50µg + formoterol fumarate 6µg",{"trials":1720,"activeCount":100},[],{"trials":1722,"activeCount":100},[],{"intervention":1718,"totalTrials":96,"cells":1724},{"EARLY_PHASE1":1725,"PHASE1":1727,"PHASE2":1729,"PHASE3":1731,"PHASE4":1737,"NA":1739},{"trials":1726,"activeCount":100},[],{"trials":1728,"activeCount":100},[],{"trials":1730,"activeCount":100},[],{"trials":1732,"activeCount":100},[1733],{"nctId":1710,"briefTitle":1711,"status":243,"phases":1734,"primaryCompletion":1713,"completion":1714,"start":1082,"enrollment":247,"conditions":1735,"interventions":1736},[91],[1716],[1699,1718],{"trials":1738,"activeCount":100},[],{"trials":1740,"activeCount":100},[],{"intervention":1742,"totalTrials":96,"cells":1743},"Foster® NEXThaler® 100\u002F6 µg\u002Funit dose",{"EARLY_PHASE1":1744,"PHASE1":1746,"PHASE2":1748,"PHASE3":1750,"PHASE4":1760,"NA":1762},{"trials":1745,"activeCount":100},[],{"trials":1747,"activeCount":100},[],{"trials":1749,"activeCount":100},[],{"trials":1751,"activeCount":100},[1752],{"nctId":1753,"briefTitle":1754,"status":243,"phases":1755,"primaryCompletion":1714,"completion":1714,"start":520,"enrollment":1756,"conditions":1757,"interventions":1758},"NCT01570478","A Study in Patients With Asthma",[91],108,[15],[1742,1759],"Seretide® Accuhaler® 250\u002F50 µg\u002Factuation",{"trials":1761,"activeCount":100},[],{"trials":1763,"activeCount":100},[],{"intervention":1759,"totalTrials":96,"cells":1765},{"EARLY_PHASE1":1766,"PHASE1":1768,"PHASE2":1770,"PHASE3":1772,"PHASE4":1778,"NA":1780},{"trials":1767,"activeCount":100},[],{"trials":1769,"activeCount":100},[],{"trials":1771,"activeCount":100},[],{"trials":1773,"activeCount":100},[1774],{"nctId":1753,"briefTitle":1754,"status":243,"phases":1775,"primaryCompletion":1714,"completion":1714,"start":520,"enrollment":1756,"conditions":1776,"interventions":1777},[91],[15],[1742,1759],{"trials":1779,"activeCount":100},[],{"trials":1781,"activeCount":100},[],{"intervention":888,"totalTrials":96,"cells":1783},{"EARLY_PHASE1":1784,"PHASE1":1786,"PHASE2":1788,"PHASE3":1790,"PHASE4":1796,"NA":1798},{"trials":1785,"activeCount":100},[],{"trials":1787,"activeCount":100},[],{"trials":1789,"activeCount":100},[],{"trials":1791,"activeCount":100},[1792],{"nctId":879,"briefTitle":880,"status":243,"phases":1793,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":1794,"interventions":1795},[91],[21,886],[847,888,889],{"trials":1797,"activeCount":100},[],{"trials":1799,"activeCount":100},[],{"intervention":1801,"totalTrials":96,"cells":1802},"salbutamol 100 mcg",{"EARLY_PHASE1":1803,"PHASE1":1805,"PHASE2":1807,"PHASE3":1809,"PHASE4":1821,"NA":1823},{"trials":1804,"activeCount":100},[],{"trials":1806,"activeCount":100},[],{"trials":1808,"activeCount":100},[],{"trials":1810,"activeCount":100},[1811],{"nctId":1812,"briefTitle":1813,"status":243,"phases":1814,"primaryCompletion":1815,"completion":1815,"start":1816,"enrollment":1259,"conditions":1817,"interventions":1818},"NCT00528723","Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma",[91],"2009-01","2007-11",[898],[1801,1819,1820],"BDP\u002Fsalbutamol HFA pMDI","BDP\u002Fsalbutamol CFC pMDI",{"trials":1822,"activeCount":100},[],{"trials":1824,"activeCount":100},[],{"intervention":1819,"totalTrials":96,"cells":1826},{"EARLY_PHASE1":1827,"PHASE1":1829,"PHASE2":1831,"PHASE3":1833,"PHASE4":1839,"NA":1841},{"trials":1828,"activeCount":100},[],{"trials":1830,"activeCount":100},[],{"trials":1832,"activeCount":100},[],{"trials":1834,"activeCount":100},[1835],{"nctId":1812,"briefTitle":1813,"status":243,"phases":1836,"primaryCompletion":1815,"completion":1815,"start":1816,"enrollment":1259,"conditions":1837,"interventions":1838},[91],[898],[1801,1819,1820],{"trials":1840,"activeCount":100},[],{"trials":1842,"activeCount":100},[],{"intervention":1820,"totalTrials":96,"cells":1844},{"EARLY_PHASE1":1845,"PHASE1":1847,"PHASE2":1849,"PHASE3":1851,"PHASE4":1857,"NA":1859},{"trials":1846,"activeCount":100},[],{"trials":1848,"activeCount":100},[],{"trials":1850,"activeCount":100},[],{"trials":1852,"activeCount":100},[1853],{"nctId":1812,"briefTitle":1813,"status":243,"phases":1854,"primaryCompletion":1815,"completion":1815,"start":1816,"enrollment":1259,"conditions":1855,"interventions":1856},[91],[898],[1801,1819,1820],{"trials":1858,"activeCount":100},[],{"trials":1860,"activeCount":100},[],{"intervention":1862,"totalTrials":96,"cells":1863},"beclomethasone\u002Fformoterol (100\u002F6µg) pMDI",{"EARLY_PHASE1":1864,"PHASE1":1866,"PHASE2":1868,"PHASE3":1870,"PHASE4":1883,"NA":1885},{"trials":1865,"activeCount":100},[],{"trials":1867,"activeCount":100},[],{"trials":1869,"activeCount":100},[],{"trials":1871,"activeCount":100},[1872],{"nctId":1873,"briefTitle":1874,"status":243,"phases":1875,"primaryCompletion":1876,"completion":1876,"start":1877,"enrollment":1878,"conditions":1879,"interventions":1880},"NCT00476268","Efficacy and Tolerability of Beclometasone\u002FFormoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma",[91],"2005-01","2004-02",824,[15],[1862,1881,1882],"Beclometasone dipropionate 250 µg\u002Funit dose pMDI","Formoterol powder 12 µg\u002Funit dose",{"trials":1884,"activeCount":100},[],{"trials":1886,"activeCount":100},[],{"intervention":1881,"totalTrials":96,"cells":1888},{"EARLY_PHASE1":1889,"PHASE1":1891,"PHASE2":1893,"PHASE3":1895,"PHASE4":1901,"NA":1903},{"trials":1890,"activeCount":100},[],{"trials":1892,"activeCount":100},[],{"trials":1894,"activeCount":100},[],{"trials":1896,"activeCount":100},[1897],{"nctId":1873,"briefTitle":1874,"status":243,"phases":1898,"primaryCompletion":1876,"completion":1876,"start":1877,"enrollment":1878,"conditions":1899,"interventions":1900},[91],[15],[1862,1881,1882],{"trials":1902,"activeCount":100},[],{"trials":1904,"activeCount":100},[],{"intervention":1882,"totalTrials":96,"cells":1906},{"EARLY_PHASE1":1907,"PHASE1":1909,"PHASE2":1911,"PHASE3":1913,"PHASE4":1919,"NA":1921},{"trials":1908,"activeCount":100},[],{"trials":1910,"activeCount":100},[],{"trials":1912,"activeCount":100},[],{"trials":1914,"activeCount":100},[1915],{"nctId":1873,"briefTitle":1874,"status":243,"phases":1916,"primaryCompletion":1876,"completion":1876,"start":1877,"enrollment":1878,"conditions":1917,"interventions":1918},[91],[15],[1862,1881,1882],{"trials":1920,"activeCount":100},[],{"trials":1922,"activeCount":100},[],{"intervention":1924,"totalTrials":96,"cells":1925},"CHF 5993 200\u002F6\u002F12.5 µg",{"EARLY_PHASE1":1926,"PHASE1":1928,"PHASE2":1930,"PHASE3":1932,"PHASE4":1945,"NA":1947},{"trials":1927,"activeCount":100},[],{"trials":1929,"activeCount":100},[],{"trials":1931,"activeCount":100},[],{"trials":1933,"activeCount":100},[1934],{"nctId":1935,"briefTitle":1936,"status":243,"phases":1937,"primaryCompletion":1938,"completion":1938,"start":1939,"enrollment":1940,"conditions":1941,"interventions":1942},"NCT02676089","TRIple in Asthma hiGh strenGth vErsus Ics\u002FLaba hs and tiotRopium (TRIGGER)",[91],"2018-05-28","2016-04-06",1437,[15],[1924,1943,1944],"CHF 1535 200\u002F6 µg","CHF 1535 200\u002F6 µg + Tiotropium Respimat 2.5 µg",{"trials":1946,"activeCount":100},[],{"trials":1948,"activeCount":100},[],{"intervention":1943,"totalTrials":96,"cells":1950},{"EARLY_PHASE1":1951,"PHASE1":1953,"PHASE2":1955,"PHASE3":1957,"PHASE4":1963,"NA":1965},{"trials":1952,"activeCount":100},[],{"trials":1954,"activeCount":100},[],{"trials":1956,"activeCount":100},[],{"trials":1958,"activeCount":100},[1959],{"nctId":1935,"briefTitle":1936,"status":243,"phases":1960,"primaryCompletion":1938,"completion":1938,"start":1939,"enrollment":1940,"conditions":1961,"interventions":1962},[91],[15],[1924,1943,1944],{"trials":1964,"activeCount":100},[],{"trials":1966,"activeCount":100},[],{"intervention":1944,"totalTrials":96,"cells":1968},{"EARLY_PHASE1":1969,"PHASE1":1971,"PHASE2":1973,"PHASE3":1975,"PHASE4":1981,"NA":1983},{"trials":1970,"activeCount":100},[],{"trials":1972,"activeCount":100},[],{"trials":1974,"activeCount":100},[],{"trials":1976,"activeCount":100},[1977],{"nctId":1935,"briefTitle":1936,"status":243,"phases":1978,"primaryCompletion":1938,"completion":1938,"start":1939,"enrollment":1940,"conditions":1979,"interventions":1980},[91],[15],[1924,1943,1944],{"trials":1982,"activeCount":100},[],{"trials":1984,"activeCount":100},[],{"intervention":1986,"totalTrials":96,"cells":1987},"LISA combination product",{"EARLY_PHASE1":1988,"PHASE1":1990,"PHASE2":1992,"PHASE3":1994,"PHASE4":2006,"NA":2008},{"trials":1989,"activeCount":100},[],{"trials":1991,"activeCount":100},[],{"trials":1993,"activeCount":100},[],{"trials":1995,"activeCount":100},[1996],{"nctId":1997,"briefTitle":1998,"status":813,"phases":1999,"primaryCompletion":2000,"completion":2000,"start":1636,"enrollment":2001,"conditions":2002,"interventions":2004},"NCT02772081","A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration",[91],"2022-08-13",33,[2003],"Respiratory Distress Syndrome (RDS)",[1986,2005],"Curosurf through conventional administration",{"trials":2007,"activeCount":100},[],{"trials":2009,"activeCount":100},[],{"intervention":2005,"totalTrials":96,"cells":2011},{"EARLY_PHASE1":2012,"PHASE1":2014,"PHASE2":2016,"PHASE3":2018,"PHASE4":2024,"NA":2026},{"trials":2013,"activeCount":100},[],{"trials":2015,"activeCount":100},[],{"trials":2017,"activeCount":100},[],{"trials":2019,"activeCount":100},[2020],{"nctId":1997,"briefTitle":1998,"status":813,"phases":2021,"primaryCompletion":2000,"completion":2000,"start":1636,"enrollment":2001,"conditions":2022,"interventions":2023},[91],[2003],[1986,2005],{"trials":2025,"activeCount":100},[],{"trials":2027,"activeCount":100},[],{"intervention":1202,"totalTrials":96,"cells":2029},{"EARLY_PHASE1":2030,"PHASE1":2032,"PHASE2":2034,"PHASE3":2036,"PHASE4":2042,"NA":2044},{"trials":2031,"activeCount":100},[],{"trials":2033,"activeCount":100},[],{"trials":2035,"activeCount":100},[],{"trials":2037,"activeCount":100},[2038],{"nctId":1195,"briefTitle":1196,"status":243,"phases":2039,"primaryCompletion":1198,"completion":1198,"start":590,"enrollment":1199,"conditions":2040,"interventions":2041},[91],[18],[1184,1202],{"trials":2043,"activeCount":100},[],{"trials":2045,"activeCount":100},[],{"intervention":2047,"totalTrials":96,"cells":2048},"tobramycin \u002F Bramitob",{"EARLY_PHASE1":2049,"PHASE1":2051,"PHASE2":2053,"PHASE3":2055,"PHASE4":2068,"NA":2070},{"trials":2050,"activeCount":100},[],{"trials":2052,"activeCount":100},[],{"trials":2054,"activeCount":100},[],{"trials":2056,"activeCount":100},[2057],{"nctId":2058,"briefTitle":2059,"status":243,"phases":2060,"primaryCompletion":2061,"completion":2062,"start":2063,"enrollment":2064,"conditions":2065,"interventions":2066},"NCT00885365","A Study Comparing the Efficacy and Tolerability of Tobrineb®\u002FActitob®\u002FBramitob® Versus TOBI®",[91],"2010-04","2010-05","2009-04",324,[32],[2047,2067],"tobramycin \u002F TOBI",{"trials":2069,"activeCount":100},[],{"trials":2071,"activeCount":100},[],{"intervention":2067,"totalTrials":96,"cells":2073},{"EARLY_PHASE1":2074,"PHASE1":2076,"PHASE2":2078,"PHASE3":2080,"PHASE4":2086,"NA":2088},{"trials":2075,"activeCount":100},[],{"trials":2077,"activeCount":100},[],{"trials":2079,"activeCount":100},[],{"trials":2081,"activeCount":100},[2082],{"nctId":2058,"briefTitle":2059,"status":243,"phases":2083,"primaryCompletion":2061,"completion":2062,"start":2063,"enrollment":2064,"conditions":2084,"interventions":2085},[91],[32],[2047,2067],{"trials":2087,"activeCount":100},[],{"trials":2089,"activeCount":100},[],{"intervention":2091,"totalTrials":96,"cells":2092},"combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg",{"EARLY_PHASE1":2093,"PHASE1":2095,"PHASE2":2097,"PHASE3":2099,"PHASE4":2110,"NA":2112},{"trials":2094,"activeCount":100},[],{"trials":2096,"activeCount":100},[],{"trials":2098,"activeCount":100},[],{"trials":2100,"activeCount":100},[2101],{"nctId":2102,"briefTitle":1711,"status":425,"phases":2103,"primaryCompletion":2104,"completion":2105,"start":1714,"enrollment":100,"conditions":2106,"interventions":2108},"NCT01658891",[91],"2015-11","2016-02",[2107],"Asthma in Children",[2091,2109],"free combination of beclomethasone dipropionate 100µg + Formoterol fumarate 6µg",{"trials":2111,"activeCount":100},[],{"trials":2113,"activeCount":100},[],{"intervention":2109,"totalTrials":96,"cells":2115},{"EARLY_PHASE1":2116,"PHASE1":2118,"PHASE2":2120,"PHASE3":2122,"PHASE4":2128,"NA":2130},{"trials":2117,"activeCount":100},[],{"trials":2119,"activeCount":100},[],{"trials":2121,"activeCount":100},[],{"trials":2123,"activeCount":100},[2124],{"nctId":2102,"briefTitle":1711,"status":425,"phases":2125,"primaryCompletion":2104,"completion":2105,"start":1714,"enrollment":100,"conditions":2126,"interventions":2127},[91],[2107],[2091,2109],{"trials":2129,"activeCount":100},[],{"trials":2131,"activeCount":100},[],{"intervention":1262,"totalTrials":96,"cells":2133},{"EARLY_PHASE1":2134,"PHASE1":2136,"PHASE2":2138,"PHASE3":2140,"PHASE4":2146,"NA":2148},{"trials":2135,"activeCount":100},[],{"trials":2137,"activeCount":100},[],{"trials":2139,"activeCount":100},[],{"trials":2141,"activeCount":100},[2142],{"nctId":1254,"briefTitle":1255,"status":243,"phases":2143,"completion":1257,"start":1258,"enrollment":1259,"conditions":2144,"interventions":2145},[91],[898],[1243,1262],{"trials":2147,"activeCount":100},[],{"trials":2149,"activeCount":100},[],{"intervention":901,"totalTrials":96,"cells":2151},{"EARLY_PHASE1":2152,"PHASE1":2154,"PHASE2":2156,"PHASE3":2158,"PHASE4":2164,"NA":2166},{"trials":2153,"activeCount":100},[],{"trials":2155,"activeCount":100},[],{"trials":2157,"activeCount":100},[],{"trials":2159,"activeCount":100},[2160],{"nctId":891,"briefTitle":892,"status":243,"phases":2161,"completion":894,"start":895,"enrollment":896,"conditions":2162,"interventions":2163},[91],[898],[900,901,902],{"trials":2165,"activeCount":100},[],{"trials":2167,"activeCount":100},[],{"intervention":1086,"totalTrials":96,"cells":2169},{"EARLY_PHASE1":2170,"PHASE1":2172,"PHASE2":2174,"PHASE3":2176,"PHASE4":2182,"NA":2184},{"trials":2171,"activeCount":100},[],{"trials":2173,"activeCount":100},[],{"trials":2175,"activeCount":100},[],{"trials":2177,"activeCount":100},[2178],{"nctId":1079,"briefTitle":1080,"status":243,"phases":2179,"primaryCompletion":711,"completion":711,"start":1082,"enrollment":1083,"conditions":2180,"interventions":2181},[91],[15],[1086,1087,1087],{"trials":2183,"activeCount":100},[],{"trials":2185,"activeCount":100},[],{"intervention":943,"totalTrials":96,"cells":2187},{"EARLY_PHASE1":2188,"PHASE1":2190,"PHASE2":2192,"PHASE3":2194,"PHASE4":2200,"NA":2202},{"trials":2189,"activeCount":100},[],{"trials":2191,"activeCount":100},[],{"trials":2193,"activeCount":100},[],{"trials":2195,"activeCount":100},[2196],{"nctId":935,"briefTitle":936,"status":243,"phases":2197,"primaryCompletion":938,"completion":938,"start":939,"enrollment":940,"conditions":2198,"interventions":2199},[91],[15],[902,943],{"trials":2201,"activeCount":100},[],{"trials":2203,"activeCount":100},[],{"intervention":987,"totalTrials":96,"cells":2205},{"EARLY_PHASE1":2206,"PHASE1":2208,"PHASE2":2210,"PHASE3":2212,"PHASE4":2218,"NA":2220},{"trials":2207,"activeCount":100},[],{"trials":2209,"activeCount":100},[],{"trials":2211,"activeCount":100},[],{"trials":2213,"activeCount":100},[2214],{"nctId":979,"briefTitle":980,"status":243,"phases":2215,"primaryCompletion":982,"completion":983,"start":960,"enrollment":984,"conditions":2216,"interventions":2217},[91],[18],[949,987],{"trials":2219,"activeCount":100},[],{"trials":2221,"activeCount":100},[],{"intervention":2223,"totalTrials":96,"cells":2224},"Experimental: CHF6001 1600µg",{"EARLY_PHASE1":2225,"PHASE1":2227,"PHASE2":2229,"PHASE3":2231,"PHASE4":2243,"NA":2245},{"trials":2226,"activeCount":100},[],{"trials":2228,"activeCount":100},[],{"trials":2230,"activeCount":100},[],{"trials":2232,"activeCount":100},[2233],{"nctId":2234,"briefTitle":2235,"status":813,"phases":2236,"primaryCompletion":2237,"completion":2237,"start":2238,"enrollment":2239,"conditions":2240,"interventions":2241},"NCT04636801","A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)",[91],"2025-10-31","2021-07-14",4710,[18],[2223,2242],"Experimental: CHF6001 3200µg",{"trials":2244,"activeCount":100},[],{"trials":2246,"activeCount":100},[],{"intervention":2242,"totalTrials":96,"cells":2248},{"EARLY_PHASE1":2249,"PHASE1":2251,"PHASE2":2253,"PHASE3":2255,"PHASE4":2261,"NA":2263},{"trials":2250,"activeCount":100},[],{"trials":2252,"activeCount":100},[],{"trials":2254,"activeCount":100},[],{"trials":2256,"activeCount":100},[2257],{"nctId":2234,"briefTitle":2235,"status":813,"phases":2258,"primaryCompletion":2237,"completion":2237,"start":2238,"enrollment":2239,"conditions":2259,"interventions":2260},[91],[18],[2223,2242],{"trials":2262,"activeCount":100},[],{"trials":2264,"activeCount":100},[],{"intervention":2266,"totalTrials":96,"cells":2267},"CHF5993 200\u002F6\u002F12.5 μg pMDI HFA-152a",{"EARLY_PHASE1":2268,"PHASE1":2270,"PHASE2":2272,"PHASE3":2274,"PHASE4":2287,"NA":2289},{"trials":2269,"activeCount":100},[],{"trials":2271,"activeCount":100},[],{"trials":2273,"activeCount":100},[],{"trials":2275,"activeCount":100},[2276],{"nctId":2277,"briefTitle":2278,"status":243,"phases":2279,"primaryCompletion":2280,"completion":2281,"start":2282,"enrollment":2283,"conditions":2284,"interventions":2285},"NCT06264674","Comparison Between CHF5993 pMDI 200\u002F6\u002F12.5 µg HFA-152a VS CHF5993 pMDI 200\u002F6\u002F12.5 µg HFA-134a in Subjects With Asthma (TRECOS).",[91],"2025-02-18","2025-02-24","2023-11-27",827,[15],[2266,2286],"Inhaler CHF5993 200\u002F6\u002F12.5 μg pMDI HFA-134a",{"trials":2288,"activeCount":100},[],{"trials":2290,"activeCount":100},[],{"intervention":2286,"totalTrials":96,"cells":2292},{"EARLY_PHASE1":2293,"PHASE1":2295,"PHASE2":2297,"PHASE3":2299,"PHASE4":2305,"NA":2307},{"trials":2294,"activeCount":100},[],{"trials":2296,"activeCount":100},[],{"trials":2298,"activeCount":100},[],{"trials":2300,"activeCount":100},[2301],{"nctId":2277,"briefTitle":2278,"status":243,"phases":2302,"primaryCompletion":2280,"completion":2281,"start":2282,"enrollment":2283,"conditions":2303,"interventions":2304},[91],[15],[2266,2286],{"trials":2306,"activeCount":100},[],{"trials":2308,"activeCount":100},[],{"intervention":1123,"totalTrials":96,"cells":2310},{"EARLY_PHASE1":2311,"PHASE1":2313,"PHASE2":2315,"PHASE3":2317,"PHASE4":2323,"NA":2325},{"trials":2312,"activeCount":100},[],{"trials":2314,"activeCount":100},[],{"trials":2316,"activeCount":100},[],{"trials":2318,"activeCount":100},[2319],{"nctId":1115,"briefTitle":1116,"status":243,"phases":2320,"primaryCompletion":1118,"completion":1118,"start":1119,"enrollment":1120,"conditions":2321,"interventions":2322},[91],[15],[1093,1123],{"trials":2324,"activeCount":100},[],{"trials":2326,"activeCount":100},[],{"intervention":2328,"totalTrials":96,"cells":2329},"CHF1535 200\u002F6 µg pMDI",{"EARLY_PHASE1":2330,"PHASE1":2332,"PHASE2":2334,"PHASE3":2336,"PHASE4":2348,"NA":2350},{"trials":2331,"activeCount":100},[],{"trials":2333,"activeCount":100},[],{"trials":2335,"activeCount":100},[],{"trials":2337,"activeCount":100},[2338],{"nctId":2339,"briefTitle":2340,"status":243,"phases":2341,"primaryCompletion":2342,"completion":2342,"start":2343,"enrollment":2344,"conditions":2345,"interventions":2346},"NCT01577082","Efficacy and Safety of CHF 1535 200\u002F6µg in Not Adequately Controlled Asthmatic Patients",[91],"2012-11-29","2012-04-20",542,[15],[2328,2347],"BDP HFA 100 µg pMDI",{"trials":2349,"activeCount":100},[],{"trials":2351,"activeCount":100},[],{"intervention":2347,"totalTrials":96,"cells":2353},{"EARLY_PHASE1":2354,"PHASE1":2356,"PHASE2":2358,"PHASE3":2360,"PHASE4":2366,"NA":2368},{"trials":2355,"activeCount":100},[],{"trials":2357,"activeCount":100},[],{"trials":2359,"activeCount":100},[],{"trials":2361,"activeCount":100},[2362],{"nctId":2339,"briefTitle":2340,"status":243,"phases":2363,"primaryCompletion":2342,"completion":2342,"start":2343,"enrollment":2344,"conditions":2364,"interventions":2365},[91],[15],[2328,2347],{"trials":2367,"activeCount":100},[],{"trials":2369,"activeCount":100},[],{"intervention":2371,"totalTrials":96,"cells":2372},"Foster 100\u002F6mg NEXThaler",{"EARLY_PHASE1":2373,"PHASE1":2375,"PHASE2":2377,"PHASE3":2379,"PHASE4":2391,"NA":2393},{"trials":2374,"activeCount":100},[],{"trials":2376,"activeCount":100},[],{"trials":2378,"activeCount":100},[],{"trials":2380,"activeCount":100},[2381],{"nctId":2382,"briefTitle":2383,"status":243,"phases":2384,"primaryCompletion":2385,"completion":2385,"start":2386,"enrollment":2387,"conditions":2388,"interventions":2389},"NCT03453112","Foster 100\u002F6 mg NEXThaler Versus Foster 100\u002F6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.",[91],"2021-12-28","2017-10-09",494,[15],[2371,2390],"Foster 100\u002F6mg pMDI",{"trials":2392,"activeCount":100},[],{"trials":2394,"activeCount":100},[],{"intervention":2390,"totalTrials":96,"cells":2396},{"EARLY_PHASE1":2397,"PHASE1":2399,"PHASE2":2401,"PHASE3":2403,"PHASE4":2409,"NA":2411},{"trials":2398,"activeCount":100},[],{"trials":2400,"activeCount":100},[],{"trials":2402,"activeCount":100},[],{"trials":2404,"activeCount":100},[2405],{"nctId":2382,"briefTitle":2383,"status":243,"phases":2406,"primaryCompletion":2385,"completion":2385,"start":2386,"enrollment":2387,"conditions":2407,"interventions":2408},[91],[15],[2371,2390],{"trials":2410,"activeCount":100},[],{"trials":2412,"activeCount":100},[],{"intervention":2414,"totalTrials":96,"cells":2415},"Beclomethasone dipropionate 100 µg \u002F Formoterol fumarate 6 µg",{"EARLY_PHASE1":2416,"PHASE1":2418,"PHASE2":2420,"PHASE3":2422,"PHASE4":2433,"NA":2435},{"trials":2417,"activeCount":100},[],{"trials":2419,"activeCount":100},[],{"trials":2421,"activeCount":100},[],{"trials":2423,"activeCount":100},[2424],{"nctId":2425,"briefTitle":2426,"status":243,"phases":2427,"primaryCompletion":2428,"completion":2428,"start":2429,"enrollment":2430,"conditions":2431,"interventions":2432},"NCT04886999","Study in Adult Patients With Moderate to Severe Asthma",[91],"2023-02-01","2022-02-24",78,[15],[2414,2414],{"trials":2434,"activeCount":100},[],{"trials":2436,"activeCount":100},[],{"intervention":2438,"totalTrials":96,"cells":2439},"Fixed combination Beclomethasone Dipropionate\u002FFormoterol HFA 134a-pMDI",{"EARLY_PHASE1":2440,"PHASE1":2442,"PHASE2":2444,"PHASE3":2446,"PHASE4":2456,"NA":2458},{"trials":2441,"activeCount":100},[],{"trials":2443,"activeCount":100},[],{"trials":2445,"activeCount":100},[],{"trials":2447,"activeCount":100},[2448],{"nctId":2449,"briefTitle":2450,"status":243,"phases":2451,"completion":1257,"start":2452,"enrollment":2453,"conditions":2454,"interventions":2455},"NCT00862264","Efficacy and Tolerability of Beclomethasone Dipropionate\u002FFormoterol Single Inhaler in Patients With Mild to Moderate Persistent Asthma",[91],"2004-08",286,[15],[2438],{"trials":2457,"activeCount":100},[],{"trials":2459,"activeCount":100},[],{"intervention":1271,"totalTrials":96,"cells":2461},{"EARLY_PHASE1":2462,"PHASE1":2464,"PHASE2":2466,"PHASE3":2468,"PHASE4":2474,"NA":2476},{"trials":2463,"activeCount":100},[],{"trials":2465,"activeCount":100},[],{"trials":2467,"activeCount":100},[],{"trials":2469,"activeCount":100},[2470],{"nctId":1264,"briefTitle":1265,"status":243,"phases":2471,"primaryCompletion":1028,"completion":1267,"start":922,"enrollment":1268,"conditions":2472,"interventions":2473},[91],[898],[1243,1271],{"trials":2475,"activeCount":100},[],{"trials":2477,"activeCount":100},[],{"intervention":2479,"totalTrials":96,"cells":2480},"CHF 5993 + Ultibro matched placebo",{"EARLY_PHASE1":2481,"PHASE1":2483,"PHASE2":2485,"PHASE3":2487,"PHASE4":2499,"NA":2501},{"trials":2482,"activeCount":100},[],{"trials":2484,"activeCount":100},[],{"trials":2486,"activeCount":100},[],{"trials":2488,"activeCount":100},[2489],{"nctId":2490,"briefTitle":2491,"status":243,"phases":2492,"primaryCompletion":2493,"completion":2493,"start":2494,"enrollment":2495,"conditions":2496,"interventions":2497},"NCT02579850","2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients",[91],"2017-07-10","2015-05-29",1532,[27],[2479,2498],"Ultibro + CHF 5993 matched placebo",{"trials":2500,"activeCount":100},[],{"trials":2502,"activeCount":100},[],{"intervention":2498,"totalTrials":96,"cells":2504},{"EARLY_PHASE1":2505,"PHASE1":2507,"PHASE2":2509,"PHASE3":2511,"PHASE4":2517,"NA":2519},{"trials":2506,"activeCount":100},[],{"trials":2508,"activeCount":100},[],{"trials":2510,"activeCount":100},[],{"trials":2512,"activeCount":100},[2513],{"nctId":2490,"briefTitle":2491,"status":243,"phases":2514,"primaryCompletion":2493,"completion":2493,"start":2494,"enrollment":2495,"conditions":2515,"interventions":2516},[91],[27],[2479,2498],{"trials":2518,"activeCount":100},[],{"trials":2520,"activeCount":100},[],{"intervention":1503,"totalTrials":96,"cells":2522},{"EARLY_PHASE1":2523,"PHASE1":2525,"PHASE2":2527,"PHASE3":2529,"PHASE4":2535,"NA":2537},{"trials":2524,"activeCount":100},[],{"trials":2526,"activeCount":100},[],{"trials":2528,"activeCount":100},[],{"trials":2530,"activeCount":100},[2531],{"nctId":1497,"briefTitle":1498,"status":813,"phases":2532,"primaryCompletion":1500,"completion":1500,"start":1082,"enrollment":549,"conditions":2533,"interventions":2534},[91],[18],[1486,1503],{"trials":2536,"activeCount":100},[],{"trials":2538,"activeCount":100},[],{"intervention":2540,"totalTrials":96,"cells":2541},"Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI",{"EARLY_PHASE1":2542,"PHASE1":2544,"PHASE2":2546,"PHASE3":2548,"PHASE4":2562,"NA":2564},{"trials":2543,"activeCount":100},[],{"trials":2545,"activeCount":100},[],{"trials":2547,"activeCount":100},[],{"trials":2549,"activeCount":100},[2550],{"nctId":2551,"briefTitle":2552,"status":243,"phases":2553,"primaryCompletion":2554,"completion":2555,"start":2556,"enrollment":2557,"conditions":2558,"interventions":2559},"NCT00476099","Efficacy and Safety Study of Beclometasone\u002FFormoterol Single Inhaler in Patients With COPD",[91],"2008-08","2008-11","2006-12",828,[18],[2540,2560,2561],"Budesonide 200 µg plus formoterol 6 µg DPI","Formoterol 12 µg DPI",{"trials":2563,"activeCount":100},[],{"trials":2565,"activeCount":100},[],{"intervention":2560,"totalTrials":96,"cells":2567},{"EARLY_PHASE1":2568,"PHASE1":2570,"PHASE2":2572,"PHASE3":2574,"PHASE4":2580,"NA":2582},{"trials":2569,"activeCount":100},[],{"trials":2571,"activeCount":100},[],{"trials":2573,"activeCount":100},[],{"trials":2575,"activeCount":100},[2576],{"nctId":2551,"briefTitle":2552,"status":243,"phases":2577,"primaryCompletion":2554,"completion":2555,"start":2556,"enrollment":2557,"conditions":2578,"interventions":2579},[91],[18],[2540,2560,2561],{"trials":2581,"activeCount":100},[],{"trials":2583,"activeCount":100},[],{"intervention":2561,"totalTrials":96,"cells":2585},{"EARLY_PHASE1":2586,"PHASE1":2588,"PHASE2":2590,"PHASE3":2592,"PHASE4":2598,"NA":2600},{"trials":2587,"activeCount":100},[],{"trials":2589,"activeCount":100},[],{"trials":2591,"activeCount":100},[],{"trials":2593,"activeCount":100},[2594],{"nctId":2551,"briefTitle":2552,"status":243,"phases":2595,"primaryCompletion":2554,"completion":2555,"start":2556,"enrollment":2557,"conditions":2596,"interventions":2597},[91],[18],[2540,2560,2561],{"trials":2599,"activeCount":100},[],{"trials":2601,"activeCount":100},[],{"intervention":1444,"totalTrials":96,"cells":2603},{"EARLY_PHASE1":2604,"PHASE1":2606,"PHASE2":2608,"PHASE3":2610,"PHASE4":2616,"NA":2618},{"trials":2605,"activeCount":100},[],{"trials":2607,"activeCount":100},[],{"trials":2609,"activeCount":100},[],{"trials":2611,"activeCount":100},[2612],{"nctId":1433,"briefTitle":1434,"status":813,"phases":2613,"primaryCompletion":1436,"completion":1437,"start":1438,"enrollment":1439,"conditions":2614,"interventions":2615},[91],[1441,1442],[1413,1444],{"trials":2617,"activeCount":100},[],{"trials":2619,"activeCount":100},[],{"intervention":2621,"totalTrials":96,"cells":2622},"tobramycin",{"EARLY_PHASE1":2623,"PHASE1":2625,"PHASE2":2627,"PHASE3":2629,"PHASE4":2639,"NA":2641},{"trials":2624,"activeCount":100},[],{"trials":2626,"activeCount":100},[],{"trials":2628,"activeCount":100},[],{"trials":2630,"activeCount":100},[2631],{"nctId":2632,"briefTitle":2633,"status":243,"phases":2634,"primaryCompletion":1004,"completion":1004,"start":2635,"enrollment":2636,"conditions":2637,"interventions":2638},"NCT01111383","A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®\u002FActitob®\u002FBramitob® Versus TOBI®",[91],"2009-09",209,[32],[2621],{"trials":2640,"activeCount":100},[],{"trials":2642,"activeCount":100},[],{"intervention":2644,"totalTrials":96,"cells":2645},"beclomethasone dipropionate suspension for nebulisation 800 mcg\u002F2 ml",{"EARLY_PHASE1":2646,"PHASE1":2648,"PHASE2":2650,"PHASE3":2652,"PHASE4":2661,"NA":2663},{"trials":2647,"activeCount":100},[],{"trials":2649,"activeCount":100},[],{"trials":2651,"activeCount":100},[],{"trials":2653,"activeCount":100},[2654],{"nctId":2655,"briefTitle":2656,"status":813,"phases":2657,"primaryCompletion":562,"completion":562,"start":2061,"enrollment":30,"conditions":2658,"interventions":2660},"NCT00938353","Efficacy of Nebulized Beclomethasone Dipropionate (BDP) in the Treatment of Moderate Croup",[91],[2659],"Croup",[2644],{"trials":2662,"activeCount":100},[],{"trials":2664,"activeCount":100},[],{"intervention":1211,"totalTrials":96,"cells":2666},{"EARLY_PHASE1":2667,"PHASE1":2669,"PHASE2":2671,"PHASE3":2673,"PHASE4":2679,"NA":2681},{"trials":2668,"activeCount":100},[],{"trials":2670,"activeCount":100},[],{"trials":2672,"activeCount":100},[],{"trials":2674,"activeCount":100},[2675],{"nctId":1204,"briefTitle":1205,"status":243,"phases":2676,"primaryCompletion":983,"completion":983,"start":970,"enrollment":1207,"conditions":2677,"interventions":2678},[91],[18],[1184,1210,1211],{"trials":2680,"activeCount":100},[],{"trials":2682,"activeCount":100},[],{"intervention":1511,"totalTrials":96,"cells":2684},{"EARLY_PHASE1":2685,"PHASE1":2687,"PHASE2":2689,"PHASE3":2691,"PHASE4":2697,"NA":2699},{"trials":2686,"activeCount":100},[],{"trials":2688,"activeCount":100},[],{"trials":2690,"activeCount":100},[],{"trials":2692,"activeCount":100},[2693],{"nctId":1505,"briefTitle":1506,"status":243,"phases":2694,"primaryCompletion":519,"completion":519,"start":712,"enrollment":1508,"conditions":2695,"interventions":2696},[91],[18],[1486,1511],{"trials":2698,"activeCount":100},[],{"trials":2700,"activeCount":100},[],{"intervention":2702,"totalTrials":96,"cells":2703},"disodium clodronate 200 mg\u002F4 ml with 1% lidocaine",{"EARLY_PHASE1":2704,"PHASE1":2706,"PHASE2":2708,"PHASE3":2710,"PHASE4":2723,"NA":2725},{"trials":2705,"activeCount":100},[],{"trials":2707,"activeCount":100},[],{"trials":2709,"activeCount":100},[],{"trials":2711,"activeCount":100},[2712],{"nctId":2713,"briefTitle":2714,"status":243,"phases":2715,"primaryCompletion":2716,"completion":2716,"start":2717,"enrollment":2718,"conditions":2719,"interventions":2721},"NCT01348243","Efficacy Of Clodronate 200 Mg\u002F4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg\u002F3,3ml I.M. Solution With 1% Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal Osteoporosis",[91],"2013-03","2011-10",260,[2720],"Postmenopausal Osteoporosis",[2702,2722],"Disodium clodronate 100 mg\u002F3,3 ml with 1% lidocaine",{"trials":2724,"activeCount":100},[],{"trials":2726,"activeCount":100},[],{"intervention":2722,"totalTrials":96,"cells":2728},{"EARLY_PHASE1":2729,"PHASE1":2731,"PHASE2":2733,"PHASE3":2735,"PHASE4":2741,"NA":2743},{"trials":2730,"activeCount":100},[],{"trials":2732,"activeCount":100},[],{"trials":2734,"activeCount":100},[],{"trials":2736,"activeCount":100},[2737],{"nctId":2713,"briefTitle":2714,"status":243,"phases":2738,"primaryCompletion":2716,"completion":2716,"start":2717,"enrollment":2718,"conditions":2739,"interventions":2740},[91],[2720],[2702,2722],{"trials":2742,"activeCount":100},[],{"trials":2744,"activeCount":100},[],{"intervention":1479,"totalTrials":96,"cells":2746},{"EARLY_PHASE1":2747,"PHASE1":2749,"PHASE2":2751,"PHASE3":2753,"PHASE4":2759,"NA":2761},{"trials":2748,"activeCount":100},[],{"trials":2750,"activeCount":100},[],{"trials":2752,"activeCount":100},[],{"trials":2754,"activeCount":100},[2755],{"nctId":1471,"briefTitle":1472,"status":813,"phases":2756,"primaryCompletion":1474,"completion":1474,"start":1475,"enrollment":1476,"conditions":2757,"interventions":2758},[91],[18],[1479,1480,1450],{"trials":2760,"activeCount":100},[],{"trials":2762,"activeCount":100},[],{"intervention":1480,"totalTrials":96,"cells":2764},{"EARLY_PHASE1":2765,"PHASE1":2767,"PHASE2":2769,"PHASE3":2771,"PHASE4":2777,"NA":2779},{"trials":2766,"activeCount":100},[],{"trials":2768,"activeCount":100},[],{"trials":2770,"activeCount":100},[],{"trials":2772,"activeCount":100},[2773],{"nctId":1471,"briefTitle":1472,"status":813,"phases":2774,"primaryCompletion":1474,"completion":1474,"start":1475,"enrollment":1476,"conditions":2775,"interventions":2776},[91],[18],[1479,1480,1450],{"trials":2778,"activeCount":100},[],{"trials":2780,"activeCount":100},[],{"intervention":2782,"totalTrials":96,"cells":2783},"beclomethasone dipropionate 800 mcg\u002F2 ml suspension for nebulization,one administration b.i.d. for 14 days",{"EARLY_PHASE1":2784,"PHASE1":2786,"PHASE2":2788,"PHASE3":2790,"PHASE4":2801,"NA":2803},{"trials":2785,"activeCount":100},[],{"trials":2787,"activeCount":100},[],{"trials":2789,"activeCount":100},[],{"trials":2791,"activeCount":100},[2792],{"nctId":2793,"briefTitle":2794,"status":243,"phases":2795,"primaryCompletion":970,"completion":970,"start":2796,"enrollment":2797,"conditions":2798,"interventions":2800},"NCT01691677","beCLomethasone Efficacy in Acute Rhinosinusitis - CLEAR Study",[91],"2013-01",166,[2799],"Acute Rhinosinusitis",[2782],{"trials":2802,"activeCount":100},[],{"trials":2804,"activeCount":100},[],{"intervention":2806,"totalTrials":96,"cells":2807},"CHF 1535 100\u002F6 µg pMDI plus Symbicort® Turbohaler® Placebo",{"EARLY_PHASE1":2808,"PHASE1":2810,"PHASE2":2812,"PHASE3":2814,"PHASE4":2826,"NA":2828},{"trials":2809,"activeCount":100},[],{"trials":2811,"activeCount":100},[],{"trials":2813,"activeCount":100},[],{"trials":2815,"activeCount":100},[2816],{"nctId":2817,"briefTitle":2818,"status":243,"phases":2819,"primaryCompletion":2820,"completion":2820,"start":2821,"enrollment":2822,"conditions":2823,"interventions":2824},"NCT03888131","Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (FORSYYN)",[91],"2022-05-06","2018-07-30",750,[18],[2806,2825],"Symbicort® Turbohaler® plus CHF 1535 pMDI Placebo",{"trials":2827,"activeCount":100},[],{"trials":2829,"activeCount":100},[],{"intervention":2825,"totalTrials":96,"cells":2831},{"EARLY_PHASE1":2832,"PHASE1":2834,"PHASE2":2836,"PHASE3":2838,"PHASE4":2844,"NA":2846},{"trials":2833,"activeCount":100},[],{"trials":2835,"activeCount":100},[],{"trials":2837,"activeCount":100},[],{"trials":2839,"activeCount":100},[2840],{"nctId":2817,"briefTitle":2818,"status":243,"phases":2841,"primaryCompletion":2820,"completion":2820,"start":2821,"enrollment":2822,"conditions":2842,"interventions":2843},[91],[18],[2806,2825],{"trials":2845,"activeCount":100},[],{"trials":2847,"activeCount":100},[],{"intervention":1009,"totalTrials":35,"cells":2849},{"EARLY_PHASE1":2850,"PHASE1":2852,"PHASE2":2865,"PHASE3":2880,"PHASE4":2882,"NA":2884},{"trials":2851,"activeCount":100},[],{"trials":2853,"activeCount":100},[2854,2861],{"nctId":2855,"briefTitle":2856,"status":243,"phases":2857,"primaryCompletion":1049,"completion":1049,"start":547,"enrollment":1154,"conditions":2858,"interventions":2860},"NCT01176851","Biopharmaceutical Study of Glyco pMDI With or Without Charcoal Block vs IV Bolus in Healthy Volunteers",[89],[2859],"Healthy",[1009,1009,1009],{"nctId":1000,"briefTitle":1001,"status":243,"phases":2862,"primaryCompletion":1003,"completion":1003,"start":1004,"enrollment":1005,"conditions":2863,"interventions":2864},[89],[21],[1008,1009,993],{"trials":2866,"activeCount":100},[2867,2871],{"nctId":1225,"briefTitle":1226,"status":243,"phases":2868,"primaryCompletion":1228,"completion":1003,"start":1050,"enrollment":1229,"conditions":2869,"interventions":2870},[89,90],[27],[1009,1210],{"nctId":2872,"briefTitle":2873,"status":243,"phases":2874,"primaryCompletion":711,"completion":2875,"start":519,"enrollment":2876,"conditions":2877,"interventions":2878},"NCT01476813","Randomized Cross Over Study to Assess Efficacy and Safety of BDP\u002FFF and Glycopyrrolate",[90],"2013-07",281,[34],[1009,1009,1009,2879],"Comparator",{"trials":2881,"activeCount":100},[],{"trials":2883,"activeCount":100},[],{"trials":2885,"activeCount":100},[],{"intervention":2887,"totalTrials":35,"cells":2888},"CHF6001",{"EARLY_PHASE1":2889,"PHASE1":2891,"PHASE2":2909,"PHASE3":2929,"PHASE4":2931,"NA":2933},{"trials":2890,"activeCount":100},[],{"trials":2892,"activeCount":100},[2893,2901],{"nctId":2894,"briefTitle":2895,"status":243,"phases":2896,"primaryCompletion":2897,"completion":2897,"start":2898,"enrollment":1005,"conditions":2899,"interventions":2900},"NCT05373953","Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects",[89],"2022-11-25","2022-05-05",[18],[2887],{"nctId":2902,"briefTitle":2903,"status":243,"phases":2904,"primaryCompletion":2905,"completion":2905,"start":2906,"enrollment":25,"conditions":2907,"interventions":2908},"NCT04756960","Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy Subjects",[89],"2021-04-29","2021-03-10",[27,21],[2887],{"trials":2910,"activeCount":100},[2911,2922],{"nctId":2912,"briefTitle":2913,"status":243,"phases":2914,"primaryCompletion":2915,"completion":2916,"start":2917,"enrollment":2918,"conditions":2919,"interventions":2920},"NCT02986321","A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD",[90],"2017-10-04","2018-01-09","2016-12-15",1130,[18],[2887,2921],"Budesonide",{"nctId":2923,"briefTitle":2924,"status":243,"phases":2925,"primaryCompletion":2926,"completion":2926,"start":1463,"enrollment":961,"conditions":2927,"interventions":2928},"NCT01689571","A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics",[90],"2013-04",[15],[2887],{"trials":2930,"activeCount":100},[],{"trials":2932,"activeCount":100},[],{"trials":2934,"activeCount":100},[],{"intervention":1467,"totalTrials":35,"cells":2936},{"EARLY_PHASE1":2937,"PHASE1":2939,"PHASE2":2971,"PHASE3":2977,"PHASE4":2979,"NA":2981},{"trials":2938,"activeCount":100},[],{"trials":2940,"activeCount":100},[2941,2951,2961],{"nctId":2942,"briefTitle":2943,"status":243,"phases":2944,"primaryCompletion":2945,"completion":2945,"start":2946,"enrollment":2947,"conditions":2948,"interventions":2949},"NCT06395610","Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers",[89],"2024-06-18","2024-03-28",24,[18],[1467,2950],"Erythromycin",{"nctId":2952,"briefTitle":2953,"status":243,"phases":2954,"primaryCompletion":2955,"completion":2955,"start":2956,"enrollment":1289,"conditions":2957,"interventions":2958},"NCT06892756","Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug Interaction 2 (DDI2) Study",[89],"2025-06-20","2025-03-18",[27],[2959,2960,1467],"CHF6001 dry powder inhaler","Cyclosporine",{"nctId":2962,"briefTitle":2963,"status":243,"phases":2964,"primaryCompletion":2965,"completion":2966,"start":2967,"enrollment":2947,"conditions":2968,"interventions":2969},"NCT04739774","Investigation of the Effect of Inhibition of CYP3A4\u002F5 by Itraconazole on the PK of CHF6001 (Tanimilast)",[89],"2021-04-20","2021-04-26","2021-02-22",[18],[1467,2970],"Itraconazole",{"trials":2972,"activeCount":100},[2973],{"nctId":1459,"briefTitle":1460,"status":243,"phases":2974,"primaryCompletion":1462,"completion":1462,"start":1463,"enrollment":1464,"conditions":2975,"interventions":2976},[90],[21],[1467,1450],{"trials":2978,"activeCount":100},[],{"trials":2980,"activeCount":100},[],{"trials":2982,"activeCount":100},[],{"intervention":2984,"totalTrials":234,"cells":2985},"CHF 5074 1x",{"EARLY_PHASE1":2986,"PHASE1":2988,"PHASE2":2990,"PHASE3":3011,"PHASE4":3013,"NA":3015},{"trials":2987,"activeCount":100},[],{"trials":2989,"activeCount":100},[],{"trials":2991,"activeCount":100},[2992,3003],{"nctId":2993,"briefTitle":2994,"status":243,"phases":2995,"primaryCompletion":1500,"completion":1500,"start":2996,"enrollment":2997,"conditions":2998,"interventions":3000},"NCT01421056","Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)",[90],"2011-07",74,[2999],"Alzheimer's Disease",[2984,3001,3002],"CHF 5074 2x","CHF 5074 3x",{"nctId":3004,"briefTitle":3005,"status":243,"phases":3006,"primaryCompletion":1462,"completion":1462,"start":3007,"enrollment":3008,"conditions":3009,"interventions":3010},"NCT01602393","Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase",[90],"2012-05",51,[2999],[2984,3001,3002],{"trials":3012,"activeCount":100},[],{"trials":3014,"activeCount":100},[],{"trials":3016,"activeCount":100},[],{"intervention":3001,"totalTrials":234,"cells":3018},{"EARLY_PHASE1":3019,"PHASE1":3021,"PHASE2":3023,"PHASE3":3033,"PHASE4":3035,"NA":3037},{"trials":3020,"activeCount":100},[],{"trials":3022,"activeCount":100},[],{"trials":3024,"activeCount":100},[3025,3029],{"nctId":2993,"briefTitle":2994,"status":243,"phases":3026,"primaryCompletion":1500,"completion":1500,"start":2996,"enrollment":2997,"conditions":3027,"interventions":3028},[90],[2999],[2984,3001,3002],{"nctId":3004,"briefTitle":3005,"status":243,"phases":3030,"primaryCompletion":1462,"completion":1462,"start":3007,"enrollment":3008,"conditions":3031,"interventions":3032},[90],[2999],[2984,3001,3002],{"trials":3034,"activeCount":100},[],{"trials":3036,"activeCount":100},[],{"trials":3038,"activeCount":100},[],{"intervention":3002,"totalTrials":234,"cells":3040},{"EARLY_PHASE1":3041,"PHASE1":3043,"PHASE2":3045,"PHASE3":3055,"PHASE4":3057,"NA":3059},{"trials":3042,"activeCount":100},[],{"trials":3044,"activeCount":100},[],{"trials":3046,"activeCount":100},[3047,3051],{"nctId":2993,"briefTitle":2994,"status":243,"phases":3048,"primaryCompletion":1500,"completion":1500,"start":2996,"enrollment":2997,"conditions":3049,"interventions":3050},[90],[2999],[2984,3001,3002],{"nctId":3004,"briefTitle":3005,"status":243,"phases":3052,"primaryCompletion":1462,"completion":1462,"start":3007,"enrollment":3008,"conditions":3053,"interventions":3054},[90],[2999],[2984,3001,3002],{"trials":3056,"activeCount":100},[],{"trials":3058,"activeCount":100},[],{"trials":3060,"activeCount":100},[],{"intervention":3062,"totalTrials":234,"cells":3063},"CHF 4226 pMDI",{"EARLY_PHASE1":3064,"PHASE1":3066,"PHASE2":3078,"PHASE3":3087,"PHASE4":3089,"NA":3091},{"trials":3065,"activeCount":100},[],{"trials":3067,"activeCount":100},[3068],{"nctId":3069,"briefTitle":3070,"status":243,"phases":3071,"primaryCompletion":3072,"completion":3072,"start":3073,"enrollment":3074,"conditions":3075,"interventions":3076},"NCT00777595","Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers",[89],"2008-12","2008-10",47,[18],[3062,3062,3077],"Moxifloxacin",{"trials":3079,"activeCount":100},[3080],{"nctId":3081,"briefTitle":3082,"status":243,"phases":3083,"primaryCompletion":3084,"completion":3084,"start":3072,"enrollment":1154,"conditions":3085,"interventions":3086},"NCT00782535","Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[90],"2009-03",[18],[3062,3062],{"trials":3088,"activeCount":100},[],{"trials":3090,"activeCount":100},[],{"trials":3092,"activeCount":100},[],{"intervention":3094,"totalTrials":234,"cells":3095},"carmoterol",{"EARLY_PHASE1":3096,"PHASE1":3098,"PHASE2":3100,"PHASE3":3118,"PHASE4":3120,"NA":3122},{"trials":3097,"activeCount":100},[],{"trials":3099,"activeCount":100},[],{"trials":3101,"activeCount":100},[3102,3111],{"nctId":3103,"briefTitle":3104,"status":243,"phases":3105,"primaryCompletion":3106,"completion":3106,"start":1027,"enrollment":3107,"conditions":3108,"interventions":3109},"NCT00605891","Dose Finding Study of CHF 4226 for Treating Patients With COPD",[90],"2007-06",278,[18],[3094,3094,3094,3110],"salmeterol",{"nctId":3112,"briefTitle":3113,"status":243,"phases":3114,"primaryCompletion":3073,"completion":3073,"start":3115,"enrollment":9,"conditions":3116,"interventions":3117},"NCT00640484","Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD",[90],"2008-04",[18],[3094,3094,3110],{"trials":3119,"activeCount":100},[],{"trials":3121,"activeCount":100},[],{"trials":3123,"activeCount":100},[],{"intervention":3110,"totalTrials":234,"cells":3125},{"EARLY_PHASE1":3126,"PHASE1":3128,"PHASE2":3130,"PHASE3":3140,"PHASE4":3142,"NA":3144},{"trials":3127,"activeCount":100},[],{"trials":3129,"activeCount":100},[],{"trials":3131,"activeCount":100},[3132,3136],{"nctId":3103,"briefTitle":3104,"status":243,"phases":3133,"primaryCompletion":3106,"completion":3106,"start":1027,"enrollment":3107,"conditions":3134,"interventions":3135},[90],[18],[3094,3094,3094,3110],{"nctId":3112,"briefTitle":3113,"status":243,"phases":3137,"primaryCompletion":3073,"completion":3073,"start":3115,"enrollment":9,"conditions":3138,"interventions":3139},[90],[18],[3094,3094,3110],{"trials":3141,"activeCount":100},[],{"trials":3143,"activeCount":100},[],{"trials":3145,"activeCount":100},[],{"intervention":3147,"totalTrials":234,"cells":3148},"CHF 5259",{"EARLY_PHASE1":3149,"PHASE1":3151,"PHASE2":3153,"PHASE3":3172,"PHASE4":3174,"NA":3176},{"trials":3150,"activeCount":100},[],{"trials":3152,"activeCount":100},[],{"trials":3154,"activeCount":100},[3155,3165],{"nctId":3156,"briefTitle":3157,"status":243,"phases":3158,"primaryCompletion":3159,"completion":3160,"start":861,"enrollment":3161,"conditions":3162,"interventions":3163},"NCT03084796","A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease",[90],"2018-05-23","2018-06-06",733,[21,18],[3147,3164],"Tiotropium Bromide 18 µg Inhalation",{"nctId":3166,"briefTitle":3167,"status":243,"phases":3168,"primaryCompletion":959,"completion":959,"start":3169,"enrollment":465,"conditions":3170,"interventions":3171},"NCT02189577","Efficacy and Safety of Glycopyrrolate Bromide of COPD Patients",[90],"2014-06",[18],[3147],{"trials":3173,"activeCount":100},[],{"trials":3175,"activeCount":100},[],{"trials":3177,"activeCount":100},[],{"intervention":3179,"totalTrials":234,"cells":3180},"free comb. beclomethasone DPI and formoterol DPI",{"EARLY_PHASE1":3181,"PHASE1":3183,"PHASE2":3185,"PHASE3":3206,"PHASE4":3208,"NA":3210},{"trials":3182,"activeCount":100},[],{"trials":3184,"activeCount":100},[],{"trials":3186,"activeCount":100},[3187,3197],{"nctId":3188,"briefTitle":3189,"status":243,"phases":3190,"primaryCompletion":3191,"completion":3191,"start":3192,"enrollment":3193,"conditions":3194,"interventions":3195},"NCT01468272","Clinical Pharmacology of CHF 1535 50\u002F6 ug Next DPI in Children 5-11 Years Old",[90],"2012-08","2011-11",26,[2107],[3179,3196],"CHF 1535 50\u002F6 NEXT DPI",{"nctId":3198,"briefTitle":3199,"status":243,"phases":3200,"primaryCompletion":3201,"completion":3201,"start":3202,"enrollment":3193,"conditions":3203,"interventions":3204},"NCT02787967","Clinical Pharmacology of 35\u002F4 NEXThaler® in Children 5-11 Years Old",[90],"2017-06","2016-08",[15],[3205,3179],"CHF 1535 35\u002F4µg NEXThaler®",{"trials":3207,"activeCount":100},[],{"trials":3209,"activeCount":100},[],{"trials":3211,"activeCount":100},[],{"intervention":3213,"totalTrials":234,"cells":3214},"BDP\u002FFormoterol",{"EARLY_PHASE1":3215,"PHASE1":3217,"PHASE2":3219,"PHASE3":3237,"PHASE4":3239,"NA":3241},{"trials":3216,"activeCount":100},[],{"trials":3218,"activeCount":100},[],{"trials":3220,"activeCount":100},[3221,3228],{"nctId":3222,"briefTitle":3223,"status":243,"phases":3224,"primaryCompletion":3225,"completion":3225,"start":1004,"enrollment":2947,"conditions":3226,"interventions":3227},"NCT01349257","Pharmacokinetic Clinical Study of CHF1535 NEXT DPI® Versus CHF1535 pMDI",[90],"2011-06",[15],[3213],{"nctId":3229,"briefTitle":3230,"status":243,"phases":3231,"primaryCompletion":2554,"completion":2554,"start":3232,"enrollment":12,"conditions":3233,"interventions":3235},"NCT01343745","Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)\u002FFormoterol Pressurised Metered Dose Inhaler (pMDI)",[90],"2008-02",[3234],"Mild Persistent Asthma",[3236,3236],"BDP\u002Fformoterol",{"trials":3238,"activeCount":100},[],{"trials":3240,"activeCount":100},[],{"trials":3242,"activeCount":100},[],{"intervention":3244,"totalTrials":96,"cells":3245},"CHF1535 NEXT DPI",{"EARLY_PHASE1":3246,"PHASE1":3248,"PHASE2":3250,"PHASE3":3259,"PHASE4":3261,"NA":3263},{"trials":3247,"activeCount":100},[],{"trials":3249,"activeCount":100},[],{"trials":3251,"activeCount":100},[3252],{"nctId":3253,"briefTitle":3254,"status":243,"phases":3255,"primaryCompletion":1082,"completion":1082,"start":1049,"enrollment":9,"conditions":3256,"interventions":3257},"NCT01191424","A Study Comparing the Pharmacokinetic, Pharmacodynamic and Safety of CHF 1535 (Fixed Combination of Beclomethasone + Formoterol) Administered Via the NEXT DPI, Versus the Free Combination of Licenced Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescent and Adult Patients.",[90],[15],[3244,3258],"BDP DPI and formoterol DPI",{"trials":3260,"activeCount":100},[],{"trials":3262,"activeCount":100},[],{"trials":3264,"activeCount":100},[],{"intervention":3258,"totalTrials":96,"cells":3266},{"EARLY_PHASE1":3267,"PHASE1":3269,"PHASE2":3271,"PHASE3":3277,"PHASE4":3279,"NA":3281},{"trials":3268,"activeCount":100},[],{"trials":3270,"activeCount":100},[],{"trials":3272,"activeCount":100},[3273],{"nctId":3253,"briefTitle":3254,"status":243,"phases":3274,"primaryCompletion":1082,"completion":1082,"start":1049,"enrollment":9,"conditions":3275,"interventions":3276},[90],[15],[3244,3258],{"trials":3278,"activeCount":100},[],{"trials":3280,"activeCount":100},[],{"trials":3282,"activeCount":100},[],{"intervention":865,"totalTrials":96,"cells":3284},{"EARLY_PHASE1":3285,"PHASE1":3287,"PHASE2":3289,"PHASE3":3295,"PHASE4":3297,"NA":3299},{"trials":3286,"activeCount":100},[],{"trials":3288,"activeCount":100},[],{"trials":3290,"activeCount":100},[3291],{"nctId":856,"briefTitle":857,"status":243,"phases":3292,"primaryCompletion":859,"completion":860,"start":861,"enrollment":862,"conditions":3293,"interventions":3294},[90],[15],[865,847],{"trials":3296,"activeCount":100},[],{"trials":3298,"activeCount":100},[],{"trials":3300,"activeCount":100},[],{"intervention":3302,"totalTrials":96,"cells":3303},"CUROSURF®",{"EARLY_PHASE1":3304,"PHASE1":3306,"PHASE2":3308,"PHASE3":3319,"PHASE4":3321,"NA":3323},{"trials":3305,"activeCount":100},[],{"trials":3307,"activeCount":100},[],{"trials":3309,"activeCount":100},[3310],{"nctId":3311,"briefTitle":3312,"status":813,"phases":3313,"primaryCompletion":3314,"completion":3314,"start":3315,"enrollment":151,"conditions":3316,"interventions":3318},"NCT04502433","Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)",[90],"2022-03-17","2021-01-06",[3317],"Acute Respiratory Distress Syndrome",[3302],{"trials":3320,"activeCount":100},[],{"trials":3322,"activeCount":100},[],{"trials":3324,"activeCount":100},[],{"intervention":2921,"totalTrials":96,"cells":3326},{"EARLY_PHASE1":3327,"PHASE1":3329,"PHASE2":3331,"PHASE3":3337,"PHASE4":3339,"NA":3341},{"trials":3328,"activeCount":100},[],{"trials":3330,"activeCount":100},[],{"trials":3332,"activeCount":100},[3333],{"nctId":2912,"briefTitle":2913,"status":243,"phases":3334,"primaryCompletion":2915,"completion":2916,"start":2917,"enrollment":2918,"conditions":3335,"interventions":3336},[90],[18],[2887,2921],{"trials":3338,"activeCount":100},[],{"trials":3340,"activeCount":100},[],{"trials":3342,"activeCount":100},[],{"intervention":3344,"totalTrials":96,"cells":3345},"Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg",{"EARLY_PHASE1":3346,"PHASE1":3348,"PHASE2":3350,"PHASE3":3362,"PHASE4":3364,"NA":3366},{"trials":3347,"activeCount":100},[],{"trials":3349,"activeCount":100},[],{"trials":3351,"activeCount":100},[3352],{"nctId":3353,"briefTitle":3354,"status":243,"phases":3355,"primaryCompletion":3356,"completion":3356,"start":3357,"enrollment":3358,"conditions":3359,"interventions":3360},"NCT02148120","A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThaler",[90],"2014-10","2014-04",60,[15],[3344,3361],"Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg",{"trials":3363,"activeCount":100},[],{"trials":3365,"activeCount":100},[],{"trials":3367,"activeCount":100},[],{"intervention":3361,"totalTrials":96,"cells":3369},{"EARLY_PHASE1":3370,"PHASE1":3372,"PHASE2":3374,"PHASE3":3380,"PHASE4":3382,"NA":3384},{"trials":3371,"activeCount":100},[],{"trials":3373,"activeCount":100},[],{"trials":3375,"activeCount":100},[3376],{"nctId":3353,"briefTitle":3354,"status":243,"phases":3377,"primaryCompletion":3356,"completion":3356,"start":3357,"enrollment":3358,"conditions":3378,"interventions":3379},[90],[15],[3344,3361],{"trials":3381,"activeCount":100},[],{"trials":3383,"activeCount":100},[],{"trials":3385,"activeCount":100},[],{"intervention":3387,"totalTrials":96,"cells":3388},"CHF5259 or Placebo administration",{"EARLY_PHASE1":3389,"PHASE1":3391,"PHASE2":3393,"PHASE3":3404,"PHASE4":3406,"NA":3408},{"trials":3390,"activeCount":100},[],{"trials":3392,"activeCount":100},[],{"trials":3394,"activeCount":100},[3395],{"nctId":3396,"briefTitle":3397,"status":243,"phases":3398,"primaryCompletion":3399,"completion":3399,"start":3400,"enrollment":3401,"conditions":3402,"interventions":3403},"NCT02680197","Study to Evaluate Efficacy\u002FSafety of 4 Doses of CHF5259 Via Dry Powder Inhaler (DPI) in Patients With COPD",[90],"2017-02-06","2016-02-29",262,[27],[3387],{"trials":3405,"activeCount":100},[],{"trials":3407,"activeCount":100},[],{"trials":3409,"activeCount":100},[],{"intervention":3411,"totalTrials":96,"cells":3412},"CHF 5259 12.5 µg + Qvar",{"EARLY_PHASE1":3413,"PHASE1":3415,"PHASE2":3417,"PHASE3":3429,"PHASE4":3431,"NA":3433},{"trials":3414,"activeCount":100},[],{"trials":3416,"activeCount":100},[],{"trials":3418,"activeCount":100},[3419],{"nctId":3420,"briefTitle":3421,"status":243,"phases":3422,"primaryCompletion":3423,"completion":3423,"start":3424,"enrollment":3425,"conditions":3426,"interventions":3427},"NCT02296411","Efficacy of LAMA Added to ICS in Treatment of Asthma (ELITRA)",[90],"2015-08-13","2014-11-21",98,[15],[3411,3428],"CHF 5259 placebo + Qvar",{"trials":3430,"activeCount":100},[],{"trials":3432,"activeCount":100},[],{"trials":3434,"activeCount":100},[],{"intervention":3428,"totalTrials":96,"cells":3436},{"EARLY_PHASE1":3437,"PHASE1":3439,"PHASE2":3441,"PHASE3":3447,"PHASE4":3449,"NA":3451},{"trials":3438,"activeCount":100},[],{"trials":3440,"activeCount":100},[],{"trials":3442,"activeCount":100},[3443],{"nctId":3420,"briefTitle":3421,"status":243,"phases":3444,"primaryCompletion":3423,"completion":3423,"start":3424,"enrollment":3425,"conditions":3445,"interventions":3446},[90],[15],[3411,3428],{"trials":3448,"activeCount":100},[],{"trials":3450,"activeCount":100},[],{"trials":3452,"activeCount":100},[],{"intervention":3454,"totalTrials":96,"cells":3455},"CHF1535 + CHF5992 dose 1 BID",{"EARLY_PHASE1":3456,"PHASE1":3458,"PHASE2":3460,"PHASE3":3473,"PHASE4":3475,"NA":3477},{"trials":3457,"activeCount":100},[],{"trials":3459,"activeCount":100},[],{"trials":3461,"activeCount":100},[3462],{"nctId":3463,"briefTitle":3464,"status":243,"phases":3465,"primaryCompletion":711,"completion":2796,"start":3466,"enrollment":3467,"conditions":3468,"interventions":3470},"NCT01584505","Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD",[90],"2012-04",191,[3469],"Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",[3454,3471,3472],"CHF1535 + CHF5992 dose2 BID","CHF1535 daily dose",{"trials":3474,"activeCount":100},[],{"trials":3476,"activeCount":100},[],{"trials":3478,"activeCount":100},[],{"intervention":3471,"totalTrials":96,"cells":3480},{"EARLY_PHASE1":3481,"PHASE1":3483,"PHASE2":3485,"PHASE3":3491,"PHASE4":3493,"NA":3495},{"trials":3482,"activeCount":100},[],{"trials":3484,"activeCount":100},[],{"trials":3486,"activeCount":100},[3487],{"nctId":3463,"briefTitle":3464,"status":243,"phases":3488,"primaryCompletion":711,"completion":2796,"start":3466,"enrollment":3467,"conditions":3489,"interventions":3490},[90],[3469],[3454,3471,3472],{"trials":3492,"activeCount":100},[],{"trials":3494,"activeCount":100},[],{"trials":3496,"activeCount":100},[],{"intervention":3472,"totalTrials":96,"cells":3498},{"EARLY_PHASE1":3499,"PHASE1":3501,"PHASE2":3503,"PHASE3":3509,"PHASE4":3511,"NA":3513},{"trials":3500,"activeCount":100},[],{"trials":3502,"activeCount":100},[],{"trials":3504,"activeCount":100},[3505],{"nctId":3463,"briefTitle":3464,"status":243,"phases":3506,"primaryCompletion":711,"completion":2796,"start":3466,"enrollment":3467,"conditions":3507,"interventions":3508},[90],[3469],[3454,3471,3472],{"trials":3510,"activeCount":100},[],{"trials":3512,"activeCount":100},[],{"trials":3514,"activeCount":100},[],{"intervention":3516,"totalTrials":96,"cells":3517},"CHF6366",{"EARLY_PHASE1":3518,"PHASE1":3520,"PHASE2":3522,"PHASE3":3534,"PHASE4":3536,"NA":3538},{"trials":3519,"activeCount":100},[],{"trials":3521,"activeCount":100},[],{"trials":3523,"activeCount":100},[3524],{"nctId":3525,"briefTitle":3526,"status":243,"phases":3527,"primaryCompletion":3528,"completion":3528,"start":3529,"enrollment":3530,"conditions":3531,"interventions":3532},"NCT03378648","A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366",[89,90],"2019-04-16","2017-12-28",118,[15,18],[3516,3533],"umeclidinium bromide and vilanterol trifenatate",{"trials":3535,"activeCount":100},[],{"trials":3537,"activeCount":100},[],{"trials":3539,"activeCount":100},[],{"intervention":3533,"totalTrials":96,"cells":3541},{"EARLY_PHASE1":3542,"PHASE1":3544,"PHASE2":3546,"PHASE3":3552,"PHASE4":3554,"NA":3556},{"trials":3543,"activeCount":100},[],{"trials":3545,"activeCount":100},[],{"trials":3547,"activeCount":100},[3548],{"nctId":3525,"briefTitle":3526,"status":243,"phases":3549,"primaryCompletion":3528,"completion":3528,"start":3529,"enrollment":3530,"conditions":3550,"interventions":3551},[89,90],[15,18],[3516,3533],{"trials":3553,"activeCount":100},[],{"trials":3555,"activeCount":100},[],{"trials":3557,"activeCount":100},[],{"intervention":3559,"totalTrials":96,"cells":3560},"NEXThaler 100\u002F6 mcg DPI",{"EARLY_PHASE1":3561,"PHASE1":3563,"PHASE2":3565,"PHASE3":3577,"PHASE4":3579,"NA":3581},{"trials":3562,"activeCount":100},[],{"trials":3564,"activeCount":100},[],{"trials":3566,"activeCount":100},[3567],{"nctId":3568,"briefTitle":3569,"status":243,"phases":3570,"primaryCompletion":2796,"completion":2796,"start":1500,"enrollment":1289,"conditions":3571,"interventions":3573},"NCT01738087","Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder",[90],[3572],"Asthmatic",[3559,3574,3575,3576],"Flixotide Accuhaler 500 mcg","NEXThaler 200\u002F6 mcg DPI","NEXThaler placebo",{"trials":3578,"activeCount":100},[],{"trials":3580,"activeCount":100},[],{"trials":3582,"activeCount":100},[],{"intervention":3574,"totalTrials":96,"cells":3584},{"EARLY_PHASE1":3585,"PHASE1":3587,"PHASE2":3589,"PHASE3":3595,"PHASE4":3597,"NA":3599},{"trials":3586,"activeCount":100},[],{"trials":3588,"activeCount":100},[],{"trials":3590,"activeCount":100},[3591],{"nctId":3568,"briefTitle":3569,"status":243,"phases":3592,"primaryCompletion":2796,"completion":2796,"start":1500,"enrollment":1289,"conditions":3593,"interventions":3594},[90],[3572],[3559,3574,3575,3576],{"trials":3596,"activeCount":100},[],{"trials":3598,"activeCount":100},[],{"trials":3600,"activeCount":100},[],{"intervention":3575,"totalTrials":96,"cells":3602},{"EARLY_PHASE1":3603,"PHASE1":3605,"PHASE2":3607,"PHASE3":3613,"PHASE4":3615,"NA":3617},{"trials":3604,"activeCount":100},[],{"trials":3606,"activeCount":100},[],{"trials":3608,"activeCount":100},[3609],{"nctId":3568,"briefTitle":3569,"status":243,"phases":3610,"primaryCompletion":2796,"completion":2796,"start":1500,"enrollment":1289,"conditions":3611,"interventions":3612},[90],[3572],[3559,3574,3575,3576],{"trials":3614,"activeCount":100},[],{"trials":3616,"activeCount":100},[],{"trials":3618,"activeCount":100},[],{"intervention":3576,"totalTrials":96,"cells":3620},{"EARLY_PHASE1":3621,"PHASE1":3623,"PHASE2":3625,"PHASE3":3631,"PHASE4":3633,"NA":3635},{"trials":3622,"activeCount":100},[],{"trials":3624,"activeCount":100},[],{"trials":3626,"activeCount":100},[3627],{"nctId":3568,"briefTitle":3569,"status":243,"phases":3628,"primaryCompletion":2796,"completion":2796,"start":1500,"enrollment":1289,"conditions":3629,"interventions":3630},[90],[3572],[3559,3574,3575,3576],{"trials":3632,"activeCount":100},[],{"trials":3634,"activeCount":100},[],{"trials":3636,"activeCount":100},[],{"intervention":3638,"totalTrials":96,"cells":3639},"CHF 6001",{"EARLY_PHASE1":3640,"PHASE1":3642,"PHASE2":3644,"PHASE3":3655,"PHASE4":3657,"NA":3659},{"trials":3641,"activeCount":100},[],{"trials":3643,"activeCount":100},[],{"trials":3645,"activeCount":100},[3646],{"nctId":3647,"briefTitle":3648,"status":243,"phases":3649,"primaryCompletion":3650,"completion":3650,"start":3651,"enrollment":3652,"conditions":3653,"interventions":3654},"NCT06900816","A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001",[90],"2025-08-11","2025-03-28",50,[15],[3638,3638],{"trials":3656,"activeCount":100},[],{"trials":3658,"activeCount":100},[],{"trials":3660,"activeCount":100},[],{"intervention":3662,"totalTrials":96,"cells":3663},"CHF6467 active",{"EARLY_PHASE1":3664,"PHASE1":3666,"PHASE2":3668,"PHASE3":3680,"PHASE4":3682,"NA":3684},{"trials":3665,"activeCount":100},[],{"trials":3667,"activeCount":100},[],{"trials":3669,"activeCount":100},[3670],{"nctId":3671,"briefTitle":3672,"status":243,"phases":3673,"primaryCompletion":3674,"completion":3674,"start":3675,"enrollment":3676,"conditions":3677,"interventions":3679},"NCT04077671","CHF6467 SAD and MAD in Patients With Diabetic Foot Ulcer",[89,90],"2021-01-07","2018-10-17",93,[3678],"Diabetic Neuropathic Foot Ulcers",[3662],{"trials":3681,"activeCount":100},[],{"trials":3683,"activeCount":100},[],{"trials":3685,"activeCount":100},[],{"intervention":3687,"totalTrials":96,"cells":3688},"CHF 1531 pMDI",{"EARLY_PHASE1":3689,"PHASE1":3691,"PHASE2":3693,"PHASE3":3706,"PHASE4":3708,"NA":3710},{"trials":3690,"activeCount":100},[],{"trials":3692,"activeCount":100},[],{"trials":3694,"activeCount":100},[3695],{"nctId":3696,"briefTitle":3697,"status":243,"phases":3698,"primaryCompletion":3699,"completion":3700,"start":3701,"enrollment":3702,"conditions":3703,"interventions":3704},"NCT03086460","A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)",[90],"2018-07-23","2018-07-28","2017-09-08",67,[15],[3687,3705],"Formoterol Inhalation Solution",{"trials":3707,"activeCount":100},[],{"trials":3709,"activeCount":100},[],{"trials":3711,"activeCount":100},[],{"intervention":3705,"totalTrials":96,"cells":3713},{"EARLY_PHASE1":3714,"PHASE1":3716,"PHASE2":3718,"PHASE3":3724,"PHASE4":3726,"NA":3728},{"trials":3715,"activeCount":100},[],{"trials":3717,"activeCount":100},[],{"trials":3719,"activeCount":100},[3720],{"nctId":3696,"briefTitle":3697,"status":243,"phases":3721,"primaryCompletion":3699,"completion":3700,"start":3701,"enrollment":3702,"conditions":3722,"interventions":3723},[90],[15],[3687,3705],{"trials":3725,"activeCount":100},[],{"trials":3727,"activeCount":100},[],{"trials":3729,"activeCount":100},[],{"intervention":3731,"totalTrials":96,"cells":3732},"nCPAP",{"EARLY_PHASE1":3733,"PHASE1":3735,"PHASE2":3737,"PHASE3":3748,"PHASE4":3750,"NA":3752},{"trials":3734,"activeCount":100},[],{"trials":3736,"activeCount":100},[],{"trials":3738,"activeCount":100},[3739],{"nctId":3740,"briefTitle":3741,"status":813,"phases":3742,"primaryCompletion":3743,"completion":3743,"start":3744,"enrollment":2797,"conditions":3745,"interventions":3747},"NCT03235986","A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS)",[90],"2020-05-05","2017-08-28",[3746],"Neonatal Respiratory Distress Syndrome",[3731,3731],{"trials":3749,"activeCount":100},[],{"trials":3751,"activeCount":100},[],{"trials":3753,"activeCount":100},[],{"intervention":552,"totalTrials":96,"cells":3755},{"EARLY_PHASE1":3756,"PHASE1":3758,"PHASE2":3760,"PHASE3":3766,"PHASE4":3768,"NA":3770},{"trials":3757,"activeCount":100},[],{"trials":3759,"activeCount":100},[],{"trials":3761,"activeCount":100},[3762],{"nctId":544,"briefTitle":545,"status":243,"phases":3763,"primaryCompletion":547,"completion":547,"start":548,"enrollment":549,"conditions":3764,"interventions":3765},[90],[15],[552,553,535],{"trials":3767,"activeCount":100},[],{"trials":3769,"activeCount":100},[],{"trials":3771,"activeCount":100},[],{"intervention":553,"totalTrials":96,"cells":3773},{"EARLY_PHASE1":3774,"PHASE1":3776,"PHASE2":3778,"PHASE3":3784,"PHASE4":3786,"NA":3788},{"trials":3775,"activeCount":100},[],{"trials":3777,"activeCount":100},[],{"trials":3779,"activeCount":100},[3780],{"nctId":544,"briefTitle":545,"status":243,"phases":3781,"primaryCompletion":547,"completion":547,"start":548,"enrollment":549,"conditions":3782,"interventions":3783},[90],[15],[552,553,535],{"trials":3785,"activeCount":100},[],{"trials":3787,"activeCount":100},[],{"trials":3789,"activeCount":100},[],{"intervention":2879,"totalTrials":96,"cells":3791},{"EARLY_PHASE1":3792,"PHASE1":3794,"PHASE2":3796,"PHASE3":3802,"PHASE4":3804,"NA":3806},{"trials":3793,"activeCount":100},[],{"trials":3795,"activeCount":100},[],{"trials":3797,"activeCount":100},[3798],{"nctId":2872,"briefTitle":2873,"status":243,"phases":3799,"primaryCompletion":711,"completion":2875,"start":519,"enrollment":2876,"conditions":3800,"interventions":3801},[90],[34],[1009,1009,1009,2879],{"trials":3803,"activeCount":100},[],{"trials":3805,"activeCount":100},[],{"trials":3807,"activeCount":100},[],{"intervention":3809,"totalTrials":96,"cells":3810},"CHF 6001 Dose1",{"EARLY_PHASE1":3811,"PHASE1":3813,"PHASE2":3815,"PHASE3":3826,"PHASE4":3828,"NA":3830},{"trials":3812,"activeCount":100},[],{"trials":3814,"activeCount":100},[],{"trials":3816,"activeCount":100},[3817],{"nctId":3818,"briefTitle":3819,"status":243,"phases":3820,"primaryCompletion":3529,"completion":3529,"start":3821,"enrollment":3822,"conditions":3823,"interventions":3824},"NCT03004417","Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD",[90],"2016-10-31",61,[21],[3809,3825],"CHF 6001 Dose2",{"trials":3827,"activeCount":100},[],{"trials":3829,"activeCount":100},[],{"trials":3831,"activeCount":100},[],{"intervention":3825,"totalTrials":96,"cells":3833},{"EARLY_PHASE1":3834,"PHASE1":3836,"PHASE2":3838,"PHASE3":3844,"PHASE4":3846,"NA":3848},{"trials":3835,"activeCount":100},[],{"trials":3837,"activeCount":100},[],{"trials":3839,"activeCount":100},[3840],{"nctId":3818,"briefTitle":3819,"status":243,"phases":3841,"primaryCompletion":3529,"completion":3529,"start":3821,"enrollment":3822,"conditions":3842,"interventions":3843},[90],[21],[3809,3825],{"trials":3845,"activeCount":100},[],{"trials":3847,"activeCount":100},[],{"trials":3849,"activeCount":100},[],{"intervention":3851,"totalTrials":96,"cells":3852},"CHF 5993 DPI",{"EARLY_PHASE1":3853,"PHASE1":3855,"PHASE2":3857,"PHASE3":3871,"PHASE4":3873,"NA":3875},{"trials":3854,"activeCount":100},[],{"trials":3856,"activeCount":100},[],{"trials":3858,"activeCount":100},[3859],{"nctId":3860,"briefTitle":3861,"status":243,"phases":3862,"primaryCompletion":3863,"completion":3864,"start":3865,"enrollment":3866,"conditions":3867,"interventions":3868},"NCT03590379","Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)",[90],"2018-10-16","2019-03-06","2018-06-15",366,[18],[3851,3869,3870],"CHF5993 pMDI","CHF 1535 pMDI",{"trials":3872,"activeCount":100},[],{"trials":3874,"activeCount":100},[],{"trials":3876,"activeCount":100},[],{"intervention":3869,"totalTrials":96,"cells":3878},{"EARLY_PHASE1":3879,"PHASE1":3881,"PHASE2":3883,"PHASE3":3889,"PHASE4":3891,"NA":3893},{"trials":3880,"activeCount":100},[],{"trials":3882,"activeCount":100},[],{"trials":3884,"activeCount":100},[3885],{"nctId":3860,"briefTitle":3861,"status":243,"phases":3886,"primaryCompletion":3863,"completion":3864,"start":3865,"enrollment":3866,"conditions":3887,"interventions":3888},[90],[18],[3851,3869,3870],{"trials":3890,"activeCount":100},[],{"trials":3892,"activeCount":100},[],{"trials":3894,"activeCount":100},[],{"intervention":3870,"totalTrials":96,"cells":3896},{"EARLY_PHASE1":3897,"PHASE1":3899,"PHASE2":3901,"PHASE3":3907,"PHASE4":3909,"NA":3911},{"trials":3898,"activeCount":100},[],{"trials":3900,"activeCount":100},[],{"trials":3902,"activeCount":100},[3903],{"nctId":3860,"briefTitle":3861,"status":243,"phases":3904,"primaryCompletion":3863,"completion":3864,"start":3865,"enrollment":3866,"conditions":3905,"interventions":3906},[90],[18],[3851,3869,3870],{"trials":3908,"activeCount":100},[],{"trials":3910,"activeCount":100},[],{"trials":3912,"activeCount":100},[],{"intervention":3914,"totalTrials":96,"cells":3915},"beclomethasone+formoterol 50\u002F6",{"EARLY_PHASE1":3916,"PHASE1":3918,"PHASE2":3920,"PHASE3":3933,"PHASE4":3935,"NA":3937},{"trials":3917,"activeCount":100},[],{"trials":3919,"activeCount":100},[],{"trials":3921,"activeCount":100},[3922],{"nctId":3923,"briefTitle":3924,"status":243,"phases":3925,"primaryCompletion":3926,"completion":3926,"start":3927,"enrollment":3928,"conditions":3929,"interventions":3930},"NCT01584492","Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children",[90],"2013-02","2011-12",59,[15],[3914,3931,3931,3932],"CHF 1535 50\u002F6","Formoterol + Beclomethasone dipropionate",{"trials":3934,"activeCount":100},[],{"trials":3936,"activeCount":100},[],{"trials":3938,"activeCount":100},[],{"intervention":3931,"totalTrials":96,"cells":3940},{"EARLY_PHASE1":3941,"PHASE1":3943,"PHASE2":3945,"PHASE3":3951,"PHASE4":3953,"NA":3955},{"trials":3942,"activeCount":100},[],{"trials":3944,"activeCount":100},[],{"trials":3946,"activeCount":100},[3947],{"nctId":3923,"briefTitle":3924,"status":243,"phases":3948,"primaryCompletion":3926,"completion":3926,"start":3927,"enrollment":3928,"conditions":3949,"interventions":3950},[90],[15],[3914,3931,3931,3932],{"trials":3952,"activeCount":100},[],{"trials":3954,"activeCount":100},[],{"trials":3956,"activeCount":100},[],{"intervention":3932,"totalTrials":96,"cells":3958},{"EARLY_PHASE1":3959,"PHASE1":3961,"PHASE2":3963,"PHASE3":3969,"PHASE4":3971,"NA":3973},{"trials":3960,"activeCount":100},[],{"trials":3962,"activeCount":100},[],{"trials":3964,"activeCount":100},[3965],{"nctId":3923,"briefTitle":3924,"status":243,"phases":3966,"primaryCompletion":3926,"completion":3926,"start":3927,"enrollment":3928,"conditions":3967,"interventions":3968},[90],[15],[3914,3931,3931,3932],{"trials":3970,"activeCount":100},[],{"trials":3972,"activeCount":100},[],{"trials":3974,"activeCount":100},[],{"intervention":3976,"totalTrials":96,"cells":3977},"CHF6563",{"EARLY_PHASE1":3978,"PHASE1":3980,"PHASE2":3982,"PHASE3":3997,"PHASE4":3999,"NA":4001},{"trials":3979,"activeCount":100},[],{"trials":3981,"activeCount":100},[],{"trials":3983,"activeCount":100},[3984],{"nctId":3985,"briefTitle":3986,"status":813,"phases":3987,"primaryCompletion":3988,"completion":3988,"start":3989,"enrollment":3990,"conditions":3991,"interventions":3993},"NCT04104646","CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome",[90],"2021-12-13","2020-12-18",7,[3992],"Neonatal Opioid Withdrawal Syndrome",[3976,3994,3995,3996],"Morphine","CHF6563 matched placebo","Morphine matched placebo",{"trials":3998,"activeCount":100},[],{"trials":4000,"activeCount":100},[],{"trials":4002,"activeCount":100},[],{"intervention":3994,"totalTrials":96,"cells":4004},{"EARLY_PHASE1":4005,"PHASE1":4007,"PHASE2":4009,"PHASE3":4015,"PHASE4":4017,"NA":4019},{"trials":4006,"activeCount":100},[],{"trials":4008,"activeCount":100},[],{"trials":4010,"activeCount":100},[4011],{"nctId":3985,"briefTitle":3986,"status":813,"phases":4012,"primaryCompletion":3988,"completion":3988,"start":3989,"enrollment":3990,"conditions":4013,"interventions":4014},[90],[3992],[3976,3994,3995,3996],{"trials":4016,"activeCount":100},[],{"trials":4018,"activeCount":100},[],{"trials":4020,"activeCount":100},[],{"intervention":3995,"totalTrials":96,"cells":4022},{"EARLY_PHASE1":4023,"PHASE1":4025,"PHASE2":4027,"PHASE3":4033,"PHASE4":4035,"NA":4037},{"trials":4024,"activeCount":100},[],{"trials":4026,"activeCount":100},[],{"trials":4028,"activeCount":100},[4029],{"nctId":3985,"briefTitle":3986,"status":813,"phases":4030,"primaryCompletion":3988,"completion":3988,"start":3989,"enrollment":3990,"conditions":4031,"interventions":4032},[90],[3992],[3976,3994,3995,3996],{"trials":4034,"activeCount":100},[],{"trials":4036,"activeCount":100},[],{"trials":4038,"activeCount":100},[],{"intervention":3996,"totalTrials":96,"cells":4040},{"EARLY_PHASE1":4041,"PHASE1":4043,"PHASE2":4045,"PHASE3":4051,"PHASE4":4053,"NA":4055},{"trials":4042,"activeCount":100},[],{"trials":4044,"activeCount":100},[],{"trials":4046,"activeCount":100},[4047],{"nctId":3985,"briefTitle":3986,"status":813,"phases":4048,"primaryCompletion":3988,"completion":3988,"start":3989,"enrollment":3990,"conditions":4049,"interventions":4050},[90],[3992],[3976,3994,3995,3996],{"trials":4052,"activeCount":100},[],{"trials":4054,"activeCount":100},[],{"trials":4056,"activeCount":100},[],{"intervention":3164,"totalTrials":96,"cells":4058},{"EARLY_PHASE1":4059,"PHASE1":4061,"PHASE2":4063,"PHASE3":4069,"PHASE4":4071,"NA":4073},{"trials":4060,"activeCount":100},[],{"trials":4062,"activeCount":100},[],{"trials":4064,"activeCount":100},[4065],{"nctId":3156,"briefTitle":3157,"status":243,"phases":4066,"primaryCompletion":3159,"completion":3160,"start":861,"enrollment":3161,"conditions":4067,"interventions":4068},[90],[21,18],[3147,3164],{"trials":4070,"activeCount":100},[],{"trials":4072,"activeCount":100},[],{"trials":4074,"activeCount":100},[],{"intervention":4076,"totalTrials":96,"cells":4077},"OC000459",{"EARLY_PHASE1":4078,"PHASE1":4080,"PHASE2":4082,"PHASE3":4094,"PHASE4":4096,"NA":4098},{"trials":4079,"activeCount":100},[],{"trials":4081,"activeCount":100},[],{"trials":4083,"activeCount":100},[4084],{"nctId":4085,"briefTitle":4086,"status":243,"phases":4087,"primaryCompletion":4088,"completion":4088,"start":4089,"enrollment":4090,"conditions":4091,"interventions":4093},"NCT02560610","Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma",[90],"2018-08-02","2016-09",40,[4092],"Severe Eosinophilic Asthma",[4076],{"trials":4095,"activeCount":100},[],{"trials":4097,"activeCount":100},[],{"trials":4099,"activeCount":100},[],{"intervention":4101,"totalTrials":96,"cells":4102},"CHF6297",{"EARLY_PHASE1":4103,"PHASE1":4105,"PHASE2":4107,"PHASE3":4117,"PHASE4":4119,"NA":4121},{"trials":4104,"activeCount":100},[],{"trials":4106,"activeCount":100},[],{"trials":4108,"activeCount":100},[4109],{"nctId":4110,"briefTitle":4111,"status":813,"phases":4112,"primaryCompletion":4113,"completion":4113,"start":4114,"enrollment":3530,"conditions":4115,"interventions":4116},"NCT02815488","A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD",[89,90],"2019-03","2016-01-22",[18],[4101,4101,4101,4101],{"trials":4118,"activeCount":100},[],{"trials":4120,"activeCount":100},[],{"trials":4122,"activeCount":100},[],{"intervention":3196,"totalTrials":96,"cells":4124},{"EARLY_PHASE1":4125,"PHASE1":4127,"PHASE2":4129,"PHASE3":4135,"PHASE4":4137,"NA":4139},{"trials":4126,"activeCount":100},[],{"trials":4128,"activeCount":100},[],{"trials":4130,"activeCount":100},[4131],{"nctId":3188,"briefTitle":3189,"status":243,"phases":4132,"primaryCompletion":3191,"completion":3191,"start":3192,"enrollment":3193,"conditions":4133,"interventions":4134},[90],[2107],[3179,3196],{"trials":4136,"activeCount":100},[],{"trials":4138,"activeCount":100},[],{"trials":4140,"activeCount":100},[],{"intervention":4142,"totalTrials":96,"cells":4143},"CHF1535 pMDI + AC Plus",{"EARLY_PHASE1":4144,"PHASE1":4146,"PHASE2":4148,"PHASE3":4158,"PHASE4":4160,"NA":4162},{"trials":4145,"activeCount":100},[],{"trials":4147,"activeCount":100},[],{"trials":4149,"activeCount":100},[4150],{"nctId":4151,"briefTitle":4152,"status":243,"phases":4153,"primaryCompletion":563,"completion":563,"start":2635,"enrollment":1154,"conditions":4154,"interventions":4155},"NCT01848769","Clinical Pharmacology Study of CHF1535 pMDI 50\u002F6 µg Versus The Free Combination In Asthmatic Children 5-11 Years Old",[90],[15],[4142,4156,4157],"BDP + AC Plus","Formoterol + AC Plus",{"trials":4159,"activeCount":100},[],{"trials":4161,"activeCount":100},[],{"trials":4163,"activeCount":100},[],{"intervention":4156,"totalTrials":96,"cells":4165},{"EARLY_PHASE1":4166,"PHASE1":4168,"PHASE2":4170,"PHASE3":4176,"PHASE4":4178,"NA":4180},{"trials":4167,"activeCount":100},[],{"trials":4169,"activeCount":100},[],{"trials":4171,"activeCount":100},[4172],{"nctId":4151,"briefTitle":4152,"status":243,"phases":4173,"primaryCompletion":563,"completion":563,"start":2635,"enrollment":1154,"conditions":4174,"interventions":4175},[90],[15],[4142,4156,4157],{"trials":4177,"activeCount":100},[],{"trials":4179,"activeCount":100},[],{"trials":4181,"activeCount":100},[],{"intervention":4157,"totalTrials":96,"cells":4183},{"EARLY_PHASE1":4184,"PHASE1":4186,"PHASE2":4188,"PHASE3":4194,"PHASE4":4196,"NA":4198},{"trials":4185,"activeCount":100},[],{"trials":4187,"activeCount":100},[],{"trials":4189,"activeCount":100},[4190],{"nctId":4151,"briefTitle":4152,"status":243,"phases":4191,"primaryCompletion":563,"completion":563,"start":2635,"enrollment":1154,"conditions":4192,"interventions":4193},[90],[15],[4142,4156,4157],{"trials":4195,"activeCount":100},[],{"trials":4197,"activeCount":100},[],{"trials":4199,"activeCount":100},[],{"intervention":650,"totalTrials":96,"cells":4201},{"EARLY_PHASE1":4202,"PHASE1":4204,"PHASE2":4206,"PHASE3":4212,"PHASE4":4214,"NA":4216},{"trials":4203,"activeCount":100},[],{"trials":4205,"activeCount":100},[],{"trials":4207,"activeCount":100},[4208],{"nctId":641,"briefTitle":642,"status":243,"phases":4209,"primaryCompletion":644,"completion":644,"start":645,"enrollment":646,"conditions":4210,"interventions":4211},[90],[648],[650,632],{"trials":4213,"activeCount":100},[],{"trials":4215,"activeCount":100},[],{"trials":4217,"activeCount":100},[],{"intervention":4219,"totalTrials":96,"cells":4220},"CHF 1535 NEXThaler 800\u002F48",{"EARLY_PHASE1":4221,"PHASE1":4223,"PHASE2":4225,"PHASE3":4239,"PHASE4":4241,"NA":4243},{"trials":4222,"activeCount":100},[],{"trials":4224,"activeCount":100},[],{"trials":4226,"activeCount":100},[4227],{"nctId":4228,"briefTitle":4229,"status":243,"phases":4230,"primaryCompletion":3357,"completion":3357,"start":4231,"enrollment":4232,"conditions":4233,"interventions":4234},"NCT02000609","A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of \"Nexthaler\" Dry Powder Inhaler in COPD Patients",[90],"2013-12",49,[21],[4219,4235,4236,4237,4238],"CHF 1535 NEXThaler 200\u002F12","CHF 1535 NEXThaler PLACEBO","CHF 1535 pMDI 200\u002F12","CHF1535 pMDI 800\u002F48",{"trials":4240,"activeCount":100},[],{"trials":4242,"activeCount":100},[],{"trials":4244,"activeCount":100},[],{"intervention":4235,"totalTrials":96,"cells":4246},{"EARLY_PHASE1":4247,"PHASE1":4249,"PHASE2":4251,"PHASE3":4257,"PHASE4":4259,"NA":4261},{"trials":4248,"activeCount":100},[],{"trials":4250,"activeCount":100},[],{"trials":4252,"activeCount":100},[4253],{"nctId":4228,"briefTitle":4229,"status":243,"phases":4254,"primaryCompletion":3357,"completion":3357,"start":4231,"enrollment":4232,"conditions":4255,"interventions":4256},[90],[21],[4219,4235,4236,4237,4238],{"trials":4258,"activeCount":100},[],{"trials":4260,"activeCount":100},[],{"trials":4262,"activeCount":100},[],{"intervention":4236,"totalTrials":96,"cells":4264},{"EARLY_PHASE1":4265,"PHASE1":4267,"PHASE2":4269,"PHASE3":4275,"PHASE4":4277,"NA":4279},{"trials":4266,"activeCount":100},[],{"trials":4268,"activeCount":100},[],{"trials":4270,"activeCount":100},[4271],{"nctId":4228,"briefTitle":4229,"status":243,"phases":4272,"primaryCompletion":3357,"completion":3357,"start":4231,"enrollment":4232,"conditions":4273,"interventions":4274},[90],[21],[4219,4235,4236,4237,4238],{"trials":4276,"activeCount":100},[],{"trials":4278,"activeCount":100},[],{"trials":4280,"activeCount":100},[],{"intervention":4237,"totalTrials":96,"cells":4282},{"EARLY_PHASE1":4283,"PHASE1":4285,"PHASE2":4287,"PHASE3":4293,"PHASE4":4295,"NA":4297},{"trials":4284,"activeCount":100},[],{"trials":4286,"activeCount":100},[],{"trials":4288,"activeCount":100},[4289],{"nctId":4228,"briefTitle":4229,"status":243,"phases":4290,"primaryCompletion":3357,"completion":3357,"start":4231,"enrollment":4232,"conditions":4291,"interventions":4292},[90],[21],[4219,4235,4236,4237,4238],{"trials":4294,"activeCount":100},[],{"trials":4296,"activeCount":100},[],{"trials":4298,"activeCount":100},[],{"intervention":4238,"totalTrials":96,"cells":4300},{"EARLY_PHASE1":4301,"PHASE1":4303,"PHASE2":4305,"PHASE3":4311,"PHASE4":4313,"NA":4315},{"trials":4302,"activeCount":100},[],{"trials":4304,"activeCount":100},[],{"trials":4306,"activeCount":100},[4307],{"nctId":4228,"briefTitle":4229,"status":243,"phases":4308,"primaryCompletion":3357,"completion":3357,"start":4231,"enrollment":4232,"conditions":4309,"interventions":4310},[90],[21],[4219,4235,4236,4237,4238],{"trials":4312,"activeCount":100},[],{"trials":4314,"activeCount":100},[],{"trials":4316,"activeCount":100},[],{"intervention":4318,"totalTrials":96,"cells":4319},"Test treatments CHF 1535 100\u002F6 pMDI (Foster®) TEST1",{"EARLY_PHASE1":4320,"PHASE1":4322,"PHASE2":4324,"PHASE3":4336,"PHASE4":4338,"NA":4340},{"trials":4321,"activeCount":100},[],{"trials":4323,"activeCount":100},[],{"trials":4325,"activeCount":100},[4326],{"nctId":4327,"briefTitle":4328,"status":243,"phases":4329,"primaryCompletion":1463,"completion":1463,"start":4330,"enrollment":3358,"conditions":4331,"interventions":4332},"NCT01803087","Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients",[90],"2012-02",[15],[4318,4333,4334,4335],"CHF 1535 100\u002F6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2).","BDP pMDI 100 µg","CHF 1535 100\u002F6 pMDI",{"trials":4337,"activeCount":100},[],{"trials":4339,"activeCount":100},[],{"trials":4341,"activeCount":100},[],{"intervention":4333,"totalTrials":96,"cells":4343},{"EARLY_PHASE1":4344,"PHASE1":4346,"PHASE2":4348,"PHASE3":4354,"PHASE4":4356,"NA":4358},{"trials":4345,"activeCount":100},[],{"trials":4347,"activeCount":100},[],{"trials":4349,"activeCount":100},[4350],{"nctId":4327,"briefTitle":4328,"status":243,"phases":4351,"primaryCompletion":1463,"completion":1463,"start":4330,"enrollment":3358,"conditions":4352,"interventions":4353},[90],[15],[4318,4333,4334,4335],{"trials":4355,"activeCount":100},[],{"trials":4357,"activeCount":100},[],{"trials":4359,"activeCount":100},[],{"intervention":4334,"totalTrials":96,"cells":4361},{"EARLY_PHASE1":4362,"PHASE1":4364,"PHASE2":4366,"PHASE3":4372,"PHASE4":4374,"NA":4376},{"trials":4363,"activeCount":100},[],{"trials":4365,"activeCount":100},[],{"trials":4367,"activeCount":100},[4368],{"nctId":4327,"briefTitle":4328,"status":243,"phases":4369,"primaryCompletion":1463,"completion":1463,"start":4330,"enrollment":3358,"conditions":4370,"interventions":4371},[90],[15],[4318,4333,4334,4335],{"trials":4373,"activeCount":100},[],{"trials":4375,"activeCount":100},[],{"trials":4377,"activeCount":100},[],{"intervention":4335,"totalTrials":96,"cells":4379},{"EARLY_PHASE1":4380,"PHASE1":4382,"PHASE2":4384,"PHASE3":4390,"PHASE4":4392,"NA":4394},{"trials":4381,"activeCount":100},[],{"trials":4383,"activeCount":100},[],{"trials":4385,"activeCount":100},[4386],{"nctId":4327,"briefTitle":4328,"status":243,"phases":4387,"primaryCompletion":1463,"completion":1463,"start":4330,"enrollment":3358,"conditions":4388,"interventions":4389},[90],[15],[4318,4333,4334,4335],{"trials":4391,"activeCount":100},[],{"trials":4393,"activeCount":100},[],{"trials":4395,"activeCount":100},[],{"intervention":3205,"totalTrials":96,"cells":4397},{"EARLY_PHASE1":4398,"PHASE1":4400,"PHASE2":4402,"PHASE3":4408,"PHASE4":4410,"NA":4412},{"trials":4399,"activeCount":100},[],{"trials":4401,"activeCount":100},[],{"trials":4403,"activeCount":100},[4404],{"nctId":3198,"briefTitle":3199,"status":243,"phases":4405,"primaryCompletion":3201,"completion":3201,"start":3202,"enrollment":3193,"conditions":4406,"interventions":4407},[90],[15],[3205,3179],{"trials":4409,"activeCount":100},[],{"trials":4411,"activeCount":100},[],{"trials":4413,"activeCount":100},[],{"intervention":4415,"totalTrials":96,"cells":4416},"CHF 1535 Next DPI",{"EARLY_PHASE1":4417,"PHASE1":4419,"PHASE2":4421,"PHASE3":4432,"PHASE4":4434,"NA":4436},{"trials":4418,"activeCount":100},[],{"trials":4420,"activeCount":100},[],{"trials":4422,"activeCount":100},[4423],{"nctId":4424,"briefTitle":4425,"status":243,"phases":4426,"primaryCompletion":4427,"completion":521,"start":681,"enrollment":4428,"conditions":4429,"interventions":4430},"NCT00868023","Next DPI LABA, Multicentre, 5-way Cross-over, Adult Asthmatic Patients",[90],"2009-07",69,[15],[4415,4431,4415,4431],"Foster BDP\u002FFormoterol",{"trials":4433,"activeCount":100},[],{"trials":4435,"activeCount":100},[],{"trials":4437,"activeCount":100},[],{"intervention":4431,"totalTrials":96,"cells":4439},{"EARLY_PHASE1":4440,"PHASE1":4442,"PHASE2":4444,"PHASE3":4450,"PHASE4":4452,"NA":4454},{"trials":4441,"activeCount":100},[],{"trials":4443,"activeCount":100},[],{"trials":4445,"activeCount":100},[4446],{"nctId":4424,"briefTitle":4425,"status":243,"phases":4447,"primaryCompletion":4427,"completion":521,"start":681,"enrollment":4428,"conditions":4448,"interventions":4449},[90],[15],[4415,4431,4415,4431],{"trials":4451,"activeCount":100},[],{"trials":4453,"activeCount":100},[],{"trials":4455,"activeCount":100},[],{"intervention":4457,"totalTrials":96,"cells":4458},"Tacrolimus",{"EARLY_PHASE1":4459,"PHASE1":4461,"PHASE2":4463,"PHASE3":4474,"PHASE4":4476,"NA":4478},{"trials":4460,"activeCount":100},[],{"trials":4462,"activeCount":100},[],{"trials":4464,"activeCount":100},[4465],{"nctId":4466,"briefTitle":4467,"status":243,"phases":4468,"primaryCompletion":4469,"completion":4469,"start":1198,"enrollment":1051,"conditions":4470,"interventions":4472},"NCT02970630","Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical Study",[90],"2018-02-22",[4471],"Kidney Transplantation",[4457,4473],"Everolimus",{"trials":4475,"activeCount":100},[],{"trials":4477,"activeCount":100},[],{"trials":4479,"activeCount":100},[],{"intervention":4473,"totalTrials":96,"cells":4481},{"EARLY_PHASE1":4482,"PHASE1":4484,"PHASE2":4486,"PHASE3":4492,"PHASE4":4494,"NA":4496},{"trials":4483,"activeCount":100},[],{"trials":4485,"activeCount":100},[],{"trials":4487,"activeCount":100},[4488],{"nctId":4466,"briefTitle":4467,"status":243,"phases":4489,"primaryCompletion":4469,"completion":4469,"start":1198,"enrollment":1051,"conditions":4490,"interventions":4491},[90],[4471],[4457,4473],{"trials":4493,"activeCount":100},[],{"trials":4495,"activeCount":100},[],{"trials":4497,"activeCount":100},[],{"intervention":4499,"totalTrials":96,"cells":4500},"CHF 5259 plus Foster 100\u002F6 µg",{"EARLY_PHASE1":4501,"PHASE1":4503,"PHASE2":4505,"PHASE3":4517,"PHASE4":4519,"NA":4521},{"trials":4502,"activeCount":100},[],{"trials":4504,"activeCount":100},[],{"trials":4506,"activeCount":100},[4507],{"nctId":4508,"briefTitle":4509,"status":243,"phases":4510,"primaryCompletion":4511,"completion":4511,"start":4512,"enrollment":4513,"conditions":4514,"interventions":4515},"NCT02127866","Triple in Asthma Dose Finding",[90],"2015-03-08","2014-04-11",211,[15],[4499,4516],"Foster 100\u002F6 µg",{"trials":4518,"activeCount":100},[],{"trials":4520,"activeCount":100},[],{"trials":4522,"activeCount":100},[],{"intervention":4516,"totalTrials":96,"cells":4524},{"EARLY_PHASE1":4525,"PHASE1":4527,"PHASE2":4529,"PHASE3":4535,"PHASE4":4537,"NA":4539},{"trials":4526,"activeCount":100},[],{"trials":4528,"activeCount":100},[],{"trials":4530,"activeCount":100},[4531],{"nctId":4508,"briefTitle":4509,"status":243,"phases":4532,"primaryCompletion":4511,"completion":4511,"start":4512,"enrollment":4513,"conditions":4533,"interventions":4534},[90],[15],[4499,4516],{"trials":4536,"activeCount":100},[],{"trials":4538,"activeCount":100},[],{"trials":4540,"activeCount":100},[],{"intervention":4542,"totalTrials":96,"cells":4543},"CHF1535 NEXThaler",{"EARLY_PHASE1":4544,"PHASE1":4546,"PHASE2":4548,"PHASE3":4559,"PHASE4":4561,"NA":4563},{"trials":4545,"activeCount":100},[],{"trials":4547,"activeCount":100},[],{"trials":4549,"activeCount":100},[4550],{"nctId":4551,"briefTitle":4552,"status":243,"phases":4553,"primaryCompletion":4554,"completion":4554,"start":4555,"enrollment":1229,"conditions":4556,"interventions":4557},"NCT03108534","A Study to Evaluate the Onset of Relief From Methacholine-induced Bronchoconstriction With CHF1535 NEXThaler in Asthmatic Patients.",[90],"2017-09-19","2017-02-28",[15],[4542,4558],"CHF1535 pMDI",{"trials":4560,"activeCount":100},[],{"trials":4562,"activeCount":100},[],{"trials":4564,"activeCount":100},[],{"intervention":4558,"totalTrials":96,"cells":4566},{"EARLY_PHASE1":4567,"PHASE1":4569,"PHASE2":4571,"PHASE3":4577,"PHASE4":4579,"NA":4581},{"trials":4568,"activeCount":100},[],{"trials":4570,"activeCount":100},[],{"trials":4572,"activeCount":100},[4573],{"nctId":4551,"briefTitle":4552,"status":243,"phases":4574,"primaryCompletion":4554,"completion":4554,"start":4555,"enrollment":1229,"conditions":4575,"interventions":4576},[90],[15],[4542,4558],{"trials":4578,"activeCount":100},[],{"trials":4580,"activeCount":100},[],{"trials":4582,"activeCount":100},[],{"intervention":4584,"totalTrials":96,"cells":4585},"Experimental: CHF6001 3200 μg",{"EARLY_PHASE1":4586,"PHASE1":4588,"PHASE2":4590,"PHASE3":4602,"PHASE4":4604,"NA":4606},{"trials":4587,"activeCount":100},[],{"trials":4589,"activeCount":100},[],{"trials":4591,"activeCount":100},[4592],{"nctId":4593,"briefTitle":4594,"status":813,"phases":4595,"primaryCompletion":4596,"completion":4596,"start":4597,"enrollment":4598,"conditions":4599,"interventions":4601},"NCT06029595","Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy",[90],"2025-12-09","2023-11-26",517,[4600],"Uncontrolled Asthma",[4584],{"trials":4603,"activeCount":100},[],{"trials":4605,"activeCount":100},[],{"trials":4607,"activeCount":100},[],{"intervention":4609,"totalTrials":96,"cells":4610},"Clenil® Modulite® via AeroChamber Plus™",{"EARLY_PHASE1":4611,"PHASE1":4613,"PHASE2":4615,"PHASE3":4626,"PHASE4":4628,"NA":4630},{"trials":4612,"activeCount":100},[],{"trials":4614,"activeCount":100},[],{"trials":4616,"activeCount":100},[4617],{"nctId":4618,"briefTitle":4619,"status":243,"phases":4620,"primaryCompletion":3225,"completion":3225,"start":712,"enrollment":11,"conditions":4621,"interventions":4622},"NCT01370031","Pilot Pharmacokinetic Clenil Study With AeroChamber Plus™ or Volumatic™ Spacer Devices",[90],[15],[4609,4623,4624,4625],"Clenil® Modulite® via Volumatic™ spacer","Clenil® Modulite® via AeroChamber Plus™ plus charcoal block","Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block",{"trials":4627,"activeCount":100},[],{"trials":4629,"activeCount":100},[],{"trials":4631,"activeCount":100},[],{"intervention":4623,"totalTrials":96,"cells":4633},{"EARLY_PHASE1":4634,"PHASE1":4636,"PHASE2":4638,"PHASE3":4644,"PHASE4":4646,"NA":4648},{"trials":4635,"activeCount":100},[],{"trials":4637,"activeCount":100},[],{"trials":4639,"activeCount":100},[4640],{"nctId":4618,"briefTitle":4619,"status":243,"phases":4641,"primaryCompletion":3225,"completion":3225,"start":712,"enrollment":11,"conditions":4642,"interventions":4643},[90],[15],[4609,4623,4624,4625],{"trials":4645,"activeCount":100},[],{"trials":4647,"activeCount":100},[],{"trials":4649,"activeCount":100},[],{"intervention":4624,"totalTrials":96,"cells":4651},{"EARLY_PHASE1":4652,"PHASE1":4654,"PHASE2":4656,"PHASE3":4662,"PHASE4":4664,"NA":4666},{"trials":4653,"activeCount":100},[],{"trials":4655,"activeCount":100},[],{"trials":4657,"activeCount":100},[4658],{"nctId":4618,"briefTitle":4619,"status":243,"phases":4659,"primaryCompletion":3225,"completion":3225,"start":712,"enrollment":11,"conditions":4660,"interventions":4661},[90],[15],[4609,4623,4624,4625],{"trials":4663,"activeCount":100},[],{"trials":4665,"activeCount":100},[],{"trials":4667,"activeCount":100},[],{"intervention":4625,"totalTrials":96,"cells":4669},{"EARLY_PHASE1":4670,"PHASE1":4672,"PHASE2":4674,"PHASE3":4680,"PHASE4":4682,"NA":4684},{"trials":4671,"activeCount":100},[],{"trials":4673,"activeCount":100},[],{"trials":4675,"activeCount":100},[4676],{"nctId":4618,"briefTitle":4619,"status":243,"phases":4677,"primaryCompletion":3225,"completion":3225,"start":712,"enrollment":11,"conditions":4678,"interventions":4679},[90],[15],[4609,4623,4624,4625],{"trials":4681,"activeCount":100},[],{"trials":4683,"activeCount":100},[],{"trials":4685,"activeCount":100},[],{"intervention":2970,"totalTrials":234,"cells":4687},{"EARLY_PHASE1":4688,"PHASE1":4690,"PHASE2":4708,"PHASE3":4710,"PHASE4":4712,"NA":4714},{"trials":4689,"activeCount":100},[],{"trials":4691,"activeCount":100},[4692,4696],{"nctId":2962,"briefTitle":2963,"status":243,"phases":4693,"primaryCompletion":2965,"completion":2966,"start":2967,"enrollment":2947,"conditions":4694,"interventions":4695},[89],[18],[1467,2970],{"nctId":4697,"briefTitle":4698,"status":243,"phases":4699,"primaryCompletion":4700,"completion":4700,"start":4701,"enrollment":4702,"conditions":4703,"interventions":4705},"NCT06746064","A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF10073 After Single and Multiple Doses in Healthy Volunteers and the Effect of Itraconazole on CHF10073 Exposure",[89],"2026-02-04","2025-01-13",155,[4704],"Pulmonary Fibrosis",[4706,4706,4706,4707,4706],"CHF10073","itraconazole",{"trials":4709,"activeCount":100},[],{"trials":4711,"activeCount":100},[],{"trials":4713,"activeCount":100},[],{"trials":4715,"activeCount":100},[],{"intervention":4717,"totalTrials":96,"cells":4718},"synthetic surfactant",{"EARLY_PHASE1":4719,"PHASE1":4721,"PHASE2":4731,"PHASE3":4733,"PHASE4":4735,"NA":4737},{"trials":4720,"activeCount":100},[],{"trials":4722,"activeCount":100},[4723],{"nctId":4724,"briefTitle":4725,"status":243,"phases":4726,"primaryCompletion":4727,"completion":4727,"start":1463,"enrollment":4090,"conditions":4728,"interventions":4730},"NCT01651637","First In Human Study on Synthetic Surfactant CHF 5633 in Respiratory Distress Syndrome",[89],"2015-01-23",[4729],"Respiratory Distress Syndrome in Premature Infants",[4717],{"trials":4732,"activeCount":100},[],{"trials":4734,"activeCount":100},[],{"trials":4736,"activeCount":100},[],{"trials":4738,"activeCount":100},[],{"intervention":4740,"totalTrials":96,"cells":4741},"Single Ascending Dose",{"EARLY_PHASE1":4742,"PHASE1":4744,"PHASE2":4755,"PHASE3":4757,"PHASE4":4759,"NA":4761},{"trials":4743,"activeCount":100},[],{"trials":4745,"activeCount":100},[4746],{"nctId":4747,"briefTitle":4748,"status":243,"phases":4749,"primaryCompletion":590,"completion":590,"start":4750,"enrollment":4751,"conditions":4752,"interventions":4753},"NCT02386761","A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001",[89],"2014-11",48,[18],[4740,4754],"Multiple Ascending Dose",{"trials":4756,"activeCount":100},[],{"trials":4758,"activeCount":100},[],{"trials":4760,"activeCount":100},[],{"trials":4762,"activeCount":100},[],{"intervention":4754,"totalTrials":96,"cells":4764},{"EARLY_PHASE1":4765,"PHASE1":4767,"PHASE2":4773,"PHASE3":4775,"PHASE4":4777,"NA":4779},{"trials":4766,"activeCount":100},[],{"trials":4768,"activeCount":100},[4769],{"nctId":4747,"briefTitle":4748,"status":243,"phases":4770,"primaryCompletion":590,"completion":590,"start":4750,"enrollment":4751,"conditions":4771,"interventions":4772},[89],[18],[4740,4754],{"trials":4774,"activeCount":100},[],{"trials":4776,"activeCount":100},[],{"trials":4778,"activeCount":100},[],{"trials":4780,"activeCount":100},[],{"intervention":4782,"totalTrials":96,"cells":4783},"CHF5259 and CHF6001",{"EARLY_PHASE1":4784,"PHASE1":4786,"PHASE2":4797,"PHASE3":4799,"PHASE4":4801,"NA":4803},{"trials":4785,"activeCount":100},[],{"trials":4787,"activeCount":100},[4788],{"nctId":4789,"briefTitle":4790,"status":243,"phases":4791,"primaryCompletion":3202,"completion":3202,"start":982,"enrollment":961,"conditions":4792,"interventions":4794},"NCT03004495","Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001",[89],[4793],"Copd",[4782,4795,4796],"CHF5259 + placebo","CHF6001 + placebo",{"trials":4798,"activeCount":100},[],{"trials":4800,"activeCount":100},[],{"trials":4802,"activeCount":100},[],{"trials":4804,"activeCount":100},[],{"intervention":4795,"totalTrials":96,"cells":4806},{"EARLY_PHASE1":4807,"PHASE1":4809,"PHASE2":4815,"PHASE3":4817,"PHASE4":4819,"NA":4821},{"trials":4808,"activeCount":100},[],{"trials":4810,"activeCount":100},[4811],{"nctId":4789,"briefTitle":4790,"status":243,"phases":4812,"primaryCompletion":3202,"completion":3202,"start":982,"enrollment":961,"conditions":4813,"interventions":4814},[89],[4793],[4782,4795,4796],{"trials":4816,"activeCount":100},[],{"trials":4818,"activeCount":100},[],{"trials":4820,"activeCount":100},[],{"trials":4822,"activeCount":100},[],{"intervention":4796,"totalTrials":96,"cells":4824},{"EARLY_PHASE1":4825,"PHASE1":4827,"PHASE2":4833,"PHASE3":4835,"PHASE4":4837,"NA":4839},{"trials":4826,"activeCount":100},[],{"trials":4828,"activeCount":100},[4829],{"nctId":4789,"briefTitle":4790,"status":243,"phases":4830,"primaryCompletion":3202,"completion":3202,"start":982,"enrollment":961,"conditions":4831,"interventions":4832},[89],[4793],[4782,4795,4796],{"trials":4834,"activeCount":100},[],{"trials":4836,"activeCount":100},[],{"trials":4838,"activeCount":100},[],{"trials":4840,"activeCount":100},[],{"intervention":4842,"totalTrials":96,"cells":4843},"Test product (T):CHF 5993 BDP\u002FFF\u002FGB 200\u002F6\u002F12.5 µg pMDI",{"EARLY_PHASE1":4844,"PHASE1":4846,"PHASE2":4858,"PHASE3":4860,"PHASE4":4862,"NA":4864},{"trials":4845,"activeCount":100},[],{"trials":4847,"activeCount":100},[4848],{"nctId":4849,"briefTitle":4850,"status":243,"phases":4851,"primaryCompletion":4852,"completion":4852,"start":4853,"enrollment":4428,"conditions":4854,"interventions":4855},"NCT05898984","Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®",[89],"2023-07-14","2023-04-24",[15],[4842,4856,4857],"Reference product 1 (R1): CHF 5993 BDP\u002FFF\u002FGB 100\u002F6\u002F12.5 µg pMDI","Reference product 2",{"trials":4859,"activeCount":100},[],{"trials":4861,"activeCount":100},[],{"trials":4863,"activeCount":100},[],{"trials":4865,"activeCount":100},[],{"intervention":4856,"totalTrials":96,"cells":4867},{"EARLY_PHASE1":4868,"PHASE1":4870,"PHASE2":4876,"PHASE3":4878,"PHASE4":4880,"NA":4882},{"trials":4869,"activeCount":100},[],{"trials":4871,"activeCount":100},[4872],{"nctId":4849,"briefTitle":4850,"status":243,"phases":4873,"primaryCompletion":4852,"completion":4852,"start":4853,"enrollment":4428,"conditions":4874,"interventions":4875},[89],[15],[4842,4856,4857],{"trials":4877,"activeCount":100},[],{"trials":4879,"activeCount":100},[],{"trials":4881,"activeCount":100},[],{"trials":4883,"activeCount":100},[],{"intervention":4857,"totalTrials":96,"cells":4885},{"EARLY_PHASE1":4886,"PHASE1":4888,"PHASE2":4894,"PHASE3":4896,"PHASE4":4898,"NA":4900},{"trials":4887,"activeCount":100},[],{"trials":4889,"activeCount":100},[4890],{"nctId":4849,"briefTitle":4850,"status":243,"phases":4891,"primaryCompletion":4852,"completion":4852,"start":4853,"enrollment":4428,"conditions":4892,"interventions":4893},[89],[15],[4842,4856,4857],{"trials":4895,"activeCount":100},[],{"trials":4897,"activeCount":100},[],{"trials":4899,"activeCount":100},[],{"trials":4901,"activeCount":100},[],{"intervention":4903,"totalTrials":96,"cells":4904},"CHF10067 starting dose -- 1000mg",{"EARLY_PHASE1":4905,"PHASE1":4907,"PHASE2":4920,"PHASE3":4922,"PHASE4":4924,"NA":4926},{"trials":4906,"activeCount":100},[],{"trials":4908,"activeCount":100},[4909],{"nctId":4910,"briefTitle":4911,"status":243,"phases":4912,"primaryCompletion":4913,"completion":4913,"start":4914,"enrollment":4915,"conditions":4916,"interventions":4917},"NCT05513950","A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (SAD).",[89],"2024-06-17","2023-01-25",52,[279],[4903,4918,4919],"CHF10067 intermediate dose -- 2000mg","CHF10067 high dose -- 3000mg",{"trials":4921,"activeCount":100},[],{"trials":4923,"activeCount":100},[],{"trials":4925,"activeCount":100},[],{"trials":4927,"activeCount":100},[],{"intervention":4918,"totalTrials":96,"cells":4929},{"EARLY_PHASE1":4930,"PHASE1":4932,"PHASE2":4938,"PHASE3":4940,"PHASE4":4942,"NA":4944},{"trials":4931,"activeCount":100},[],{"trials":4933,"activeCount":100},[4934],{"nctId":4910,"briefTitle":4911,"status":243,"phases":4935,"primaryCompletion":4913,"completion":4913,"start":4914,"enrollment":4915,"conditions":4936,"interventions":4937},[89],[279],[4903,4918,4919],{"trials":4939,"activeCount":100},[],{"trials":4941,"activeCount":100},[],{"trials":4943,"activeCount":100},[],{"trials":4945,"activeCount":100},[],{"intervention":4919,"totalTrials":96,"cells":4947},{"EARLY_PHASE1":4948,"PHASE1":4950,"PHASE2":4956,"PHASE3":4958,"PHASE4":4960,"NA":4962},{"trials":4949,"activeCount":100},[],{"trials":4951,"activeCount":100},[4952],{"nctId":4910,"briefTitle":4911,"status":243,"phases":4953,"primaryCompletion":4913,"completion":4913,"start":4914,"enrollment":4915,"conditions":4954,"interventions":4955},[89],[279],[4903,4918,4919],{"trials":4957,"activeCount":100},[],{"trials":4959,"activeCount":100},[],{"trials":4961,"activeCount":100},[],{"trials":4963,"activeCount":100},[],{"intervention":4965,"totalTrials":96,"cells":4966},"CHF 5993 HS 200\u002F6\u002F25 pMDI",{"EARLY_PHASE1":4967,"PHASE1":4969,"PHASE2":4980,"PHASE3":4982,"PHASE4":4984,"NA":4986},{"trials":4968,"activeCount":100},[],{"trials":4970,"activeCount":100},[4971],{"nctId":4972,"briefTitle":4973,"status":243,"phases":4974,"primaryCompletion":969,"completion":602,"start":959,"enrollment":3652,"conditions":4975,"interventions":4976},"NCT02359292","Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers",[89],[15],[4965,4977,4978,4979],"CHF 5993 MS 100\u002F6\u002F25 pMDI","CHF 5993 HS 200\u002F6\u002F25 pMDI + Charcoal Block","CHF 5993 MS 100\u002F6\u002F25 pMDI + Charcoal Block",{"trials":4981,"activeCount":100},[],{"trials":4983,"activeCount":100},[],{"trials":4985,"activeCount":100},[],{"trials":4987,"activeCount":100},[],{"intervention":4977,"totalTrials":96,"cells":4989},{"EARLY_PHASE1":4990,"PHASE1":4992,"PHASE2":4998,"PHASE3":5000,"PHASE4":5002,"NA":5004},{"trials":4991,"activeCount":100},[],{"trials":4993,"activeCount":100},[4994],{"nctId":4972,"briefTitle":4973,"status":243,"phases":4995,"primaryCompletion":969,"completion":602,"start":959,"enrollment":3652,"conditions":4996,"interventions":4997},[89],[15],[4965,4977,4978,4979],{"trials":4999,"activeCount":100},[],{"trials":5001,"activeCount":100},[],{"trials":5003,"activeCount":100},[],{"trials":5005,"activeCount":100},[],{"intervention":4978,"totalTrials":96,"cells":5007},{"EARLY_PHASE1":5008,"PHASE1":5010,"PHASE2":5016,"PHASE3":5018,"PHASE4":5020,"NA":5022},{"trials":5009,"activeCount":100},[],{"trials":5011,"activeCount":100},[5012],{"nctId":4972,"briefTitle":4973,"status":243,"phases":5013,"primaryCompletion":969,"completion":602,"start":959,"enrollment":3652,"conditions":5014,"interventions":5015},[89],[15],[4965,4977,4978,4979],{"trials":5017,"activeCount":100},[],{"trials":5019,"activeCount":100},[],{"trials":5021,"activeCount":100},[],{"trials":5023,"activeCount":100},[],{"intervention":4979,"totalTrials":96,"cells":5025},{"EARLY_PHASE1":5026,"PHASE1":5028,"PHASE2":5034,"PHASE3":5036,"PHASE4":5038,"NA":5040},{"trials":5027,"activeCount":100},[],{"trials":5029,"activeCount":100},[5030],{"nctId":4972,"briefTitle":4973,"status":243,"phases":5031,"primaryCompletion":969,"completion":602,"start":959,"enrollment":3652,"conditions":5032,"interventions":5033},[89],[15],[4965,4977,4978,4979],{"trials":5035,"activeCount":100},[],{"trials":5037,"activeCount":100},[],{"trials":5039,"activeCount":100},[],{"trials":5041,"activeCount":100},[],{"intervention":3077,"totalTrials":96,"cells":5043},{"EARLY_PHASE1":5044,"PHASE1":5046,"PHASE2":5052,"PHASE3":5054,"PHASE4":5056,"NA":5058},{"trials":5045,"activeCount":100},[],{"trials":5047,"activeCount":100},[5048],{"nctId":3069,"briefTitle":3070,"status":243,"phases":5049,"primaryCompletion":3072,"completion":3072,"start":3073,"enrollment":3074,"conditions":5050,"interventions":5051},[89],[18],[3062,3062,3077],{"trials":5053,"activeCount":100},[],{"trials":5055,"activeCount":100},[],{"trials":5057,"activeCount":100},[],{"trials":5059,"activeCount":100},[],{"intervention":2950,"totalTrials":96,"cells":5061},{"EARLY_PHASE1":5062,"PHASE1":5064,"PHASE2":5070,"PHASE3":5072,"PHASE4":5074,"NA":5076},{"trials":5063,"activeCount":100},[],{"trials":5065,"activeCount":100},[5066],{"nctId":2942,"briefTitle":2943,"status":243,"phases":5067,"primaryCompletion":2945,"completion":2945,"start":2946,"enrollment":2947,"conditions":5068,"interventions":5069},[89],[18],[1467,2950],{"trials":5071,"activeCount":100},[],{"trials":5073,"activeCount":100},[],{"trials":5075,"activeCount":100},[],{"trials":5077,"activeCount":100},[],{"intervention":5079,"totalTrials":96,"cells":5080},"CHF6523",{"EARLY_PHASE1":5081,"PHASE1":5083,"PHASE2":5094,"PHASE3":5096,"PHASE4":5098,"NA":5100},{"trials":5082,"activeCount":100},[],{"trials":5084,"activeCount":100},[5085],{"nctId":5086,"briefTitle":5087,"status":243,"phases":5088,"primaryCompletion":5089,"completion":5089,"start":5090,"enrollment":5091,"conditions":5092,"interventions":5093},"NCT04032535","Investigate the Safety, Tolerability and Pharmacokinetics of CHF6523 in Healthy and in COPD Subjects",[89],"2022-12-05","2019-07-24",136,[21],[5079],{"trials":5095,"activeCount":100},[],{"trials":5097,"activeCount":100},[],{"trials":5099,"activeCount":100},[],{"trials":5101,"activeCount":100},[],{"intervention":5103,"totalTrials":96,"cells":5104},"Cangrelor",{"EARLY_PHASE1":5105,"PHASE1":5107,"PHASE2":5120,"PHASE3":5122,"PHASE4":5124,"NA":5126},{"trials":5106,"activeCount":100},[],{"trials":5108,"activeCount":100},[5109],{"nctId":5110,"briefTitle":5111,"status":243,"phases":5112,"primaryCompletion":5113,"completion":5114,"start":5115,"enrollment":151,"conditions":5116,"interventions":5119},"NCT02765633","Cangrelor Neonatal PK\u002FPD and Safety Study",[89],"2019-08-31","2019-12-23","2017-01-03",[5117,5118],"Partial Obstruction of Systemic to Pulmonary Artery Shunt","Complete Obstruction of Systemic to Pulmonary Artery Shunt",[5103],{"trials":5121,"activeCount":100},[],{"trials":5123,"activeCount":100},[],{"trials":5125,"activeCount":100},[],{"trials":5127,"activeCount":100},[],{"intervention":2959,"totalTrials":96,"cells":5129},{"EARLY_PHASE1":5130,"PHASE1":5132,"PHASE2":5138,"PHASE3":5140,"PHASE4":5142,"NA":5144},{"trials":5131,"activeCount":100},[],{"trials":5133,"activeCount":100},[5134],{"nctId":2952,"briefTitle":2953,"status":243,"phases":5135,"primaryCompletion":2955,"completion":2955,"start":2956,"enrollment":1289,"conditions":5136,"interventions":5137},[89],[27],[2959,2960,1467],{"trials":5139,"activeCount":100},[],{"trials":5141,"activeCount":100},[],{"trials":5143,"activeCount":100},[],{"trials":5145,"activeCount":100},[],{"intervention":2960,"totalTrials":96,"cells":5147},{"EARLY_PHASE1":5148,"PHASE1":5150,"PHASE2":5156,"PHASE3":5158,"PHASE4":5160,"NA":5162},{"trials":5149,"activeCount":100},[],{"trials":5151,"activeCount":100},[5152],{"nctId":2952,"briefTitle":2953,"status":243,"phases":5153,"primaryCompletion":2955,"completion":2955,"start":2956,"enrollment":1289,"conditions":5154,"interventions":5155},[89],[27],[2959,2960,1467],{"trials":5157,"activeCount":100},[],{"trials":5159,"activeCount":100},[],{"trials":5161,"activeCount":100},[],{"trials":5163,"activeCount":100},[],{"intervention":5165,"totalTrials":96,"cells":5166},"pMDI standard actuator",{"EARLY_PHASE1":5167,"PHASE1":5169,"PHASE2":5178,"PHASE3":5180,"PHASE4":5182,"NA":5184},{"trials":5168,"activeCount":100},[],{"trials":5170,"activeCount":100},[5171],{"nctId":5172,"briefTitle":5173,"status":243,"phases":5174,"primaryCompletion":5175,"completion":5175,"start":2556,"enrollment":8,"conditions":5176,"interventions":5177},"NCT01280175","Foster With or Without Charcoal Block or Aerochamber Plus",[89],"2007-02",[374],[5165],{"trials":5179,"activeCount":100},[],{"trials":5181,"activeCount":100},[],{"trials":5183,"activeCount":100},[],{"trials":5185,"activeCount":100},[],{"intervention":1295,"totalTrials":96,"cells":5187},{"EARLY_PHASE1":5188,"PHASE1":5190,"PHASE2":5196,"PHASE3":5198,"PHASE4":5200,"NA":5202},{"trials":5189,"activeCount":100},[],{"trials":5191,"activeCount":100},[5192],{"nctId":1284,"briefTitle":1285,"status":243,"phases":5193,"primaryCompletion":1287,"completion":1287,"start":1288,"enrollment":1289,"conditions":5194,"interventions":5195},[89],[15],[1277,1292,1293,1294,1295,1296],{"trials":5197,"activeCount":100},[],{"trials":5199,"activeCount":100},[],{"trials":5201,"activeCount":100},[],{"trials":5203,"activeCount":100},[],{"intervention":1296,"totalTrials":96,"cells":5205},{"EARLY_PHASE1":5206,"PHASE1":5208,"PHASE2":5214,"PHASE3":5216,"PHASE4":5218,"NA":5220},{"trials":5207,"activeCount":100},[],{"trials":5209,"activeCount":100},[5210],{"nctId":1284,"briefTitle":1285,"status":243,"phases":5211,"primaryCompletion":1287,"completion":1287,"start":1288,"enrollment":1289,"conditions":5212,"interventions":5213},[89],[15],[1277,1292,1293,1294,1295,1296],{"trials":5215,"activeCount":100},[],{"trials":5217,"activeCount":100},[],{"trials":5219,"activeCount":100},[],{"trials":5221,"activeCount":100},[],{"intervention":5223,"totalTrials":96,"cells":5224},"Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide",{"EARLY_PHASE1":5225,"PHASE1":5227,"PHASE2":5238,"PHASE3":5240,"PHASE4":5242,"NA":5244},{"trials":5226,"activeCount":100},[],{"trials":5228,"activeCount":100},[5229],{"nctId":5230,"briefTitle":5231,"status":813,"phases":5232,"primaryCompletion":5233,"completion":5233,"start":5234,"enrollment":5235,"conditions":5236,"interventions":5237},"NCT03795350","Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients",[89],"2020-04-03","2019-01-14",19,[18,15],[5223],{"trials":5239,"activeCount":100},[],{"trials":5241,"activeCount":100},[],{"trials":5243,"activeCount":100},[],{"trials":5245,"activeCount":100},[],{"intervention":5247,"totalTrials":96,"cells":5248},"Therapeutic Dose 1",{"EARLY_PHASE1":5249,"PHASE1":5251,"PHASE2":5263,"PHASE3":5265,"PHASE4":5267,"NA":5269},{"trials":5250,"activeCount":100},[],{"trials":5252,"activeCount":100},[5253],{"nctId":5254,"briefTitle":5255,"status":243,"phases":5256,"primaryCompletion":5090,"completion":5090,"start":5257,"enrollment":5258,"conditions":5259,"interventions":5260},"NCT03859414","PK of BDP\u002FFF\u002FGB Single-inhaler Triple Therapy in Japanese vs. Caucasians",[89],"2019-03-18",32,[15,18],[5247,5261,5262],"Therapeutic Dose 2","Supra-therapeutic Dose",{"trials":5264,"activeCount":100},[],{"trials":5266,"activeCount":100},[],{"trials":5268,"activeCount":100},[],{"trials":5270,"activeCount":100},[],{"intervention":5261,"totalTrials":96,"cells":5272},{"EARLY_PHASE1":5273,"PHASE1":5275,"PHASE2":5281,"PHASE3":5283,"PHASE4":5285,"NA":5287},{"trials":5274,"activeCount":100},[],{"trials":5276,"activeCount":100},[5277],{"nctId":5254,"briefTitle":5255,"status":243,"phases":5278,"primaryCompletion":5090,"completion":5090,"start":5257,"enrollment":5258,"conditions":5279,"interventions":5280},[89],[15,18],[5247,5261,5262],{"trials":5282,"activeCount":100},[],{"trials":5284,"activeCount":100},[],{"trials":5286,"activeCount":100},[],{"trials":5288,"activeCount":100},[],{"intervention":5262,"totalTrials":96,"cells":5290},{"EARLY_PHASE1":5291,"PHASE1":5293,"PHASE2":5299,"PHASE3":5301,"PHASE4":5303,"NA":5305},{"trials":5292,"activeCount":100},[],{"trials":5294,"activeCount":100},[5295],{"nctId":5254,"briefTitle":5255,"status":243,"phases":5296,"primaryCompletion":5090,"completion":5090,"start":5257,"enrollment":5258,"conditions":5297,"interventions":5298},[89],[15,18],[5247,5261,5262],{"trials":5300,"activeCount":100},[],{"trials":5302,"activeCount":100},[],{"trials":5304,"activeCount":100},[],{"trials":5306,"activeCount":100},[],{"intervention":5308,"totalTrials":96,"cells":5309},"CHF 5993 100\u002F6\u002F12,5 pMDI",{"EARLY_PHASE1":5310,"PHASE1":5312,"PHASE2":5326,"PHASE3":5328,"PHASE4":5330,"NA":5332},{"trials":5311,"activeCount":100},[],{"trials":5313,"activeCount":100},[5314],{"nctId":5315,"briefTitle":5316,"status":243,"phases":5317,"primaryCompletion":5318,"completion":5318,"start":5319,"enrollment":3652,"conditions":5320,"interventions":5321},"NCT02743013","Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers",[89],"2016-07","2016-04",[21],[5308,5322,5323,5324,5325],"CHF 5993 100\u002F6\u002F12,5 DPI Test 1","CHF 5993 100\u002F6\u002F12,5 DPI Test 2","CHF 5993 100\u002F6\u002F12,5 pMDI replicate","CHF 5993 100\u002F6\u002F12,5 pMDI with Valved Holding Chamber",{"trials":5327,"activeCount":100},[],{"trials":5329,"activeCount":100},[],{"trials":5331,"activeCount":100},[],{"trials":5333,"activeCount":100},[],{"intervention":5322,"totalTrials":96,"cells":5335},{"EARLY_PHASE1":5336,"PHASE1":5338,"PHASE2":5344,"PHASE3":5346,"PHASE4":5348,"NA":5350},{"trials":5337,"activeCount":100},[],{"trials":5339,"activeCount":100},[5340],{"nctId":5315,"briefTitle":5316,"status":243,"phases":5341,"primaryCompletion":5318,"completion":5318,"start":5319,"enrollment":3652,"conditions":5342,"interventions":5343},[89],[21],[5308,5322,5323,5324,5325],{"trials":5345,"activeCount":100},[],{"trials":5347,"activeCount":100},[],{"trials":5349,"activeCount":100},[],{"trials":5351,"activeCount":100},[],{"intervention":5323,"totalTrials":96,"cells":5353},{"EARLY_PHASE1":5354,"PHASE1":5356,"PHASE2":5362,"PHASE3":5364,"PHASE4":5366,"NA":5368},{"trials":5355,"activeCount":100},[],{"trials":5357,"activeCount":100},[5358],{"nctId":5315,"briefTitle":5316,"status":243,"phases":5359,"primaryCompletion":5318,"completion":5318,"start":5319,"enrollment":3652,"conditions":5360,"interventions":5361},[89],[21],[5308,5322,5323,5324,5325],{"trials":5363,"activeCount":100},[],{"trials":5365,"activeCount":100},[],{"trials":5367,"activeCount":100},[],{"trials":5369,"activeCount":100},[],{"intervention":5324,"totalTrials":96,"cells":5371},{"EARLY_PHASE1":5372,"PHASE1":5374,"PHASE2":5380,"PHASE3":5382,"PHASE4":5384,"NA":5386},{"trials":5373,"activeCount":100},[],{"trials":5375,"activeCount":100},[5376],{"nctId":5315,"briefTitle":5316,"status":243,"phases":5377,"primaryCompletion":5318,"completion":5318,"start":5319,"enrollment":3652,"conditions":5378,"interventions":5379},[89],[21],[5308,5322,5323,5324,5325],{"trials":5381,"activeCount":100},[],{"trials":5383,"activeCount":100},[],{"trials":5385,"activeCount":100},[],{"trials":5387,"activeCount":100},[],{"intervention":5325,"totalTrials":96,"cells":5389},{"EARLY_PHASE1":5390,"PHASE1":5392,"PHASE2":5398,"PHASE3":5400,"PHASE4":5402,"NA":5404},{"trials":5391,"activeCount":100},[],{"trials":5393,"activeCount":100},[5394],{"nctId":5315,"briefTitle":5316,"status":243,"phases":5395,"primaryCompletion":5318,"completion":5318,"start":5319,"enrollment":3652,"conditions":5396,"interventions":5397},[89],[21],[5308,5322,5323,5324,5325],{"trials":5399,"activeCount":100},[],{"trials":5401,"activeCount":100},[],{"trials":5403,"activeCount":100},[],{"trials":5405,"activeCount":100},[],{"intervention":5407,"totalTrials":96,"cells":5408},"CHF 6001 SD or placebo",{"EARLY_PHASE1":5409,"PHASE1":5411,"PHASE2":5420,"PHASE3":5422,"PHASE4":5424,"NA":5426},{"trials":5410,"activeCount":100},[],{"trials":5412,"activeCount":100},[5413],{"nctId":5414,"briefTitle":5415,"status":243,"phases":5416,"primaryCompletion":3007,"completion":3007,"start":2996,"enrollment":2997,"conditions":5417,"interventions":5418},"NCT01703052","Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers (HV)",[89],[27],[5407,5419],"CHF 6001 MD or placebo",{"trials":5421,"activeCount":100},[],{"trials":5423,"activeCount":100},[],{"trials":5425,"activeCount":100},[],{"trials":5427,"activeCount":100},[],{"intervention":5419,"totalTrials":96,"cells":5429},{"EARLY_PHASE1":5430,"PHASE1":5432,"PHASE2":5438,"PHASE3":5440,"PHASE4":5442,"NA":5444},{"trials":5431,"activeCount":100},[],{"trials":5433,"activeCount":100},[5434],{"nctId":5414,"briefTitle":5415,"status":243,"phases":5435,"primaryCompletion":3007,"completion":3007,"start":2996,"enrollment":2997,"conditions":5436,"interventions":5437},[89],[27],[5407,5419],{"trials":5439,"activeCount":100},[],{"trials":5441,"activeCount":100},[],{"trials":5443,"activeCount":100},[],{"trials":5445,"activeCount":100},[],{"intervention":5447,"totalTrials":96,"cells":5448},"CH6001",{"EARLY_PHASE1":5449,"PHASE1":5451,"PHASE2":5461,"PHASE3":5463,"PHASE4":5465,"NA":5467},{"trials":5450,"activeCount":100},[],{"trials":5452,"activeCount":100},[5453],{"nctId":5454,"briefTitle":5455,"status":243,"phases":5456,"primaryCompletion":5457,"completion":5457,"start":5458,"enrollment":1005,"conditions":5459,"interventions":5460},"NCT05431426","PK of CHF6001 in Subjects With Mild, Moderate and Severe Renal Impairment vs. Healthy Volunteers",[89],"2022-12-27","2022-07-29",[18],[5447],{"trials":5462,"activeCount":100},[],{"trials":5464,"activeCount":100},[],{"trials":5466,"activeCount":100},[],{"trials":5468,"activeCount":100},[],{"intervention":5470,"totalTrials":96,"cells":5471},"Bramitob® administered by PARI LC® PLUS nebulizer",{"EARLY_PHASE1":5472,"PHASE1":5474,"PHASE2":5483,"PHASE3":5485,"PHASE4":5487,"NA":5489},{"trials":5473,"activeCount":100},[],{"trials":5475,"activeCount":100},[5476],{"nctId":5477,"briefTitle":5478,"status":243,"phases":5479,"primaryCompletion":2717,"completion":2717,"start":547,"enrollment":1637,"conditions":5480,"interventions":5481},"NCT01116089","Pharmacokinetic Study of Bramitob® Administered for Inhalation by PARI eFlow® vs PARI LC® PLUS Nebulizer",[89],[32],[5470,5482],"Bramitob® administered by PARI eFlow® rapid electronic nebulizer",{"trials":5484,"activeCount":100},[],{"trials":5486,"activeCount":100},[],{"trials":5488,"activeCount":100},[],{"trials":5490,"activeCount":100},[],{"intervention":5482,"totalTrials":96,"cells":5492},{"EARLY_PHASE1":5493,"PHASE1":5495,"PHASE2":5501,"PHASE3":5503,"PHASE4":5505,"NA":5507},{"trials":5494,"activeCount":100},[],{"trials":5496,"activeCount":100},[5497],{"nctId":5477,"briefTitle":5478,"status":243,"phases":5498,"primaryCompletion":2717,"completion":2717,"start":547,"enrollment":1637,"conditions":5499,"interventions":5500},[89],[32],[5470,5482],{"trials":5502,"activeCount":100},[],{"trials":5504,"activeCount":100},[],{"trials":5506,"activeCount":100},[],{"trials":5508,"activeCount":100},[],{"intervention":5510,"totalTrials":96,"cells":5511},"CHF 6333",{"EARLY_PHASE1":5512,"PHASE1":5514,"PHASE2":5524,"PHASE3":5526,"PHASE4":5528,"NA":5530},{"trials":5513,"activeCount":100},[],{"trials":5515,"activeCount":100},[5516],{"nctId":5517,"briefTitle":5518,"status":243,"phases":5519,"primaryCompletion":5520,"completion":5520,"start":5521,"enrollment":372,"conditions":5522,"interventions":5523},"NCT04010799","A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis",[89],"2021-03-08","2019-05-27",[32,249],[5510],{"trials":5525,"activeCount":100},[],{"trials":5527,"activeCount":100},[],{"trials":5529,"activeCount":100},[],{"trials":5531,"activeCount":100},[],{"intervention":1008,"totalTrials":96,"cells":5533},{"EARLY_PHASE1":5534,"PHASE1":5536,"PHASE2":5542,"PHASE3":5544,"PHASE4":5546,"NA":5548},{"trials":5535,"activeCount":100},[],{"trials":5537,"activeCount":100},[5538],{"nctId":1000,"briefTitle":1001,"status":243,"phases":5539,"primaryCompletion":1003,"completion":1003,"start":1004,"enrollment":1005,"conditions":5540,"interventions":5541},[89],[21],[1008,1009,993],{"trials":5543,"activeCount":100},[],{"trials":5545,"activeCount":100},[],{"trials":5547,"activeCount":100},[],{"trials":5549,"activeCount":100},[],{"intervention":5551,"totalTrials":96,"cells":5552},"CHF 5993 pMDI",{"EARLY_PHASE1":5553,"PHASE1":5555,"PHASE2":5567,"PHASE3":5569,"PHASE4":5571,"NA":5573},{"trials":5554,"activeCount":100},[],{"trials":5556,"activeCount":100},[5557],{"nctId":5558,"briefTitle":5559,"status":243,"phases":5560,"primaryCompletion":5561,"completion":5562,"start":5563,"enrollment":1637,"conditions":5564,"interventions":5565},"NCT02287272","Drug-drug Interaction Study of CHF5993 With Cimetidine",[89],"2014-07","2014-09","2014-05",[21],[5551,5566],"Cimetidine plus CHF5993 pMDI",{"trials":5568,"activeCount":100},[],{"trials":5570,"activeCount":100},[],{"trials":5572,"activeCount":100},[],{"trials":5574,"activeCount":100},[],{"intervention":5566,"totalTrials":96,"cells":5576},{"EARLY_PHASE1":5577,"PHASE1":5579,"PHASE2":5585,"PHASE3":5587,"PHASE4":5589,"NA":5591},{"trials":5578,"activeCount":100},[],{"trials":5580,"activeCount":100},[5581],{"nctId":5558,"briefTitle":5559,"status":243,"phases":5582,"primaryCompletion":5561,"completion":5562,"start":5563,"enrollment":1637,"conditions":5583,"interventions":5584},[89],[21],[5551,5566],{"trials":5586,"activeCount":100},[],{"trials":5588,"activeCount":100},[],{"trials":5590,"activeCount":100},[],{"trials":5592,"activeCount":100},[],{"intervention":4706,"totalTrials":96,"cells":5594},{"EARLY_PHASE1":5595,"PHASE1":5597,"PHASE2":5603,"PHASE3":5605,"PHASE4":5607,"NA":5609},{"trials":5596,"activeCount":100},[],{"trials":5598,"activeCount":100},[5599],{"nctId":4697,"briefTitle":4698,"status":243,"phases":5600,"primaryCompletion":4700,"completion":4700,"start":4701,"enrollment":4702,"conditions":5601,"interventions":5602},[89],[4704],[4706,4706,4706,4707,4706],{"trials":5604,"activeCount":100},[],{"trials":5606,"activeCount":100},[],{"trials":5608,"activeCount":100},[],{"trials":5610,"activeCount":100},[],{"intervention":484,"totalTrials":96,"cells":5612},{"EARLY_PHASE1":5613,"PHASE1":5615,"PHASE2":5621,"PHASE3":5623,"PHASE4":5625,"NA":5627},{"trials":5614,"activeCount":100},[],{"trials":5616,"activeCount":100},[5617],{"nctId":476,"briefTitle":477,"status":243,"phases":5618,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":5619,"interventions":5620},[89],[15,27],[469,484,485,486],{"trials":5622,"activeCount":100},[],{"trials":5624,"activeCount":100},[],{"trials":5626,"activeCount":100},[],{"trials":5628,"activeCount":100},[],{"intervention":485,"totalTrials":96,"cells":5630},{"EARLY_PHASE1":5631,"PHASE1":5633,"PHASE2":5639,"PHASE3":5641,"PHASE4":5643,"NA":5645},{"trials":5632,"activeCount":100},[],{"trials":5634,"activeCount":100},[5635],{"nctId":476,"briefTitle":477,"status":243,"phases":5636,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":5637,"interventions":5638},[89],[15,27],[469,484,485,486],{"trials":5640,"activeCount":100},[],{"trials":5642,"activeCount":100},[],{"trials":5644,"activeCount":100},[],{"trials":5646,"activeCount":100},[],{"intervention":486,"totalTrials":96,"cells":5648},{"EARLY_PHASE1":5649,"PHASE1":5651,"PHASE2":5657,"PHASE3":5659,"PHASE4":5661,"NA":5663},{"trials":5650,"activeCount":100},[],{"trials":5652,"activeCount":100},[5653],{"nctId":476,"briefTitle":477,"status":243,"phases":5654,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":5655,"interventions":5656},[89],[15,27],[469,484,485,486],{"trials":5658,"activeCount":100},[],{"trials":5660,"activeCount":100},[],{"trials":5662,"activeCount":100},[],{"trials":5664,"activeCount":100},[],{"intervention":5666,"totalTrials":908,"cells":5667},"pegunigalsidase alfa",{"EARLY_PHASE1":5668,"PHASE1":5670,"PHASE2":5672,"PHASE3":5674,"PHASE4":5694,"NA":5696},{"trials":5669,"activeCount":100},[],{"trials":5671,"activeCount":100},[],{"trials":5673,"activeCount":100},[],{"trials":5675,"activeCount":100},[5676,5685],{"nctId":5677,"briefTitle":5678,"status":243,"phases":5679,"primaryCompletion":5680,"completion":5680,"start":5681,"enrollment":5682,"conditions":5683,"interventions":5684},"NCT03614234","Open Label Extension of 2 mg\u002Fkg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients",[91],"2026-04-13","2018-11-13",29,[24],[5666],{"nctId":5686,"briefTitle":5687,"status":243,"phases":5688,"primaryCompletion":5689,"completion":5689,"start":5690,"enrollment":5691,"conditions":5692,"interventions":5693},"NCT03566017","Open Label Extension Study of 1 mg\u002Fkg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease",[91],"2025-01-21","2018-09-16",97,[24],[5666],{"trials":5695,"activeCount":100},[],{"trials":5697,"activeCount":100},[5698],{"nctId":5699,"briefTitle":5700,"status":5701,"phases":5702,"conditions":5703,"interventions":5704},"NCT04552691","Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients","APPROVED_FOR_MARKETING",[],[24],[5705],"Pegunigalsidase Alfa",{"intervention":5707,"totalTrials":96,"cells":5708},"Immunosuppressive",{"EARLY_PHASE1":5709,"PHASE1":5711,"PHASE2":5713,"PHASE3":5715,"PHASE4":5717,"NA":5719},{"trials":5710,"activeCount":100},[],{"trials":5712,"activeCount":100},[],{"trials":5714,"activeCount":100},[],{"trials":5716,"activeCount":100},[],{"trials":5718,"activeCount":100},[],{"trials":5720,"activeCount":100},[5721],{"nctId":5722,"briefTitle":5723,"status":243,"phases":5724,"primaryCompletion":5725,"completion":5725,"start":5726,"enrollment":5727,"conditions":5728,"interventions":5730},"NCT03558373","The Adherence of Immunosuppressive Therapy Including Tacrolimus Once-daily in Italian Kidney Transplant Recipients",[],"2020-02-26","2018-07-31",158,[5729],"Kidney Transplant",[5707],{"intervention":5732,"totalTrials":96,"cells":5733},"elapegademase-lvlr",{"EARLY_PHASE1":5734,"PHASE1":5736,"PHASE2":5738,"PHASE3":5740,"PHASE4":5742,"NA":5744},{"trials":5735,"activeCount":100},[],{"trials":5737,"activeCount":100},[],{"trials":5739,"activeCount":100},[],{"trials":5741,"activeCount":100},[],{"trials":5743,"activeCount":100},[],{"trials":5745,"activeCount":100},[5746],{"nctId":5747,"briefTitle":5748,"status":243,"phases":5749,"primaryCompletion":5750,"completion":5750,"start":5751,"enrollment":5258,"conditions":5752,"interventions":5754},"NCT03878069","Registry Study of Revcovi Treatment in Patients With ADA-SCID",[],"2023-01-18","2019-09-30",[5753],"Adenosine Deaminase Severe Combined Immunodeficiency",[5732]]